UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 20222023
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
For the transition period from ______ to _______
Commission File Number: 000-53223
MARIZYME, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 82-5464863 | |
| (State or Other Jurisdiction of | (I.R.S. Employer | |
| Incorporation or Organization) | Identification No.) |
555 Heritage Drive, Suite 205, Jupiter, Florida33458 (Address of principal executive offices) (Zip Code) |
(561)935-9955
(Registrant’s telephone number)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| ☐ | Large accelerated filer | ☐ | Accelerated filer |
| ☒ | Non-accelerated filer | ☒ | Smaller reporting company |
| ☐ | Emerging growth company |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Not applicable. |
As of November 14, 2022,2023, the registrant had shares of common stock ($0.001 par value) outstanding.
MARIZYME, INC.
FORM 10-Q
TABLE OF CONTENTS
| 2 |
PART I – FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARIZYME, INC.
Condensed Consolidated Balance Sheets
| September 30, 2022 | December 31, 2021 | September 30, 2023 | December 31, 2022 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| ASSETS: | ||||||||||||||||
| Current | ||||||||||||||||
| Cash | $ | 1,182,248 | $ | 4,072,339 | $ | 474,944 | $ | 510,865 | ||||||||
| Accounts receivable | 54,225 | 8,650 | 43,218 | 87,801 | ||||||||||||
| Other receivables | 14,134 | 41,307 | 35,773 | 15,310 | ||||||||||||
| Prepaid expenses | 839,818 | 257,169 | 661,394 | 1,125,761 | ||||||||||||
| Inventory | 251,187 | 22,353 | 99,019 | 215,566 | ||||||||||||
| Total current assets | 2,341,612 | 4,401,818 | 1,314,348 | 1,955,303 | ||||||||||||
| Non-current | ||||||||||||||||
| Property, plant and equipment, net | 12,613 | 12,817 | 12,500 | 12,545 | ||||||||||||
| Operating lease right-of-use assets, net | 1,576,445 | 1,158,776 | 1,198,207 | 1,485,023 | ||||||||||||
| Intangible assets, net | 52,235,313 | 52,866,192 | 27,044,141 | 27,675,020 | ||||||||||||
| Prepaid royalties, non-current | 339,091 | 339,091 | 129,989 | 339,091 | ||||||||||||
| Deposits | 30,000 | 30,000 | 30,000 | 30,000 | ||||||||||||
| Goodwill | 7,190,656 | 7,190,656 | 7,190,656 | 7,190,656 | ||||||||||||
| Total non-current assets | 61,384,118 | 61,597,532 | 35,605,493 | 36,732,335 | ||||||||||||
| Total assets | $ | 63,725,730 | $ | 65,999,350 | $ | 36,919,841 | $ | 38,687,638 | ||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY: | ||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT): | ||||||||||||||||
| Current | ||||||||||||||||
| Accounts payable and accrued expenses | $ | 848,345 | $ | 1,596,147 | $ | 2,136,592 | $ | 1,365,443 | ||||||||
| Note payable | 213,563 | 127,798 | ||||||||||||||
| Notes payable | 240,916 | 1,132,829 | ||||||||||||||
| Due to related parties | 123,266 | 1,132,634 | 187,097 | - | ||||||||||||
| Convertible notes – Units Private Placement | 19,124,357 | - | ||||||||||||||
| Convertible notes – OID | 993,785 | - | ||||||||||||||
| Derivative liabilities | 25,555,092 | - | ||||||||||||||
| Operating lease obligations | 420,913 | 277,142 | 431,435 | 423,495 | ||||||||||||
| Total current liabilities | 1,606,087 | 3,133,721 | 48,669,274 | 2,921,767 | ||||||||||||
| Non-current | ||||||||||||||||
| Operating lease obligations, net of current portion | 1,155,532 | 881,634 | 766,772 | 1,061,528 | ||||||||||||
| Note payable, net of current portion | - | 469,252 | ||||||||||||||
| Convertible notes | 1,648,795 | 26,065 | ||||||||||||||
| Convertible notes - Units Private Placement | 38,596 | 2,751,633 | ||||||||||||||
| Derivative liabilities | 4,923,725 | 2,485,346 | - | 4,823,725 | ||||||||||||
| Contingent liabilities | 13,444,000 | 11,313,000 | 9,395,000 | 9,707,000 | ||||||||||||
| Total non-current liabilities | 21,172,052 | 15,175,297 | 10,200,368 | 18,343,886 | ||||||||||||
| Total liabilities | 22,778,139 | 18,309,018 | 58,869,642 | 21,265,653 | ||||||||||||
| Commitments and contingencies (Note 10) | - | - | - | - | ||||||||||||
| Stockholders’ equity: | ||||||||||||||||
| Preferred stock, $ par value, shares authorized, shares issued and outstanding as of September 30, 2022 and December 31, 2021 | - | - | ||||||||||||||
| Common stock, par value $, shares authorized, issued and outstanding shares - and at September 30, 2022 and December 31, 2021, respectively | 40,828 | 40,528 | ||||||||||||||
| Stockholders’ equity (deficit): | ||||||||||||||||
| Preferred stock, $ par value, shares authorized, shares issued and outstanding as of September 30, 2023 and December 31, 2022 | - | - | ||||||||||||||
| Common stock, par value $, shares authorized, issued and outstanding shares - at September 30, 2023 and at December 31, 2022 | 46,666 | 40,528 | ||||||||||||||
| Additional paid-in capital | 103,331,833 | 95,473,367 | 119,574,221 | 103,370,890 | ||||||||||||
| Accumulated deficit | (62,425,070 | ) | (47,823,563 | ) | (141,570,688 | ) | (85,989,433 | ) | ||||||||
| Total stockholders’ equity | 40,947,591 | 47,690,332 | ||||||||||||||
| Total liabilities and stockholders’ equity | $ | 63,725,730 | $ | 65,999,350 | ||||||||||||
| Total stockholders’ equity (deficit) | (21,949,801 | ) | 17,421,985 | |||||||||||||
| Total liabilities and stockholders’ equity (deficit) | $ | 36,919,841 | $ | 38,687,638 | ||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 3 |
MARIZYME, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
| 2022 | 2021 | 2022 | 2021 | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||
| Revenue | $ | 76,012 | $ | 37,215 | $ | 137,821 | $ | 271,952 | $ | 181,535 | $ | 76,012 | $ | 495,248 | $ | 137,821 | ||||||||||||||||
| Direct cost of revenue | 50,989 | 15,503 | 139,875 | 26,528 | ||||||||||||||||||||||||||||
| Gross profit | 130,546 | 60,509 | 355,373 | 111,293 | ||||||||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||||||||
| Direct cost of revenue | 15,503 | 18,356 | 26,528 | 168,419 | ||||||||||||||||||||||||||||
| Professional fees (includes related party amounts of $155,000 $90,000, $422,000, and $270,000 respectively) | 303,574 | 460,378 | 1,721,479 | 1,445,004 | ||||||||||||||||||||||||||||
| Professional fees (includes related party amounts of $72,000, $163,200, $216,000 and $266,400 respectively) | 921,552 | 303,574 | 1,818,202 | 1,721,479 | ||||||||||||||||||||||||||||
| Salary expenses | 330,221 | 517,192 | 2,147,967 | 2,084,430 | 329,564 | 330,221 | 931,536 | 2,147,967 | ||||||||||||||||||||||||
| Research and development | 708,220 | 241,748 | 3,297,986 | 877,936 | 492,235 | 708,220 | 1,789,625 | 3,297,986 | ||||||||||||||||||||||||
| Stock-based compensation | 271,517 | 64,074 | 1,664,191 | 626,449 | 86,132 | 271,517 | 457,860 | 1,664,191 | ||||||||||||||||||||||||
| Depreciation and amortization | 210,361 | 1,425 | 631,083 | 5,849 | 210,293 | 210,361 | 630,924 | 631,083 | ||||||||||||||||||||||||
| Royalty expense | 13,014 | - | 211,262 | - | ||||||||||||||||||||||||||||
| Other general and administrative expenses | 469,656 | 489,820 | 1,478,726 | 944,248 | 2,934,966 | 469,656 | 6,310,039 | 1,478,726 | ||||||||||||||||||||||||
| Total operating expenses | 2,309,052 | 1,792,993 | 10,967,960 | 6,152,335 | 4,987,756 | 2,293,549 | 12,149,448 | 10,941,432 | ||||||||||||||||||||||||
| Total operating loss | $ | (2,233,040 | ) | $ | (1,755,778 | ) | $ | (10,830,139 | ) | $ | (5,880,383 | ) | (4,857,210 | ) | (2,233,040 | ) | (11,794,075 | ) | (10,830,139 | ) | ||||||||||||
| Other income (expense) | ||||||||||||||||||||||||||||||||
| Interest and accretion expenses | (810,598 | ) | (70,221 | ) | (1,640,368 | ) | (74,410 | ) | (7,405,668 | ) | (810,598 | ) | (22,527,538 | ) | (1,640,368 | ) | ||||||||||||||||
| Change in fair value of contingent liabilities | 1,491,000 | 194,000 | (2,131,000 | ) | 472,000 | (1,678,000 | ) | 1,491,000 | 312,000 | (2,131,000 | ) | |||||||||||||||||||||
| Change in fair value of derivative liabilities | (14,454,397 | ) | - | (14,454,397 | ) | - | ||||||||||||||||||||||||||
| Loss on debt extinguishment | (80,001 | ) | - | (764,683 | ) | - | ||||||||||||||||||||||||||
| Loss on issuance of debt | (3,974,993 | ) | - | (6,352,562 | ) | - | ||||||||||||||||||||||||||
| Total other income (expense) | 680,402 | 123,779 | (3,771,368 | ) | 397,590 | (27,593,059 | ) | 680,402 | (43,787,180 | ) | (3,771,368 | ) | ||||||||||||||||||||
| Net loss | $ | (1,552,638 | ) | $ | (1,631,999 | ) | $ | (14,601,507 | ) | $ | (5,482,793 | ) | $ | (32,450,269 | ) | $ | (1,552,638 | ) | $ | (55,581,255 | ) | $ | (14,601,507 | ) | ||||||||
| Loss per share – basic and diluted | $ | (0.04 | ) | $ | (0.05 | ) | $ | (0.36 | ) | $ | (0.15 | ) | $ | ) | $ | ) | $ | ) | $ | ) | ||||||||||||
| Weighted average number of shares of common stock outstanding – basic and diluted | 40,828,188 | 35,928,188 | 40,762,254 | 35,928,188 | ||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 4 |
MARIZYME, INC.
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
For the Three and Nine Months Ended September 30, 20222023 and 20212022
(Unaudited)
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Common Stock | Additional Paid-in | Accumulated | Total Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2020 | 35,928,188 | $ | 35,928 | $ | 82,077,334 | $ | (36,825,634 | ) | $ | 45,287,628 | ||||||||||
| Stock-based compensation expense | - | - | 334,385 | - | 334,385 | |||||||||||||||
| Net loss - restated | - | - | - | (2,211,866 | ) | (2,211,866 | ) | |||||||||||||
| Balance, March 31, 2021 (unaudited) | 35,928,188 | 35,928 | 82,411,719 | (39,037,500 | ) | 43,410,147 | ||||||||||||||
| Stock-based compensation expense | - | - | 194,657 | - | 194,657 | |||||||||||||||
| Adjustment of warrants value in connection with finalizing the business combination | - | - | (732,300 | ) | - | (732,300 | ) | |||||||||||||
| Net loss - restated | - | - | - | (1,638,928 | ) | (1,638,928 | ) | |||||||||||||
| Balance, June 30, 2021 (unaudited) | 35,928,188 | 35,928 | 81,874,076 | (40,676,428 | ) | 41,233,576 | ||||||||||||||
| Stock-based compensation expense | - | - | 64,074 | - | 64,074 | |||||||||||||||
| Warrants issued in connection with convertible notes | - | - | 571,807 | - | 571,807 | |||||||||||||||
| Net loss | - | - | - | (1,631,999 | ) | (1,631,999 | ) | |||||||||||||
| Balance, September 30, 2021(unaudited) | 35,928,188 | $ | 35,928 | $ | 82,509,957 | $ | (42,308,427 | ) | $ | 40,237,458 | ||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Common Stock | Additional Paid-in | Accumulated | Total Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2021 | 40,528,188 | $ | 40,528 | $ | 95,473,367 | $ | (47,823,563 | ) | $ | 47,690,332 | ||||||||||
| Stock-based compensation expense | - | - | 716,432 | - | 716,432 | |||||||||||||||
| Issuance of warrants | - | - | 2,969,916 | - | 2,969,916 | |||||||||||||||
| Exercise of warrants | 300,000 | 300 | 2,700 | - | 3,000 | |||||||||||||||
| Net loss | - | - | - | (6,124,885 | ) | (6,124,885 | ) | |||||||||||||
| Balance, March 31, 2022 (unaudited) | 40,828,188 | 40,828 | 99,162,415 | (53,948,448 | ) | 45,254,795 | ||||||||||||||
| Stock-based compensation expense | - | - | 676,242 | - | 676,242 | |||||||||||||||
| Issuance of warrants | - | - | 2,341,659 | - | 2,341,659 | |||||||||||||||
| Net loss | - | - | - | (6,923,984 | ) | (6,923,984 | ) | |||||||||||||
| Balance, June 30, 2022 (unaudited) | 40,828,188 | 40,828 | 102,180,316 | (60,872,432 | ) | 41,348,712 | ||||||||||||||
| Stock-based compensation expense | - | - | 271,517 | - | 271,517 | |||||||||||||||
| Issuance of warrants | - | - | 880,000 | - | 880,000 | |||||||||||||||
| Net loss | - | - | - | (1,552,638 | ) | (1,552,638 | ) | |||||||||||||
| Balance, September 30, 2022 (unaudited) | 40,828,188 | $ | 40,828 | $ | 103,331,833 | $ | (62,425,070 | ) | $ | 40,947,591 | ||||||||||
| Common Stock | Additional Paid-in | Accumulated | Total Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2021 | 40,528,188 | $ | 40,528 | $ | 95,473,367 | $ | (47,823,563 | ) | $ | 47,690,332 | ||||||||||
| Stock-based compensation expense | - | - | 716,432 | - | 716,432 | |||||||||||||||
| Issuance of warrants | - | - | 2,969,916 | - | 2,969,916 | |||||||||||||||
| Exercise of warrants | 300,000 | 300 | 2,700 | - | 3,000 | |||||||||||||||
| Net loss | - | - | - | (6,124,885 | ) | (6,124,885 | ) | |||||||||||||
| Balance, March 31, 2022 (unaudited) | 40,828,188 | $ | 40,828 | 99,162,415 | (53,948,448 | ) | 45,254,795 | |||||||||||||
| Stock-based compensation expense | - | - | 676,242 | - | 676,242 | |||||||||||||||
| Issuance of warrants | - | - | 2,341,659 | - | 2,341,659 | |||||||||||||||
| Net loss | - | - | - | (6,923,984 | ) | (6,923,984 | ) | |||||||||||||
| Balance, June 30, 2022 (unaudited) | 40,828,188 | 40,828 | 102,180,316 | (60,872,432 | ) | 41,348,712 | ||||||||||||||
| Beginning balance, value | 40,828,188 | $ | 40,828 | $ | 102,180,316 | $ | (60,872,432 | ) | $ | 41,348,712 | ||||||||||
| Stock-based compensation expense | - | - | 271,517 | - | 271,517 | |||||||||||||||
| Issuance of warrants | - | - | 880,000 | - | 880,000 | |||||||||||||||
| Net loss | - | - | - | (1,552,638 | ) | (1,552,638 | ) | |||||||||||||
| Balance, September 30, 2022 (unaudited) | 40,828,188 | $ | 40,828 | $ | 103,331,833 | $ | (62,425,070 | ) | $ | 40,947,591 | ||||||||||
| Ending balance, value | 40,828,188 | $ | 40,828 | $ | 103,331,833 | $ | (62,425,070 | ) | $ | 40,947,591 | ||||||||||
| Common Stock | Additional Paid-in | Accumulated | Total Stockholders’ | |||||||||||||||||
| Shares | Amount | Capital | Deficit | Equity | ||||||||||||||||
| Balance, December 31, 2022 | 40,528,191 | $ | 40,528 | $ | 103,370,890 | $ | (85,989,433 | ) | $ | 17,421,985 | ||||||||||
| Stock-based compensation expense | - | - | 210,966 | - | 210,966 | |||||||||||||||
| Issuance of shares | 240,000 | 240 | 153,360 | - | 153,600 | |||||||||||||||
| Net loss | - | - | - | (2,554,584 | ) | (2,554,584 | ) | |||||||||||||
| Balance, March 31, 2023 (unaudited) | 40,768,191 | 40,768 | 103,735,216 | (88,544,017 | ) | 15,231,967 | ||||||||||||||
| Stock-based compensation expense | - | - | 160,762 | - | 160,762 | |||||||||||||||
| Issuance of shares | 1,946,410 | 1,946 | 221,540 | - | 223,486 | |||||||||||||||
| Exercise of warrants | 2,652,159 | 2,652 | 262,564 | - | 265,216 | |||||||||||||||
| Issuance of warrants on debt extinguishment | - | - | 19,058,426 | - | 19,058,426 | |||||||||||||||
| Issuance of warrants on promissory note | - | - | 1,333,128 | - | 1,333,128 | |||||||||||||||
| Warrants cancelled in debt extinguishment | - | - | (8,426,927 | ) | - | (8,426,927 | ) | |||||||||||||
| Net loss | - | - | - | (20,576,402 | ) | (20,576,402 | ) | |||||||||||||
| Balance, June 30, 2023 (unaudited) | 45,366,760 | 45,366 | 116,344,709 | (109,120,419 | ) | 7,269,656 | ||||||||||||||
| Balance | 45,366,760 | 45,366 | 116,344,709 | (109,120,419 | ) | 7,269,656 | ||||||||||||||
| Stock-based compensation expense | - | - | 86,132 | - | 86,132 | |||||||||||||||
| Issuance of shares | 1,300,000 | 1,300 | 208,700 | - | 210,000 | |||||||||||||||
| Issuance of warrants for services provided | - | - | 2,934,680 | - | 2,934,680 | |||||||||||||||
| Net loss | - | - | - | (32,450,269 | ) | (32,450,269 | ) | |||||||||||||
| Balance, September 30, 2023 (unaudited) | 46,666,760 | $ | 46,666 | $ | 119,574,221 | $ | (141,570,688 | ) | $ | (21,949,801 | ) | |||||||||
| Balance | 46,666,760 | $ | 46,666 | $ | 119,574,221 | $ | (141,570,688 | ) | $ | (21,949,801 | ) | |||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 5 |
MARIZYME, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| 2022 | 2021 | 2023 | 2022 | |||||||||||||
| Nine Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2022 | 2021 | 2023 | 2022 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net loss | $ | (14,601,507 | ) | $ | (5,482,793 | ) | $ | (55,581,255 | ) | $ | (14,601,507 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||
| Depreciation and amortization | 631,083 | (76,013 | ) | 630,924 | 631,083 | |||||||||||
| Stock-based compensation | 1,664,191 | 593,116 | 457,860 | 1,664,191 | ||||||||||||
| Stock-based compensation - restricted common stock | - | 33,333 | ||||||||||||||
| Interest and accretion on convertible notes and notes payable | 1,637,951 | 74,410 | 22,527,538 | 1,637,951 | ||||||||||||
| Issuance of warrants for services | 1,850,533 | - | 2,934,680 | 1,850,533 | ||||||||||||
| Change in fair value of contingent liabilities | 2,131,000 | (472,000 | ) | (312,000 | ) | 2,131,000 | ||||||||||
| Change in fair value of derivative liabilities | 14,454,397 | - | ||||||||||||||
| Loss on debt extinguishment | 764,683 | - | ||||||||||||||
| Loss on issuance of debt | 6,352,562 | - | ||||||||||||||
| Shares issued as part of the Confidential Settlement Agreement | 153,600 | - | ||||||||||||||
| Shares issued for services | 168,000 | - | ||||||||||||||
| Warrants issued as part of promissory note agreement | 1,333,128 | - | ||||||||||||||
| Change in operating assets and liabilities: | ||||||||||||||||
| Accounts and other receivables | (18,402 | ) | (55,706 | ) | ||||||||||||
| Accounts and other receivable | 24,120 | (18,402 | ) | |||||||||||||
| Prepaid expenses | (582,649 | ) | 38,057 | 464,367 | (582,649 | ) | ||||||||||
| Inventory | (228,834 | ) | 40,950 | 116,547 | (228,834 | ) | ||||||||||
| Accounts payable and accrued expenses | (740,034 | ) | 721,078 | 1,852,865 | (740,034 | ) | ||||||||||
| Due to related parties | (1,009,368 | ) | 272,530 | 187,097 | (1,009,368 | ) | ||||||||||
| Net cash used in operating activities | (9,266,036 | ) | (4,313,038 | ) | (3,470,887 | ) | (9,266,036 | ) | ||||||||
| Cash flows from financing activities: | ||||||||||||||||
| Proceeds from promissory notes, net of issuance cost | 6,500,743 | 1,060,949 | ||||||||||||||
| Proceeds from promissory notes, due to related parties | - | 366,000 | ||||||||||||||
| Repayment of notes payable | (127,798 | ) | - | |||||||||||||
| Proceeds from exercise of warrants | 3,000 | - | ||||||||||||||
| Proceeds from financing, net of issuance cost | 2,334,000 | 6,500,743 | ||||||||||||||
| Proceeds from shares issued for exercise of warrants | 265,216 | 3,000 | ||||||||||||||
| Proceeds from promissory notes | 1,000,000 | - | ||||||||||||||
Repayments of promissory notes | (164,250 | ) | (127,798 | ) | ||||||||||||
| Net cash provided by financing activities | 6,375,945 | 1,426,949 | 3,434,966 | 6,375,945 | ||||||||||||
| Net change in cash | (2,890,091 | ) | (2,886,089 | ) | (35,921 | ) | (2,890,091 | ) | ||||||||
| Cash at beginning of period | 4,072,339 | 2,902,762 | 510,865 | 4,072,339 | ||||||||||||
| Cash at end of period | $ | 1,182,248 | $ | 16,673 | $ | 474,944 | $ | 1,182,248 | ||||||||
| Supplemental disclosure of cash flow information: | ||||||||||||||||
| Cash paid for interest | $ | - | $ | - | $ | - | $ | - | ||||||||
| Cash paid for taxes | $ | - | $ | - | $ | - | $ | - | ||||||||
| Non-cash investing and financing activities: | ||||||||||||||||
| Derivative liabilities and debt discount issued in connection with convertible notes | $ | 2,438,379 | $ | 391,648 | $ | 25,555,092 | $ | 2,438,379 | ||||||||
| Warrants and debt discount issued in connection with convertible notes | $ | 4,341,042 | $ | 571,807 | $ | 19,403,385 | $ | 4,341,042 | ||||||||
| Settlement of notes payable with convertible notes | $ | 278,678 | $ | - | ||||||||||||
| Contingent liabilities | $ | - | $ | 9,926,000 | ||||||||||||
| Settlement of debt with convertible notes | $ | 2,264,133 | $ | 278,678 | ||||||||||||
| Warrants cancelled in debt extinguishment | $ | 8,426,927 | $ | - | ||||||||||||
| Shares issued on conversion of convertible notes | $ | 84,140 | $ | - | ||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| 6 |
MARIZYME, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 20222023
NOTE 1 – DESCRIPTION OF BUSINESS
Marizyme, Inc. (the “Company” or “Marizyme”) is a Nevada corporation originally incorporated on March 20, 2007,, under the name SWAV Enterprises, Ltd. On September 6, 2010, the Company name was changed to GBS Enterprises Inc. and from 2010, to September 2018, the Company was in the software products and advisory services business for email and instant messaging applications. The Company divested that business between December 2016 and September 2018, and focused on the acquisition of life science technologies.
On March 21, 2018, the Company’s name was changed to Marizyme, Inc., to reflect the new life sciences focus. Marizyme’s common stock is currently quoted on the OTCQB tier of OTC Markets’ QB tierMarkets Group, Inc. under the symbol “MRZM”.
NOTE 2 – GOING CONCERN
The Company’s unaudited condensed consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs, which require the Company to rely on investing and to allow itfinancing activities in order to continue as a going concern. The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $62,425,070141,570,688 at September 30, 20222023 (December 31, 20212022 - $47,823,56385,989,433). Additionally,At September 30, 2023, the Company has negative working capital of $735,52547,354,926 (December 31, 20212022 - $1,268,097966,464) and $1,182,248474,944 (December 31, 20212022 - $4,072,339510,865) of cash on hand, which may not be sufficient to fund operations for the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
Under the going concern assumption, an entity is ordinarily viewed as continuing its business for the foreseeable future with neither the intention or necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to the laws and regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business.
The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully develop its intangible assets and receive a clearancean approval from the U.S. Food and Drug Administration (the “FDA”(“FDA”) to extend the selling of theits products into the U.S. market which will allowmay result in the Company to attainattaining profitable operations.
During the next twelve months from the date the unaudited condensed consolidated financial statements were issued, the Company’s foreseeable cash requirements will relate to continuous operations of its business, maintaining its good standing and making the required filing with the Securities and Exchange Commission (the “SEC”(“SEC”), and the payment of expenses associated with its product development. The Company may experience a cash shortfall and be required to raise additional capital. Management intends to raise additional funds by way of a private or public offerings.offering. While the Company believes in the viability of its strategy to continue to develop and expand its products and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.
The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries: My Health Logic IncInc. (“My Health Logic” or “MHL”), Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”), (collectively – “Somah”), and Marizyme Sciences, Inc. (“Marizyme Sciences”). All intercompany transactions have been eliminated on consolidation.
| 7 |
The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 202224, 2023 (the “2021“2022 Form 10-K”). The condensed consolidated balance sheet as of December 31, 20212022 was derived from audited consolidated financial statements included in the 20212022 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 1 to those consolidated financial statements.
Interim results may not be indicative of the results that may be expected for the full year or any future periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary to fairly present the results of operations, financial condition, cash flows and stockholders’ equity (deficit) for the periods indicated. Except as otherwise disclosed, all such adjustments are of a normal recurring nature.
Deferred Offering Cost
The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process capital stock financings as deferred offering costs until such financings are consummated. After consummation of the financing, these costs are recorded in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations. The Company had no deferred offering costs as of December 31, 2021. As of September 30, 2022,2023, the Company had recorded deferred offering costs of $271,240Nil (December 31, 2022 - $387,412) reported as a prepaid expense on the accompanying condensed consolidated balance sheets.sheets, and expensed an aggregate of $1,203,537
of deferred offering costs - $535,717 of which was related to the extinguishment of 2021 Unit Purchase Agreement (see Note 7) and $667,820 related to a planned uplisting, which was not pursued due to a management’s decision to seek different means to obtain financing.
Use of Estimates
The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities and contingent liabilities and deferred tax valuations.liabilities.
Fair Value Measurements
The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:
| ● | Level 1 – Quoted prices for identical assets or liabilities in active markets. |
| ● | Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. |
| ● | Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. |
The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
The carrying amounts of certain accounts and other receivables, accounts payable and accrued expenses, notes payable, and amounts due to related parties approximate fair value due to the short-term nature of these instruments.
| 8 |
The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk.
The contingent liabilities assumed on the acquisition of SomahSomahlution in 2020 consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy.
| i. | The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of %, expected volatility of %, expected dividend of $, and expected life of years. For the three and nine months ended September 30, | |
| ii. | The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6%. For the three and nine months ended September 30, | |
| iii. | Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6%. For the three and nine months ended September 30, | |
| iv. | The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of %, expected volatility of %, expected dividend of $, and expected life of years. No changes to the fair value of liquidation preference liability were recorded in the three and nine months ended September 30, 2023 and 2022. At September 30, |
The derivative liabilities consist of optional and automatic conversion featuresfeature and the share redemption feature attached to the convertible notes, issued pursuant to the Unit Purchase Agreement (Noteconvertible promissory notes and warrants transactions as described in Note 7.
The detachable warrants attached to the OID Convertible Notes (See Note 7) met the definition of a derivative liability. These warrants were valued using the Black-Scholes pricing method. The following weighted average assumptions were used in the Black-Scholes option pricing model: risk free rate of %, expected volatility of %, expected dividend of $, and expected life of years. For the three and nine months ended September 30, 2023, changes in these assumptions resulted in a $14,454,397 increase in fair value of this liability (September 30, 2022 – $Nil). At September 30, 2023, the fair market value of the detachable warrant liability was $25,555,092 (December 31, 2022 – $Nil).
The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.
| 9 |
Marizyme measures the following financial instruments at fair value on a recurring basis. As of September 30, 2022,2023, and December 31, 2021,2022, the fair values of these financial instruments were as follows:
SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS
| September 30, 2023 | Level 1 | Level 2 | Level 3 | |||||||||||||||||||||
| Fair Value Hierarchy | Fair Value Hierarchy | |||||||||||||||||||||||
| September 30, 2022 | Level 1 | Level 2 | Level 3 | |||||||||||||||||||||
| September 30, 2023 | Level 1 | Level 2 | Level 3 | |||||||||||||||||||||
| Liabilities | ||||||||||||||||||||||||
| Derivative liabilities | $ | - | $ | - | $ | 4,923,725 | $ | - | $ | - | $ | 25,555,092 | ||||||||||||
| Contingent liabilities | - | - | 13,444,000 | - | - | 9,395,000 | ||||||||||||||||||
| Total | $ | - | $ | - | $ | 18,367,725 | $ | - | $ | - | $ | 34,950,092 | ||||||||||||
| Fair Value Hierarchy | ||||||||||||
| December 31, 2021 | Level 1 | Level 2 | Level 3 | |||||||||
| Liabilities | ||||||||||||
| Derivative liabilities | $ | - | $ | - | $ | 2,485,346 | ||||||
| Contingent liabilities | - | - | 11,313,000 | |||||||||
| Total | $ | - | $ | - | $ | 13,798,346 | ||||||
| December 31, 2022 | Level 1 | Level 2 | Level 3 | |||||||||
| Fair Value Hierarchy | ||||||||||||
| December 31, 2022 | Level 1 | Level 2 | Level 3 | |||||||||
| Liabilities | ||||||||||||
| Derivative liabilities | $ | - | $ | - | $ | 4,823,725 | ||||||
| Contingent liabilities | - | - | 9,707,000 | |||||||||
| Total | $ | - | $ | - | $ | 14,530,725 | ||||||
The following table provides a roll forwardrollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs:
RECONCILIATIONSCHEDULE OF LIABILITIES AT FAIR VALUE MEASURED
| Derivative and Contingent Liabilities | ||||
| Balance at December 31, 2021 | $ | 13,798,346 | ||
| Change in fair value of contingent liabilities | 2,131,000 | |||
| Derivative liabilities issued pursuant to Unit Purchase Agreement | 2,438,379 | |||
| Balance at September 30, 2022 | $ | 18,367,725 | ||
| Derivative Liabilities | Contingent Liabilities | |||||||
| Derivative and Contingent Liabilities | ||||||||
| Balance at December 31, 2022 | $ | 4,823,725 | $9,707,000 | |||||
| Change in fair value of contingent liabilities | - | (312,000 | ) | |||||
| Derivative liabilities extinguished pursuant to Unit Purchase Agreement (Note 7) | (4,823,725 | ) | - | |||||
| Derivative liabilities issued pursuant to OID Purchase Agreement (Note 7) | 11,100,695 | - | ||||||
| Change in fair value of derivative liabilities | 14,454,397 | - | ||||||
| Balance at September 30, 2023 | $ | 25,555,092 | $ | 9,395,000 | ||||
Research and Development Expenses and Accruals
All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, for individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of Duragraft,DuraGraft, and costs related to manufacturing DuragraftDuraGraft for clinical trials. The Company has entered into various research and development contracts with various organizations. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be required in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.
Stock-based compensation expense for employees and directors is recognized in the Condensed Consolidated Statementscondensed consolidated statements of Operationsoperations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, the Company estimates the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. The Company estimateestimates the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, the Company estimates the grant date fair value using it’sits closing stock price on the date of grant. The Company recognizes the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. The Company recognizes the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which share-based awards vest.
Comparative InformationNew Accounting Standards and Updates from the Securities and Exchange Commission
To conform withIn June 2016, the current period’s financial statement presentation,Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments - Credit Losses (Topic 326)”. The new standard amends guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. In February 2020, the FASB issued ASU 2020-02, “Financial Instruments-Credit Losses (Topic 326)”, and “Leases (Topic 842)” - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company reclassified certain professional fees, salaries, rentfor interim and repairsannual periods in fiscal years beginning after December 15, 2022. Current Expected Credit Losses estimates of expected credit losses on trade receivables over their life will be required to be recorded at inception, based on historical information, current conditions, and maintenance expenses related to researchreasonable and development activities forsupportable forecasts. The Company adopted the three and nine months ended September 30, 2021, into the research and development expenses line itemstandard in its first quarter of 2023. There was no material impact on the Condensed Consolidated Statementsresults of Operations. Such reclassifications were not considered material and did not have any effect on the Company’s net loss for the three- and nine- month periods ended September 30, 2021.
NOTE 4 – ACQUISITION
My Health Logic Inc.
On November 1, 2021, Marizyme entered into a definitive arrangement agreement with Health Logic Interactive Inc. (“HLII”) pursuant to which the Company would acquire all of the issued and outstanding common shares of My Health Logic, a wholly owned subsidiary of HLII, in exchange for common shares of Marizyme (the “Marizyme Shares”).
Marizyme is dedicated to the acceleration, development and commercialization of medical technologies that promote patient health, therefore a strategic decision was made to acquire My Health Logic, which has provided Marizyme with access to MHL’s lab-on-chip technology platform and its patient-centric, digital point-of-care diagnostic device, MATLOC 1; and allowed for further growth and development of Marizyme’s portfolio of medical products.operations.
| 10 |
On December 22, 2021, Marizyme received the necessary regulatory, court and stock exchange approval to complete the acquisition of MHL resulting in a total of 4,600,000 Common Shares issued to HLII; 230,000 of these shares are being held and administered by Marizyme to be released to HLII, less any amounts claimed by Marizyme or its affiliates for any losses arising out of certain breaches as set out in the acquisition agreement. This resulted in HLII holding approximately 11.35% of the total number of issued and outstanding Marizyme Shares (based on Marizyme Shares issued and outstanding immediately after closing).
In accordance with Accounting Standards Codification (“ASC”) 805-10 the substance of a transaction constitutes a business combination as the business of My Health Logic Inc. meets the definition of a business under the standard. Accordingly, the transaction was accounted for in accordance with the acquisition method of accounting, and the assets acquired, and the liabilities assumed have been recorded at their respective estimated fair values as of the acquisition date. The purchase price was based on management’s estimate of fair value of the common shares issued.
According to ASC 805 the acquirer has a year from the date of acquisition to recognize measurement period adjustments. While Marizyme does not expect the carrying amount, the fair value, and the estimated useful life of identifiable assets and liabilities acquired, provided below, to change, the tax basis related to these intangible assets is not final and remains preliminary at September 30, 2022.
Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid were as follows:
SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION
| Consideration given up | ||||
| Common shares | $ | 7,774,000 | ||
| Total consideration given up | $ | 7,774,000 | ||
| Fair value of identifiable assets acquired, and liabilities assumed | ||||
| Net working deficit | $ | (613,156 | ) | |
| Property, plant, and equipment | 12,500 | |||
| Intangible assets | 6,600,000 | |||
| Goodwill | 1,774,656 | |||
| Total identifiable assets | $ | 7,774,000 |
As a result of the My Health Logic acquisition, the Company acquired its lab-on-chip technology platform, its patient-centric, digital point-of-care diagnostic device - MATLOC 1 as well as patents rights and trademarks relating to it. In addition, the Company acquired ownership rights to MATLOC patents issued in the European Union, Canada, and the United States.
The intangible assets acquired include:
As part of the acquisition, Marizyme assumed an aggregate of $468,137 in notes payable, the notes were unsecured, bore interest at a rate of 9% per annum with no maturity date. For the three and nine months ended September 30, 2022, Marizyme recognized $4,538 and $15,124 of interest expense on the notes payable, respectively (September 30, 2021 - $Nil and $Nil, respectively). The Company settled an aggregate of $278,678 of these notes payable as part of Unit Purchase Agreement issuances during the nine months ended September 30, 2022 (Note 7). As of September 30, 2022, balance of the remaining note payable was $213,563 (December 31, 2021 - $469,252).
Goodwill is attributed to the workforce and profitability of the acquired business and is not deductible for tax purposes. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 37.5% was used in the fair value assumptions for the assembled workforce acquired.
Pro-forma revenue, net income/(loss), and earnings per share are not presented for this acquisition as they are not material.
NOTE 54 – LEASES
On December 11, 2020, the Company entered into a 5.5 - yearfive-and-a-half-year lease agreement for approximately 10,300 square feet of administrative office and laboratories space, which commenced in December 2020 at a monthly rent of approximately $10,800, increasing by 2.5% annually beginning in the second year of the lease until the end of the term. Additionally, pursuant to the agreement, the Company would pay approximately $12,000 per month in operating expenses.
Effective April 1, 2022, the Company amended its lease agreement for administrative office and laboratories to add an additional 3,053 square feet of space. The monthly cost of total expended lease space is approximately $15,260 increasing to $15,641 in 2023 and will continue to increase by 2.5% annually thereafter until the end of the term. The monthly operating expenses for the total expanded premises have increased from approximately $12,000 to $17,500 per month. The term of the lease remains unchanged. As of September 30, 2022,2023, the remaining lease term was 3.832.83 years. The lease hadhas been classified as an operating lease.
The assets and liabilities from the lease were recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the discount rate of 3.95%, which is the average commercial interest available at the time.
The total rent expense for the three and nine months ended September 30, 2023 was $81,502 and $274,004, respectively (September 30, 2022 was– $103,291 and $324,544, respectively (September 30, 2021 - $77,357 and $168,769, respectively).
The following table summarizes supplemental condensed consolidated balance sheet information related to the operating leaseleases as of September 30, 2022,2023, and December 31, 2021:2022:
SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES
| September 30, 2022 | December 31, 2021 | September 30, 2023 | December 31, 2022 | |||||||||||||
| Right-of-use assets | $ | 1,576,445 | $ | 1,158,776 | ||||||||||||
| Operating lease right-of-use assets | $ | 1,198,207 | $ | 1,485,023 | ||||||||||||
| Operating lease liabilities, current | $ | 420,913 | $ | 277,142 | $ | 431,435 | $ | 423,495 | ||||||||
| Operating lease liabilities, non-current | 1,155,532 | 881,634 | 766,772 | 1,061,528 | ||||||||||||
| Total operating lease liabilities | $ | 1,576,445 | $ | 1,158,776 | $ | 1,198,207 | $ | 1,485,023 | ||||||||
As of September 30, 2022,2023, the maturities of the lease liabilities for the periods ending December 31 are as follows:
SCHEDULE OF MATURITIES OF THE LEASE LIABILITIES
| 2022 | $ | 103,291 | ||||||
| 2023 | 423,495 | $ | 105,874 | |||||
| 2024 | 434,082 | 434,082 | ||||||
| 2025 | 444,934 | 444,934 | ||||||
| 2026 | 266,034 | 266,034 | ||||||
| Total lease payments | 1,671,836 | 1,250,924 | ||||||
| Less: Present value discount | (95,391 | ) | (52,717 | ) | ||||
| Total | $ | 1,576,445 | $ | 1,198,207 | ||||
NOTE 65 – INTANGIBLE ASSETS
Krillase
As part of the asset acquisition of ACB Holding AB, Reg. No. 559119-5762, completed on September 12, 2018, Marizyme acquired all rights, titles, and interest in the Krillase technology, a group of intangible assets worth $28,600,000. Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosis. The useful lives of the intangible assets are based on the life of the patent and related technology. The patents and related technology for Krillase have not been amortized since the acquisition, as they have not yet been put into operations. The Company expects to put Krillase into operations and establish the first stream of revenue from the sale of the product in 2023.
At December 31, 2022, management determined that the carrying value of Krillase exceeded its recoverable amount. Impairment of $24,350,000 was recognized on Krillase intangible assets and recorded in the impairment of intangible assets in the consolidated statements of operations for the year ended December 31, 2022. However, for the three and nine months ended September 30, 2023 and 2022, no impairment has been recognized on Krillase intangible assets.
| 11 |
DuraGraft
As part of SomahSomahlution acquisition in 2020, Marizyme purchased $18,170,000 of intangible assets related to the DuraGraft® technology.No impairment has been recognized on DuraGraft intangible assets for the three and nine months ended September 30, 2023 and 2022.
My Health Logic
As part of My Health Logic acquisition (see Note 4),completed on December 22, 2021, Marizyme purchased MHL’s lab-on-chip technology platform and its patient-centric, digital point-of-care diagnostic device, MATLOC, fair valued at an aggregate amount of $6,600,000.No impairment has been recognized on My Health Logic intangible assets for the three and nine months ended September 30, 2023 and 2022.
SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE
| September 30, 2023 | ||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | ||||||||||
| Krillase intangible assets | $ | 4,250,000 | $ | - | $ | 4,250,000 | ||||||
| Patents in process | 122,745 | - | 122,745 | |||||||||
| DuraGraft patent | 5,256,000 | (1,280,307 | ) | 3,975,693 | ||||||||
| DuraGraft - Distributor relationship | 308,000 | (97,533 | ) | 210,467 | ||||||||
| DuraGraft IPR&D - Cyto Protectant Life Sciences | 12,606,000 | - | 12,606,000 | |||||||||
| My Health Logic - Trade name | 450,000 | (57,054 | ) | 392,946 | ||||||||
| My Health Logic - Biotechnology | 4,600,000 | (480,294 | ) | 4,119,706 | ||||||||
| My Health Logic - Software | 1,550,000 | (183,416 | ) | 1,366,584 | ||||||||
| Total intangibles | $ | 29,142,745 | $ | (2,098,604 | ) | $ | 27,044,141 | |||||
| September 30, 2022 | December 31, 2021 | December 31, 2022 | ||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Impairment | Net Carrying Amount | |||||||||||||||||||||||||||||||
| Krillase intangible assets | $ | 28,600,000 | $ | - | $ | 28,600,000 | $ | 28,600,000 | $ | - | $ | 28,600,000 | $ | 28,600,000 | $ | - | $ | (24,350,000 | ) | $ | 4,250,000 | |||||||||||||||||||
| Patents in process | 122,745 | - | 122,745 | 122,745 | - | 122,745 | 122,745 | - | - | 122,745 | ||||||||||||||||||||||||||||||
| DuraGraft patent | 5,256,000 | (875,999 | ) | 4,380,001 | 5,256,000 | (572,768 | ) | 4,683,232 | 5,256,000 | (977,076 | ) | - | 4,278,924 | |||||||||||||||||||||||||||
| Duragraft - Distributor relationship | 308,000 | (66,733 | ) | 241,267 | 308,000 | (43,633 | ) | 264,367 | ||||||||||||||||||||||||||||||||
| Duragraft IPR&D - Cyto Protectant Life Sciences | 12,606,000 | - | 12,606,000 | 12,606,000 | - | 12,606,000 | ||||||||||||||||||||||||||||||||||
| DuraGraft - Distributor relationship | 308,000 | (74,433 | ) | - | 233,567 | |||||||||||||||||||||||||||||||||||
| DuraGraft IPR&D - Cyto Protectant Life Sciences | 12,606,000 | - | - | 12,606,000 | ||||||||||||||||||||||||||||||||||||
| My Health Logic - Trade name | 450,000 | (24,911 | ) | 425,089 | 450,000 | (804 | ) | 449,196 | 450,000 | (32,947 | ) | - | 417,053 | |||||||||||||||||||||||||||
| My Health Logic - Biotechnology | 4,600,000 | (209,706 | ) | 4,390,294 | 4,600,000 | (6,765 | ) | 4,593,235 | 4,600,000 | (277,353 | ) | - | 4,322,647 | |||||||||||||||||||||||||||
| My Health Logic - Software | 1,550,000 | (80,083 | ) | 1,469,917 | 1,550,000 | (2,583 | ) | 1,547,417 | 1,550,000 | (105,916 | ) | - | 1,444,084 | |||||||||||||||||||||||||||
| Total intangibles | $ | 53,492,745 | $ | (1,257,432 | ) | $ | 52,235,313 | $ | 53,492,745 | $ | (626,553 | ) | $ | 52,866,192 | $ | 53,492,745 | $ | (1,467,725 | ) | $ | (24,350,000 | ) | $ | 27,675,020 | ||||||||||||||||
SCHEDULE OF GOODWILL
| Goodwill | DuraGraft | My Health Logic | Total | |||||||||
| Balance, September 30, 2023 and December 31, 2022 | $ | 5,416,000 | $ | 1,774,656 | $ | 7,190,656 | ||||||
| Goodwill | DuraGraft | My Health Logic | Total | |||||||||
| Balance, December 31, 2020 | $ | - | $ | - | $ | - | ||||||
| Additions on acquisitions | 5,416,000 | 1,774,656 | 7,190,656 | |||||||||
| Impairment | - | - | ||||||||||
| Balance, December 31, 2021 and September 30, 2022 | $ | 5,416,000 | $ | 1,774,656 | $ | 7,190,656 |
The following changes to the Company’s intangible assets had taken place in the periods indicated:
SCHEDULE OF INTANGIBLE ASSETS
| Balance, December 31, 2021 | $ | 52,866,192 | ||
| Impairment | (24,350,000 | ) | ||
| Amortization expense | (841,172 | ) | ||
| Balance, December 31, 2022 | 27,675,020 | |||
| Amortization expense | (630,879 | ) | ||
| Balance, September 30, 2023 | $ | 27,044,141 |
| Balance, December 31, 2020 | $ | 42,278,211 | ||
| Acquired in Somah Transaction | 4,022,271 | |||
| Acquired in My Health Logic Transaction | 6,600,000 | |||
| Additions | 2,775 | |||
| Amortization expense | (37,065 | ) | ||
| Balance, December 31, 2021 | $ | 52,866,192 | ||
| Amortization expense | (630,879 | ) | ||
| Balance, September 30, 2022 | $ | 52,235,313 |
| 12 |
Future amortizations for DuragraftDuraGraft and My Health Logic intangible assets for the remaining three months of the fiscal 2023 will be $210,293, for the next five years will befrom 2024 through 2028 - $841,172 for each year, from 2023 through 2027 and for 2029 and thereafter - $6,700,7065,649,241 for 2028 and thereafter.. Amortization related to the Krillase product and in processin-process research and development will be determined upon the Company achieving commercialization.
NOTE 6 – NOTES PAYABLE
a) On October 23, 2022, the Company issued a note payable to Hub International for $204,050 bearing interest at the annual rate of 6.75% per annum, due September 23, 2023, payable monthly starting November 23, 2022. As of September 30, 2023, the note payable was paid in full (December 31, 2022 - $164,729).
b) On December 28, 2022, the Company issued a promissory note to Hexin for the principal amount of $750,000 bearing interest at the annual rate of 20% per annum, due June 28, 2023 (the “Hexin Promissory Note”). For the three and nine months ended September 30, 2023, the Company accrued $25,914 and $64,133 in interest on the promissory note, respectively (September 30, 2022 - $Nil and $Nil, respectively). Hexin agreed to cancel the Hexin Promissory Note with the outstanding balance of $814,133 (the aggregate amount of principal plus accrued and unpaid interest as of May 30, 2023) in exchange for the issuance of OID Units (see Note 7), which the Company issued to Hexin on May 30, 2023.
c) On February 2, 2023, the Company issued an unsecured promissory note to Walleye Opportunities Master Fund Ltd. (the “Walleye Promissory Note”) for $1,000,000 with a maturity date of May 7, 2023. The note carried no interest and the principal amount was required to be repaid in full on the maturity date. In the event that the principal amount was not repaid in full on maturity date, the principal amount required to be increased to $1,250,000. As of the maturity date of the note, the principal amount was not repaid and therefore increased from $1,000,000 to $1,250,000. Walleye agreed to cancel the promissory note, with the outstanding balance of $1,250,000 in exchange for the issuance of OID Units (see Note 7), which were issued to Walleye on May 30, 2023.
d) As part of the My Health Logic Inc. acquisition, completed in November 2021, Marizyme assumed an aggregate of $468,137 in notes payable, the notes were unsecured, bore interest at a rate of 9% per annum with no maturity date. The Company settled an aggregate of $278,678 of these notes payable as part of Unit Purchase Agreement issuances during the year ended December 31, 2022 (see Note 7). For the three and nine months ended September 30, 2023, the Company accrued $5,344 and $23,710 in interest on the notes payable, respectively (September 30, 2022 - $4,538 and $15,124, respectively), and recorded an unrealized gain of $5,832 and $894 for the three and nine months ended September 30, 2023, respectively (September 30, 2022 - $Nil and $Nil, respectively). As of September 30, 2023, balance of the remaining note payable was $240,916 (December 31, 2022 - $218,100).
| 13 |
NOTE 7 - CONVERTIBLE PROMISSORY NOTES AND WARRANTS
May 2021 Unit Purchase Agreement
On May 27, 2021, Marizyme entered into a Unit Purchase Agreement to sell up to units (the ‘Units’) at a price per Unit of $. Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’);Convertible Notes and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”).
In May 2021, the Company issued and sold Units at a price of $ per Unit for gross proceeds of $74,945, consisting of Notes of $74,945, Class A Warrants for the purchase of 29,978 shares of common stock and Class B Warrants for the purchase of 29,978 shares of common stock. The Company incurred related issuance costs of $6,745 which will be amortized over the term of the Notes.
In July 2021, the Company issued and sold Units under the Unit Purchase Program for gross proceeds of $1,100,000. The Units included Notes for $1,100,000, Class A Warrants for 440,000 shares of common stock and Class B Warrants for 440,000 shares of common stock.
September 2021 Amended Unit Purchase Agreement
On September 29, 2021, due to a lower common stock price, the Company, with the consent of all Unit holders, amended the May 2021 Unit Agreements. By rescinding their investment, the Unit holders agreed to amend the Unit Purchase Agreement resulted in the following significant changes to the offering:
December 2021 Unit Purchase Agreement
On December 21, 2021, the Company entered into a Unit Purchase Agreement (the “December UPA”) to sell up to Units at a price per unit of $. Each Unit is comprised of (i) a convertible promissory note convertible into common stock of the Company at an initial conversion price of $1.75 and, (ii) a warrant to purchase two shares of Common Stock at an initial purchase price of $2.25 per share (the new Class C Warrant). Under this December UPA, the Company issued and sold Units at a per unit purchase price of $, for gross proceeds of $6,000,000. Coinciding with this December UPA, the Company also entered into an Exchange Agreement with the existing Unit holders (the December 2021 Exchange Agreements, as further described below).
December 2021 Exchange Agreements
On December 21, 2021, in conjunction with a $6.0 million investment, the Company and the existing Unit holders agreed to exchange the original securities (“Old Securities”) held by the current investors/unit holders for New Securities, consisting of (i) a New Note in the principal amount equal to the original principal amount of the Original Note, plus all accrued interest through the day prior to December 21, 2021, and (ii) a New Warrant (new Class C Warrants) in exchange for the original Class C Warrants. The Exchange of the Original Securities for the New Securities included the following significant changes:
The Company determined that the terms of the New Securities were substantially different from the Original Securities, and, as such the exchange of the Original Securities for the New Securities was accounted for as an extinguishment of debt on December 21, 2021, and the New Securities accounted for as a new debt issuance.
As a result of this substantial modification, the total of 621,087 Units previously issued were replaced with an aggregate of 832,022 pro-rata Units.
During the nine months ended September 30, 2022, the Company issued additional units under the New Securities agreement for the gross proceeds of $7,315,138. Of the total Units issued: (i) Units were issued to settle notes payable assumed on acquisition of My Health Logic (see Note 4), (ii) Units were issued to settle accounts payable, and (iii) Units were issued in exchange for services rendered to the Company in the nine months ended September 30, 2022.
The Company determined that the optional and automatic conversion feature and the share redemption feature attached to the convertible notes meet the definition of derivative liabilities and that the detachable warrants issued do not meet the definition of a liability and therefore will be accounted for as an equity instrument.
The fair value of the warrants issued in the nine months ended September 30, 2022, of $4,341,042 (December 31, 2021 - $4,299,649) and the fair value of derivative liabilities of $2,438,379 issued (December 31, 2021 - $2,485,346) have been recorded as debt discount and are being amortized to interest and accretion expense using the effective interest method over the term of the Convertible Notes.
During the three and nine months ended September 30,From May 2021 to August 2022, the Company recognized interestconducted a private placement (the “Units Private Placement”) of units (the “Units”) consisting of 10% secured convertible promissory notes (the “Convertible Notes”) and accretion expenseaccompanying warrants (the “Class C Warrants”), as were modified or amended from time to time. The most recent terms of $805,849the Convertible Notes and $1,622,730, respectively (September 30, 2021 - $70,221 and $74,410, respectively) in the condensed consolidated statements of operations.
For the months ended September 30, 2022 and December 31, 2021, the Company had the following convertible notes, net of debt discount outstanding:Class C Warrants were as follows:
SCHEDULE OF CONVERTIBLE NOTES
| Convertible Notes, Net of Debt Discount | ||||
| Balance, December 31, 2021 | $ | 26,065 | ||
| Convertible notes issued - new securities | 7,315,138 | |||
| Issuance costs | (535,717 | ) | ||
| Debt discount | (6,779,421 | ) | ||
| Debt accretion | 1,622,730 | |||
| Balance, September 30, 2022 | $ | 1,648,795 | ||
SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT
| September 30, 2022 | December 31, 2021 | |||||||
| Convertible notes - total principal | $ | 14,771,177 | $ | 7,482,104 | ||||
| Unamortized issuance costs and discount | (13,122,382 | ) | (7,456,039 | ) | ||||
| Convertible notes, net of debt discount | $ | 1,648,795 | $ | 26,065 | ||||
Convertible Notes Terms
The Convertible Notes mature in 24 months from the initial closing date and accrue 10% of simple interest per annum on the outstanding principal amountamount.. The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $1.75 per share (previously $2.25 per the September 2021 Amendment and originally $2.50 per the May Unit Purchase Agreement)share.. In the event the Company consummates, while the Convertible Note is outstanding, an equity financing with a gross aggregate amount of securities sold of not less than $10,000,000 (“Qualified Financing”), then all outstanding principal, together with all unpaid accrued interest under the Convertible Notes, shall automatically convert into shares of the equity financing at the lesser of (i) 75% of the cash price per share paid in the financing and the conversion price of $1.75 per unit.
In the event that the Company consummates, while the Convertible Note is outstanding, an equity financing with a gross aggregate amount of securities sold less than $10,000,000 (“Unqualified Financing”), then the conversion price of the Convertible Notes of $1.75 per share and the exercise price of Class C warrants of $2.25 per share will change to the equity offering price. Moreover, in that event, the Class C Warrant holders may also apply a most-favored-nations clause in their warrants to request that their Class C Warrants provide that their warrant exercise rights should be further adjusted to allow them to purchase a proportionately higher number of additional shares equal to the initial number of shares which may be purchased by exercise of their Class C Warrants, multiplied by a fraction equal to the current exercise price divided by the adjusted exercise price, which would allow such Class C Warrant holders to purchase the same aggregate dollar amount of shares as initially provided such Class C Warrants. If the Convertible Notes and Class C Warrants’ conversion or exercise rights become so adjusted as a result of such an equity financing, then the Company would be required to register the additional shares of common stock that these securities may be converted into or exercised to purchase for resale. The Convertible Notes are secured by a first priority security interest in all assets of the Company.
New Class C Warrants Terms
| ● | Exercise price is the lower of (i) $2.25 per share, or (ii) the Automatic Conversion Price (the lesser of (i) 75% of the cash price per share paid by the other purchasers of next round securities in the Qualified Financing and (ii) the Conversion Price ($2.25, subject to Customary Antidilution Adjustments). | |
| ● | Exercisable for a period of 5 years from issuance. | |
| ● | Warrant Coverage: 200%. |
The Company determined that the optional and automatic conversion feature and the share redemption feature attached to the Convertible Notes met the definition of derivative liabilities and that the detachable warrants issued did not meet the definition of a liability and therefore was accounted for as an equity instrument.
The fair value of the warrants issued and the fair value of derivative liabilities issued have been recorded as debt discount and are being amortized to interest and accretion expense using the effective interest method over the term of the Convertible Notes.
In 2021, the Company issued an aggregate of Units for the proceeds of $6,692,765 net of issuance costs. In 2022, the Company issued additional units for the proceeds of $6,500,743 net of issuance cost.
| 14 |
Adjustment to Conversion Price of Convertible Notes and Exercise Price of Class C Warrants
On April 13, 2023, the Company obtained exercise and conversion rights waivers and amendments from holders of the Convertible Notes and Class C Warrants (“Original Securities”), pursuant to which, the conversion price of the Convertible Notes and the exercise price of the Class C Warrants was adjusted to $0.10 per share (“New Securities”) and all other terms remained the same. On April 13, 2023, outstanding Convertible Notes had underlying principle of $14,432,996, and outstanding Class C Warrants were exercisable to purchase a total of shares of common stock.
The Company determined that the terms of the New Securities were substantially different from the Original Securities, and, as such the exchange of the Original Securities for the New Securities was accounted for as an extinguishment of debt on April 13, 2023, and the New Securities accounted for as a new debt issuance.
As a result of this substantial modification, a total of Units outstanding were replaced with an aggregate of pro rata Units, and a loss on debt extinguishment of $684,682 was recorded in condensed consolidated statements of operations for the nine months ended September 30, 2023 (September 30, 2022 - $Nil).
Additionally, during the nine months ended September 30, 2023, the Company issued to Univest Securities, LLC (“Univest”) and Mr. Bradley Richmond, Convertible Notes (the “Replacement Placement Agent Notes”) with a principal of $137,984 and $206,975, respectively, maturing on July 25, 2025, convertible into up to and shares of common stock if held to maturity, respectively, to replace Convertible Notes that were issued and cancelled, pursuant to October 2022 Letter Agreement, in previous years.
The Company determined that the optional conversion feature attached to the Convertible Notes did not meet the definition of derivative liabilities and that the detachable warrants issued did not meet the definition of a liability and therefore was accounted for as an equity instrument. The fair value of $19,403,385 of the warrants issued has been recorded as a component of equity and a debt discount and is being amortized to interest and accretion expense using the effective interest method over the term of the Convertible Notes.
During the three and nine months ended September 30, 2023, the Company recognized interest and accretion expense of $6,418,297 and $13,705,189, respectively, on the Original and New Securities in aggregate (September 30, 2022 - $805,849 and $1,622,730, respectively) in the condensed consolidated statements of operations.
Each of the Convertible Notes provides that any default on indebtedness of more than $100,000, other than indebtedness under the respective Convertible Notes, will also result in default under the Convertible Notes. Due to the non-repayment of the initial principal amount of $1,000,000 under the Walleye Promissory Note by its maturity date of May 7, 2023 (see Note 6), the Company also defaulted under the Convertible Notes on the same date. The Convertible Notes provide that due to this default, the Company became obligated to pay 135% of the outstanding principal amount under each of the Convertible Notes on the date on which the default occurred (the “Mandatory Default Amount”). The Mandatory Default Amount may be declared due by each holder immediately. The aggregate Mandatory Default Amount that may be due under the Convertible Notes was $28,461,827 on the date of the default, or $7,378,992 more than would otherwise have been due under the Convertible Notes on the date of the default. Therefore, as a result of the event of the default, the Company accreted $7,378,992 to the value of the Convertible Notes and included this amount in interest and accretion expenses on the condensed consolidated statement of operations. The holders of the Convertible Notes have not exercised any remedies applicable to the Convertible Notes as of the date of this report. In the event that the balance owed under the Convertible Notes, including the respective Mandatory Default Amount, is not repaid upon demand, the holders of the Convertible Notes may seek to take possession of some or all of the Company’s and its subsidiaries’ assets, force the Company and its subsidiaries into bankruptcy proceedings, or seek other legal remedies against the Company and its subsidiaries . In such an event, the Company’s business, operating results and financial condition may be materially adversely affected.
The following table summarizes supplemental balance sheet information related to the convertible notes, net of debt discount outstanding, as of September 30, 2023, and December 31, 2022:
SCHEDULE OF CONVERTIBLE NOTES
| Convertible Notes, Net of Debt Discount | ||||
| Balance, December 31, 2021 | $ | 26,065 | ||
| Principal of Convertible Notes issued - Original securities | 7,315,138 | |||
| Issuance costs | (535,717 | ) | ||
| Debt discount | (6,479,421 | ) | ||
| Debt accretion | 2,763,749 | |||
| Debt extinguishment | (338,181 | ) | ||
| Balance, December 31, 2022 | 2,751,633 | |||
| Debt accretion on Original securities | 1,835,741 | |||
| Debt extinguishment | (4,587,374 | ) | ||
| Principal of Convertible Notes issued - New securities | 19,403,385 | |||
| Debt discount | (19,403,385 | ) | ||
| Debt accretion on New Securities | 11,869,448 | |||
| Debt accretion associated with Mandatory Default Amount | 7,378,991 | |||
| Conversion of debt | (85,486 | ) | ||
| Balance, September 30, 2023 | $ | 19,162,953 | ||
| 15 |
SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT
September 30, 2023 | December 31, 2022 | |||||||
| Convertible notes - total principal | $ | 19,169,689 | $ | 14,432,996 | ||||
| Mandatory Default Amount | 7,378,991 | - | ||||||
| Unamortized issuance costs and discount | (7,385,727 | ) | (11,681,363 | ) | ||||
| Convertible Notes, Net of Debt Discount | $ | 19,162,953 | $ | 2,751,633 | ||||
| September 30, 2023 | December 31, 2022 | |||||||
| Current portion | $ | 19,124,357 | $ | - | ||||
| Non-current portion | 38,596 | 2,751,633 | ||||||
| Convertible Notes, Net of Debt Discount | $ | 19,162,953 | $ | 2,751,633 | ||||
2023 Convertible Notes and Warrants
On May 12, 2023, the Company conducted the initial closing (the “OID Units Initial Closing”) of a private placement of up to $10,000,000 for an aggregate of up to 100,000,000 units (the “OID Units”) under a Unit Purchase Agreement, dated as of the same date, with accredited investors (the “OID Purchase Agreement”), each consisting of (i) a 15% original issue discount unsecured subordinated convertible promissory note (each, a “OID Convertible Note” and collectively, the “OID Convertible Notes”), convertible into shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment, (ii) a warrant for the purchase of 125% of the shares of common stock into which the related OID Convertible Notes may be converted at $0.10 per share, subject to adjustment (the “Class E Warrant”), and (iii) a warrant for the purchase of 125% of the shares of common stock into which the related OID Convertible Note may be converted at $0.20 per share, subject to adjustment (each, a “Class F Warrant,” and each Class F Warrant together with each Class E Warrant collectively, the “OID Warrants”).
As part of the OID Units Initial Closing and on the same date, Walleye Opportunities Master Fund Ltd. (“Walleye”) paid a subscription amount of $1,000,000 and the Company issued Walleye OID Units consisting of (i) an OID Convertible Note in the principal amount of $1,176,471, convertible into shares of common stock plus additional shares based on accrued interest at $ per share, (ii) a Class E Warrant for the purchase of 14,705,880 shares of common stock, and (iii) a Class F Warrant for the purchase of 14,705,880 shares of common stock at $0.20 per share.
On May 30, 2023, the Company conducted the second closing (the “OID Units Second Closing”) of the OID Units Private Placement. In the OID Units Second Closing, Hexin Global Ltd. (“Hexin”) and Walleye agreed to the cancellation of the Hexin Promissory Note and the Walleye Promissory Note (see Note 6), respectively, and Frank Maresca (“Maresca”), a consultant to the Company, agreed to the cancellation of certain indebtedness, in exchange for OID Units and related agreements, as described below.
First, under a Cancellation and Exchange Agreement, dated as of May 30, 2023, between the Company and Hexin (the “Hexin Cancellation Agreement”), Hexin agreed to cancel the Hexin Promissory Note (see Note 6) in exchange for the issuance of OID Units consisting of (a) an OID Convertible Note in the principal amount of $957,804 for a subscription equal to $814,133, convertible into shares of common stock plus additional shares based on accrued interest at $ per share, (b) a Class E Warrant for the purchase of 11,972,550 shares of common stock at $ per share, and (c) a Class F Warrant for the purchase of 11,972,550 shares of common stock at $ per share.
Second, under a Cancellation and Exchange Agreement, dated as of May 30, 2023, between the Company and Walleye (the “Walleye Cancellation Agreement”), Walleye agreed to cancel the Walleye Promissory Note (see Note 6) in exchange for the issuance of Units consisting of (a) an OID Convertible Note in the principal amount of $1,470,589 for a subscription equal to $1,250,000, convertible into shares of common stock plus additional shares based on accrued interest at $ per share, (b) a Class E Warrant for the purchase of 18,382,362 shares of common stock at $ per share, and (c) a Class F Warrant for the purchase of 18,382,362 shares of common stock at $ per share.
Third, under a Cancellation and Exchange Agreement, dated as of May 30, 2023, between the Company and Maresca (the “Maresca Cancellation Agreement” and together with the Hexin Cancellation Agreement and the Walleye Cancellation Agreement, the “Cancellation and Exchange Agreements”), Maresca agreed to cancel $150,000 of the aggregate short-term indebtedness to Maresca, which arose in the ordinary course of business for certain consulting services provided by Maresca to the Company, in exchange for the issuance of Units consisting of (a) an OID Convertible Note in the principal amount of $176,471 for a subscription equal to $150,000 (the amount of the indebtedness being cancelled), convertible into shares of common stock plus additional shares based on accrued interest at $ per share, (b) a Class E Warrant for the purchase of 2,205,887 shares of common stock at $ per share, and (c) a Class F Warrant for the purchase of 2,205,887 shares of common stock at $ per share.
| 16 |
On July 10, 2023, Marizyme conducted the third closing (the “Third OID Units Closing”) of the private placement. In connection with the Third OID Units Closing Hexin paid a subscription amount of $1,000,000, and the Company issued OID Units consisting of (i) an OID Convertible Note in the principal amount of $1,176,471, convertible into shares of common stock plus additional shares based on accrued interest at $ per share, (ii) a Class E Warrant for the purchase of 14,705,887 shares of common stock at $ per share, and (iii) a Class F Warrant for the purchase of 14,705,880 shares of common stock at $ per share.
On August 30, 2023, the Company conducted the fourth closing (the “Fourth OID Units Closing”) of the private placement of up to $ for an aggregate of up to 100,000,000 units, under a unit purchase agreement between the Company and each of 13 investors (the “August 2023 OID Units Purchase Agreement”). In connection with the Fourth OID Units Closing, 12 of the investors paid an aggregate subscription amount of $825,000, and the Company issued to these investors OID Units consisting of (i) OID Convertible Notes in the aggregate principal amount of $970,596, convertible into shares of common stock plus additional shares based on accrued interest at $ per share, (ii) Class E Warrants for the purchase of 12,132,448 shares of common stock at $ per share, and (iii) Class F Warrants for the purchase of 12,132,448 shares of common stock at $ per share.
Also in connection with the Fourth OID Units Closing, under a Cancellation and Exchange Agreement, dated as of August 30, 2023, between the Company and Frank Maresca (the “August 2023 Maresca Cancellation Agreement”), Mr. Maresca agreed to cancel $200,000 of aggregate short-term indebtedness to Mr. Maresca, which arose in the ordinary course of business for certain consulting services provided by Mr. Maresca to the Company, in exchange for: (i) the issuance of OID Units consisting of (a) an OID Convertible Note in the principal amount of $235,295 for a subscription equal to $200,000, convertible into shares of common stock plus additional shares based on accrued interest at $ per share (the “August 2023 Maresca OID Convertible Note”), (b) a Class E Warrant for the purchase of 2,941,187 shares of common stock at $ per share, and (c) a Class F Warrant for the purchase of 2,941,187 shares of common stock at $ per share. The August 2023 Maresca Cancellation Agreement contains a release of claims against the Company relating to the cancelled indebtedness.
The Company determined that the optional conversion feature attached to the OID Convertible Notes did not meet the definition of derivative liability and that the detachable warrants issued met the definition of a liability and therefore was accounted for as a derivative liability instrument. The warrants were fair valued at $11,100,695 and recorded as derivative liabilities on the condensed consolidated balance sheets at September 30, 2023. As a result of the warrant liability exceeding the value of the debt principal, the Company recorded a $6,352,562 loss on issuance of debt that was recorded in condensed consolidated statements of operations for the nine months ended September 30, 2023 (June 30, 2022 - $Nil). These warrants were valued using the Black-Scholes pricing method. The changes in the assumptions used to value the warrants as of September 30, 2023, resulted in a $14,454,397 increase in fair value of this liability. At September 30, 2023, the fair market value of detachable warrant liability was $25,555,092 (December 31, 2022 – $Nil).
During the three and nine months ended September 30, 2023, the Company recognized interest and accretion expense of $843,699 and $993,785, respectively (September 30, 2022 - $Nil and $Nil, respectively), in the condensed consolidated statements of operations.
The following table summarizes supplemental balance sheet information related to the OID Convertible Notes, net of debt discount outstanding, as of September 30, 2023, and December 31, 2022:
SCHEDULE OF CONVERTIBLE NOTES
| OID Convertible Notes, Net of Debt Discount | ||||
| Balance, December 31, 2022 | $ | - | ||
| Issuance of convertible notes | 6,163,697 | |||
| Issuance cost | (1,415,564 | ) | ||
| Debt discounts | (4,748,133 | ) | ||
| Debt accretion | 993,785 | |||
| Balance, September 30, 2023 | $ | 993,785 | ||
SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT
September 30, 2023 | December 31, 2022 | |||||||
| OID Convertible Notes - total principal | $ | 6,163,697 | $ | - | ||||
| Unamortized issuance costs and discount | (5,169,912 | ) | - | |||||
| OID Convertible Notes, Net of Debt Discount | $ | 993,785 | $ | - | ||||
September 30, 2023 | December 31, 2022 | |||||||
| Current portion | $ | 993,785 | $ | - | ||||
| Non-current portion | - | - | ||||||
| OID Convertible Notes, Net of Debt Discount | $ | 993,785 | $ | - | ||||
| 17 |
2023 Convertible Notes Terms
The OID Convertible Notes will mature in nine months from the date of the OID Units Initial Closing and accrue 10% of interest per annum on the outstanding principal amount. The OID Convertible Notes will be unsecured and subordinated to any senior indebtedness of the Company. The OID Convertible Notes’ principal and accrued interest may generally be converted at any time at a conversion price of $0.10 per share, subject to adjustment, at the option of the holder, into shares of common stock, subject to certain limitations: (i) conversion would not cause the holder to beneficially own more than 4.99% of the Company’s common stock, or more than 9.99% if the holder beneficially owns more than 4.99% of common stock based on ownership of equity securities of the Company other than the OID Convertible Notes or the respective warrants; and (ii) the Company’s articles of incorporation have been amended to increase the number of authorized shares of common stock to a sufficient amount to permit the full conversion of the OID Convertible Notes (the “Capital Event Amendment”).
2023 Warrants Terms
The Class E Warrants and Class F Warrants are generally exercisable for a period from the date of the Capital Event Amendment until five years from the date of issue. The exercise right is subject to a similar beneficial ownership limitation that applies to conversion of the OID Convertible Notes above, i.e., exercise is permitted only if it would not cause the holder to beneficially own more than 4.99% of the Company’s common stock, or more than 9.99% if the holder beneficially owns more than 4.99% of common stock based on ownership of equity securities of the Company other than the OID Convertible Notes or the Class E Warrants and Class F Warrants.
NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT)
a) Preferred stock
| a) | Preferred stock |
The Company is authorized to issue a total number of shares of “blank check” preferred stock with a par value of $. As of September 30, 2022,2023, and December 31, 2021,2022, there were shares of preferred stock issued or outstanding.
b) Common stock
| b) | Common stock |
The Company is authorized to issue a total number of shares of common stock with a par value of $.
On August 1, 2022, the Board of Directors (the “Board”) of Marizyme approved a reverse stock split of the Company’s authorized and outstanding common stock at a ratio of 1-for-4. On August 3, 2022, the Company effected the reverse stock split by filing a Certificate of Change with the Secretary of State of the State of Nevada. As a result, the total number of shares of common stock held by each stockholder was converted automatically into the number of whole shares of common stock equal to the number of issued and outstanding shares of common stock held by such stockholder immediately prior to the reverse stock split, divided by four, subject to rounding of fractional shares. The Company expects that the reverse stock split will be reflected in the trading price of the common stock after the Financial Industry Regulatory Authority, Inc. (“FINRA”) completes its processing of the reverse stock split, which is expected to be the date on which the common stock is listed on the Nasdaq Capital Market tier operated by Nasdaq in the event that the Company’s listing application to Nasdaq is approved.
As a result of the reverse stock split, there are approximately shares of common stock outstanding, not including the shares of common stock included in the units that the Company expects to issue in this public offering or upon any exercise of the Over-Allotment Option or of any warrants included in the units issued to investors or of the representative’s warrant. No fractional shares have been or will be issued, and no cash or other consideration has been or will be paid. Instead, the Company issued one whole share of the post-reverse stock split common stock to any stockholder who otherwise would have received a fractional share as a result of the reverse stock split. The Company’s existing shareholders’ percentage ownership interests in the Company remains the same following the reverse stock split (subject to rounding of fractional shares).
As of September 30, 2022, and December 31, 2021,2023, there were and(December 31, 2022 - ) shares of common stock issued and outstanding, respectively. outstanding.
During the nine months ended September 30, 2022,2023, the Company issued shares of common stock for exercise of warrants.completed the following issuances:
| ● | The Company issued shares of common stock to Nicholas DeVito as part of the Confidential Settlement Agreement, dated November 18, 2022 (see Note 10). | |
| ● | The Company issued shares of common stock on exercise of warrants granted as part of the Somahlution acquisition, completed on July 30, 2020. | |
| ● | The Company issued shares to Mr. Frank Maresca in order to reimburse Mr. Maresca for the shares of Common Stock that were previously cancelled. | |
| ● | The Company issued shares on conversion of the debt (see Note 7). | |
| ● | The Company issued shares to Mr. Richmond in order to reimburse Mr. Richmond for the shares of Common Stock that were cancelled in previous years. | |
| ● | The Company settled trade payables of $100,000 through issuance of shares. The common shares were valued at $180,000, resulting in a loss of $80,000 on settlement of debt. |
c) Options
| c) | Options |
On May 18, 2021, the Company’s Board of Directors approved the Marizyme, Inc. Amended and Restated 2021 Stock Incentive Plan (“SIP”). The SIP incorporates stock options issued prior to May 18, 2021. The SIP authorized options for issuance. On December 27, 2022, the Board of Directors requested that stockholders ratify an amendment to the SIP to increase the maximum number of shares of common stock available for issuance pursuant to awards granted under the SIP by to , which was approved by the stockholders. As of September 30, 2022,2023, there remains options available for issuance.issuance (December 31, 2022 – ).
During the three and nine months ended September 30, 2022,2023, the Company granted (December 31, 20212022 – ) share purchase options to directors of the Company.
SCHEDULE OF STOCK OPTION ACTIVITY
| Number of Options | Weighted Average Exercise Price | Weighted Average Contractual Life | Total Intrinsic Value | Number of Options | Weighted Average Exercise Price | Weighted Average Contractual Life | Total Intrinsic Value | |||||||||||||||||||||||||
| Outstanding at December 31, 2020 | 3,800,943 | $ | 1.36 | |||||||||||||||||||||||||||||
| Granted | 1,532,500 | 1.51 | ||||||||||||||||||||||||||||||
| Forfeited | (1,682,500 | ) | 1.36 | |||||||||||||||||||||||||||||
| Outstanding at December 31, 2021 | 3,650,943 | $ | 1.24 | $ | 1,951,117 | 3,650,943 | $ | 1.24 | ||||||||||||||||||||||||
| Granted | 400,000 | 2.20 | - | 400,000 | 2.20 | |||||||||||||||||||||||||||
| Expired | (62,502 | ) | 1.25 | - | (62,502 | ) | 1.25 | |||||||||||||||||||||||||
| Forfeited | (62,498 | ) | 1.25 | - | (62,498 | ) | 1.25 | |||||||||||||||||||||||||
| Outstanding at September 30, 2022 | 3,925,943 | 1.33 | 2,344,489 | |||||||||||||||||||||||||||||
| Exercisable at September 30, 2022 | 3,050,664 | $ | 1.17 | $ | 2,256,558 | |||||||||||||||||||||||||||
| Outstanding at December 31, 2022 | 3,925,943 | $ | 1.33 | $ | - | |||||||||||||||||||||||||||
| Granted/forfeited | - | - | - | - | ||||||||||||||||||||||||||||
| Outstanding at September 30, 2023 | 3,925,943 | 1.33 | ||||||||||||||||||||||||||||||
| Exercisable at September 30, 2023 | 3,582,886 | $ | 1.28 | $ | - | |||||||||||||||||||||||||||
SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE
| Exercise Price | Exercise Price | Number of Options Outstanding | Number of Options Exercisable | Weighted Average Remaining Contractual Years | Intrinsic Value | Exercise Price | Number of Options Outstanding | Number of Options Exercisable | Weighted Average Remaining Contractual Years | Intrinsic Value | ||||||||||||||||||||||||||
| $ | 1.01 | 1,985,943 | 1,985,943 | $ | 1,767,489 | 1.01 | 1,985,943 | 1,985,943 | $ | - | ||||||||||||||||||||||||||
| 1.25 | 540,000 | 524,721 | 351,000 | 1.25 | 540,000 | 536,943 | - | |||||||||||||||||||||||||||||
| 1.37 | 200,000 | 200,000 | 106,000 | 1.37 | 200,000 | 200,000 | - | |||||||||||||||||||||||||||||
| 1.75 | 800,000 | 280,000 | 120,000 | 1.75 | 800,000 | 600,000 | - | |||||||||||||||||||||||||||||
| 2.20 | 400,000 | 60,000 | - | 2.20 | 400,000 | 260,000 | - | |||||||||||||||||||||||||||||
| $ | 1.33 | 3,925,943 | 3,050,664 | $ | 2,344,489 | 1.33 | 3,925,943 | 3,582,886 | - | |||||||||||||||||||||||||||
d) Restricted Share Units
As of September 30, 2022, the Company determined that the following performance condition attached to the restricted share awards granted in the fiscal 2021 were more likely than not to have been achieved:
| 19 |
| d) | ||
Therefore, compensationDuring the year ended December 31, 2021, the Company granted restricted share awards for an aggregate of shares of common stock to directors, senior officers and consultants of the Company, with underlying performance conditions. As of September 30, 2023, only two out of four performance conditions have been achieved. Compensation cost of $295,750Nil for the restricted share awards was recognized in stock-based compensation for the three and nine months ended September 30, 20222023 (September 30, 20212022 - $Nil) and $295,750, respectively).
| Warrants |
e) Warrants
As of September 30, 20222023 and December 31, 2021,2022, there were 20,969,751575,466,865 and 12,144,83820,048,487 warrants outstanding, respectively.
SCHEDULE OF WARRANTS OUTSTANDING
| Number | Weighted Average Price | Number | Weighted Average Price | |||||||||||||
| December 31, 2020 | 3,393,651 | $ | 4.63 | |||||||||||||
| Issued pursuant to Unit Purchase Agreement | 8,521,187 | 2.25 | ||||||||||||||
| Issued | 230,000 | 1.39 | ||||||||||||||
| December 31, 2021 | 12,144,838 | $ | 2.90 | |||||||||||||
| Balance, December 31, 2021 | 12,144,834 | $ | 2.90 | |||||||||||||
| Issued pursuant to Unit Purchase Agreement | 8,360,152 | 2.25 | 8,360,147 | 2.25 | ||||||||||||
| Issued | 878,398 | 1.16 | 878,398 | 1.16 | ||||||||||||
| Exercised | (300,000 | ) | 0.01 | (300,000 | ) | 0.01 | ||||||||||
| Expired | (113,637 | ) | 3.00 | (113,637 | ) | 3.00 | ||||||||||
| September 30, 2022 | 20,969,751 | $ | 2.61 | |||||||||||||
| Cancelled pursuant to FINRA | (578,398 | ) | 1.75 | |||||||||||||
| Cancelled as part of debt extinguishment | (342,857 | ) | 2.25 | |||||||||||||
| Balance, December 31, 2022 | 20,048,487 | $ | 2.64 | |||||||||||||
| Warrants modified pursuant to debt extinguishment (Note 7) | 355,577,447 | 0.10 | ||||||||||||||
| Issued pursuant to debt agreements (Note 7) | 162,962,773 | 0.15 | ||||||||||||||
| Issued pursuant to Hexin Promissory Note (Note 6) | 39,530,317 | 0.13 | ||||||||||||||
| Exercised | (2,652,159 | ) | 0.10 | |||||||||||||
| Balance, September 30, 2023 | 575,466,865 | $ | 0.12 | |||||||||||||
| ● | On April 13, 2023, the Company delivered offer letter agreements (the “Somahlution Warrant Offer Letter Agreements”) to the Former Somahlution Owners, which offered to allow the Former Somahlution Owners to exercise the Somahlution Warrants to purchase the number of restricted shares of common stock issuable under the Somahlution Warrants at an exercise price reduced by the Company from $5.00 per share to $0.10 per share, on or prior to April 21, 2023, for maximum total cash proceeds of $299,996. As of the conclusion of this offer period, four of the Former Somahlution Owners had entered into Somahlution Warrant Offer Letter Agreements and had exercised their Somahlution Warrants to purchase a total of shares of common stock for gross proceeds of approximately $265,216 (the “Somahlution Warrants Exercise”). |
DuringAs a result of this warrant exercise, pursuant to the nine months ended September 30, 2022,terms applicable to the Convertible Notes and the Class C Warrants (see Note 7), the conversion price of the Convertible Notes adjusted from $1.75 per share to $0.10 per share, the exercise price of the Class C Warrants adjusted from $2.25 per share to $0.10 per share, and the number of shares that the Class C Warrants may be exercised to purchase was increased proportionately. In connection with these developments and the lack of sufficient authorized shares of common stock under the Company’s articles of incorporation to meet its obligations under outstanding convertible or exercisable securities, the Company issuedalso obtained additional conversion and exercise rights waivers from Convertible Note and Class C Warrant holders. As a result of these adjustment provisions and the following:conversion and exercise terms applicable to the Class C Warrants, including the effect of the applicable waivers, the number of shares that the Class C Warrants may be exercised to purchase adjusted from shares of common stock to 114,973,110 shares.
| ● | Concurrently with the issuance of Replacement Placement Agent Notes (see Note 7), the Company issued to Univest and Mr. Richmond Class C Warrants (the “Replacement Placement Agent Class C Warrants”), such that up to and shares of common stock, respectively, are issuable upon exercise thereof. Additionally, to compensate Univest and Mr. Richmond for the cancelled in previous years securities, the Company issued to Univest and Mr. Richmond Placement Agent Warrants (the “Replacement Placement Agent Warrants”), such that up to and shares of common stock are issuable upon exercise thereof, respectively. The Replacement Placement Agent Warrants were fair valued at $259,619 and $389,429, respectively, and recorded in other general and administrative expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023. |
On January 26 and February 14, 2022, in exchange for services of Mr. Richmond, the Company granted him warrants to purchase an aggregate shares of Marizyme’s common stock at an exercise price of $0.01 per share. The warrants issued had an average term of 5 years, vested immediately, and were fair valued at $568,677 and recorded in salary expense in the condensed consolidated statements of operations for the nine months ended September 30, 2022. On March 15, 2022, Mr. Richmond exercised warrants issued to him.
| ● | From May 2023 and through to September 2023, the Company issued OID Convertible Notes for aggregate principal of $6,163,697 and convertible into up to shares of common stock not including shares convertible from interest under the Convertible Notes, Class E Warrants exercisable for the purchase of 77,046,194 shares of common stock at $0.10 per share, and Class F Warrants for the purchase of 77,046,194 shares of common stock at $0.20 per share. The OID Convertible Notes, Class E Warrants and Class F Warrants will not be convertible or exercisable until the Capital Event Amendment becomes effective. As described in Note 7, Class E and Class F warrants were accounted for as a liability, were fair valued at an aggregate amount of $25,555,092 and were recorded as a short-term derivative liability on the condensed consolidated balance sheets at September 30, 2023. |
| 20 |
| ● | Pursuant to the Hexin Promissory Note (see Note 6), on May 22, 2023, the Company issued Hexin a Class E Warrant that may be exercised to purchase 7,500,000 shares of common stock for $0.10 per share, and a Class F Warrant that may be exercised to purchase 3,750,000 shares of common stock for $0.20 per share (collectively, the “Hexin Warrants”). The Hexin Warrants will be exercisable in accordance with the exercise terms and conditions of the other Class E and Class F Warrants described above (see Note 7). The warrants issued had an average term of 5 years, vested immediately, and were fair valued at $1,333,127 and were recorded in other general and administrative expenses in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023. |
| ● | The Company agreed to issue Placement Agent Warrants (the “OID Units Placement Agent Warrants”) to Univest and/or its designee(s) at each closing of the OID Units Private Placement. The required OID Units Placement Agent Warrants will consist of Placement Agent Warrants for the purchase of 8% of the aggregate number of shares of common stock initially issuable upon conversion of the OID Convertible Notes, 8% of the aggregate number of shares of common stock initially issuable upon exercise of the Class E Warrants at $0.10 per share, and 8% of the aggregate number of shares of common stock initially issuable upon exercise of the Class F Warrants at $0.20 per share, subject to adjustment. Univest notified the Company that the Company would be permitted to defer the issuance of the OID Units Placement Agent Warrants until the final closing of the OID Units Private Placement. Under the terms of the OID Units Placement Agent Warrants, such warrants will be exercisable from the date of issuance until August 16, 2028. In the nine months ended September 30, 2023, the Company issued Class E and Class F warrants, which were fair valued at $1,316,003 and $624,670, respectively, and recorded in other general and administrative expenses in the Statement of Operations for the three and nine months ended September 30, 2023. |
On June 26, 2022, the Company issued additional 347,039 warrants to Mr. Richmond and 231,359 warrants to Univest Securities, LLC to purchase an aggregate shares of Marizyme’s common stock at an exercise price of $1.75 per share. The warrants issued had an average term of 5 years, vested immediately, and were fair valued at $1,281,854, of which $769,113 was recorded in salary expense and $512,471 in professional fees in the condensed consolidated statements of operations for the nine months ended September 30, 2022.
| f) | Stock-based compensation |
In the nine months ended September 30, 2022, pursuant to the Unit Purchase Agreement the Company issued an aggregate of 8,360,152 additional New Class C warrants with an exercise price of $2.25 share and a term of five years.
f) Stock-based compensation
During the three and nine months ended September 30, 2022,2023, the Company recorded $ and $ in non-cash share-based compensation, respectively (September 30, 2022 - $ and $ in non-cash share-based compensation in the stock-based compensation line on the condensed consolidated statements of operations, respectively (September 30, 2021 - $ and $, respectively). As of September 30, 2022, there was $ of total unrecognized compensation cost related to non-vested stock-based compensation awards. The unrecognized compensation cost is expected to be recognized over a weighted average period of years.
NOTE 9 – RELATED PARTY TRANSACTIONS
As at September 30, 2022,2023, the Company owed an aggregate of $123,266187,097 (December 31, 20212022 - $1,132,634Nil) to related parties of the Company. The majority of the balance was owed to Mr. Frank Maresca, a related party and shareholder of the Company, and comprised of the following:
For the three and |
In the nine months ended September 30, 2022,2023, the Company incurred and settled additional $133,79772,000 and $216,000, respectively (September 30, 2022 -$43,000 and $129,600, respectively), in professional servicesservice rendered by related parties of the Company and incurred and settled $149,178216,000 of various expenses incurred by these parties in relation to their services rendered to the Company. The services were provided by entities which are controlled by management and are pursuant to various consulting agreements.
During the three and nine months ended September 30, 2023, the Company also incurred $332,750 and $998,250 in compensation to Directors and Executive Officers for their services rendered, respectively (September 30, 2022 – $328,083 and $815,583, respectively), and settled $65,750 and $947,250 in compensation, respectively.
Additionally, as part of the SomahSomahlution acquisition in 2020, the Company recorded a prepaid royalty to the shareholders of Somahlution. The former primary beneficial owner is Dr. Vithal Dhaduk, currently a director, and significant shareholder of the Company. During the three and nine months ended September 30, 2023, the Company accrued $10,854 and $58,102 in royalties payable incurred on sales of the DuraGraft product outside of the U.S., respectively. This amount was offset against the prepaid royalty receivable.
During the nine months ended September 30, 2023, the Company and shareholders of Somahlution agreed to reduce the prepaid royalty balance by 50% or by $151,000. As at September 30, 2022,2023, the Company had $339,091129,989 in prepaid royalties (December 31, 20212022 - $339,091) which had been classified as non-current in the condensed consolidated balance sheets.
NOTE 10 – COMMITMENTS AND CONTINGENCIES
Legal Matters
On August 19, 2021, Dr. Neil Campbell, former President, Chief Executive Officer and director ofUnder a Confidential Settlement Agreement, dated November 18, 2022, the Company and Bruce Harmon, former Chief Financial Officer and SecretaryNicholas DeVito agreed that Mr. DeVito would dismiss a Complaint that Mr. DeVito filed on June 7, 2022 in the Circuit Court of the Company, each filed a ComplaintFifteenth Judicial Circuit in and Demand for Jury Trial against the Company and Insperity Peo Services, L.P., a Delaware limited partnership (“Insperity”), a joint employer of Dr. Campbell and Mr. Harmon with the Company under a Client Service Agreement, dated November 30, 2020 (collectively, the “Campbell/Harmon Complaints”). Both Campbell/Harmon Complaints allegePalm Beach County, Florida, Case No. 50-2022-CA-005437. The parties also agreed that the Company and Insperity violated Section 448.105 of the Florida Private Whistleblower Act as a result of the constructive terminations of Dr. Campbell and Mr. Harmon after the occurrence of violations federal and state law, including federal securities law, at the Company that exposed Dr. Campbell and Mr. Harmon to civil and criminal forms of liability and thatfollowing an anticipated reverse split, the Company was not addressingrequired to their satisfaction. Both Campbell/Harmon Complaints demand approximately $issue Mr. DeVito - $50,000“post-split” shares to be delivered in back paypaper certificate form within three (3) business days of the reverse split. The settlement agreement further provided that the delivered shares would be subject to normal and benefits, interest on back pay, front pay and/or lost earning capacity, compensatory damages, costs and attorney’s fees, and such other relief ascustomary restrictions pursuant to Rule 144 of the court deems equitable.SEC. In the nine months ended September 30,event no split occurred by December 12, 2022, both cases were dismissed with prejudicethe Company was required to issue Mr. DeVito “pre-split” shares. In addition, the parties agreed that no further continuous service is required pursuant to Section 2 of the Mutual Release of Claims Agreement between Mr. DeVito and without any financial impactthe Company dated as of August 27, 2020. Pursuant to the agreement, on January 5, 2023, the Company.Company issued shares of common stock to Mr. DeVito (see Note 8b).
Contingencies
| a. | On July 13, 2019, the Company signed a consulting agreement, whereby the individual will receive: |
| ● | $30,000 per month through July 13, | |
| ● | Option to purchase shares of common stock at a strike price of $, which vest monthly through July 13, 2021. The vesting of these options was accelerated by the Board on September 2, 2020. | |
| ● | Royalties based on sales of Krillase assets, equal to 10% of net sales of the product. During the nine months ended September 30, |
| b. | As part of the DuraGraft Acquisition, completed on July 31, 2020, the Company entered into the Agreement with |
Royalties on U.S. sales equal to:
| ● | 5% on the first $50,000,000 of net sales, | |
| ● | 4% on net sales of $50,000,001 up to $200,000,000, and | |
| ● | 2% on net sales over $200,000,000. |
Royalties on sales outside of the U.S.:
| ● | 6% on the first $50,000,000 of net sales, | |
| ● | 4% on net sales of $50,000,001 up to $200,000,000, and | |
| ● | 2% on net sales over $200,000,000. |
The royalties are in perpetuity. During the three and nine months ended September 30, 2022,2023, the Company had not earned any revenues from Krillase, andhowever the Company did not have anyincur sales of the DuraGraft products inoutside of the U.S., therefore noon which $10,854 and $58,102 in royalties have been accrued or paid inand offset against the period.prepaid royalties receivable, respectively (see Note 9).
Upon receiving FDA clearance for the DuragraftDuraGraft product and insurance reimbursement approval on the products pursuant to section 2(b) of the Asset Purchase Agreement dated December 15, 2019, the Company will:
| ● | Issue performance warrants with a strike price determined based on the average of the closing prices of the Company’s common stock for the 30 calendar days following the date of the public announcement of the FDA approval; and | |
| ● | Upon liquidation of all or substantially all of the assets relating to DuraGraft, the Company will pay 15% of the net sale proceeds up to $20 million. |
| c. | The Company has entered into arrangements for office and laboratories spaces. As of September 30, |
Risks and Uncertainties
Starting in late 2019, a novel strain of the coronavirus, or COVID-19, began to rapidly spread around the world and every state in the United States. At this time, there continues to be significant volatility and uncertainty relating to the full extent to which the COVID-19 pandemic and the various responses to it will impact the Company’s business, operations and financial results.
Most states and cities have at various times instituted quarantines, restrictions on travel, “stay at home” rules, social distancing measures and restrictions on the types of businesses that could continue to operate, as well as guidance in response to the pandemic and the need to contain it. As a result, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, including such authorities in Europe, which could result in delays of reviews and approvals. While there have been no specific notices of delay from federal or foreign government authorities, potential interruptions, delays, or changes to the operations of the FDA, or of any foreign authority with which the Company might interact, might impact the approval of any applications the Company plans and will need to file in the future.
In addition, the Company is dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill orders is critical to our business success. The COVID-19 pandemic has impacted and may continue to impact certain manufacturers and suppliers. As a result, the Company has have faced and may continue to face delays or difficulty sourcing certain products, which could negatively affect its business and financial results.
The spread of COVID-19 has also adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The pandemic has resulted, and may continue to result, in a significant disruption of global financial markets, which may reduce the Company’s ability to access capital in the future, which could negatively affect its liquidity.
If the COVID-19 pandemic does not continue to slow and the spread of COVID-19 is not contained, the Company’s business operations, including those of contract manufacturers, could be further delayed or interrupted. The duration of any business disruption cannot be reasonably estimated at this time but may materially affect the Company’s ability to operate its business and result in additional costs. It is not possible to reliably measure or quantify the impact COVID-19 has had on the financial results of the Company. If the COVID-19 pandemic continues for an extended period, it may materially adversely impact business operations and, consequently, future financial results.
NOTE 11 - SUBSEQUENT EVENTSEVENT
The Financial Industry Regulatory Authority, Inc. (“FINRA”) Staff has determined that certain securities previously received by each of Univest Securities, LLC (“Univest”) and Bradley Richmond, a registered representative of Univest, in connection with the following transactions withIn October 2023, the Company constituted underwriting compensationwas granted a De Novo – U.S. Food and Drug Administration for its first-in-class product, DuraGraft. With the granting of this de novo, DuraGraft is the first and only medical product that is FDA cleared for use as an intra-operative vascular conduit storage and flushing solution during Coronary Artery Bypass Grafting or CABG surgeries and is also the only approved product available for this indication in connection with the Company’s anticipated public offering pursuant to FINRA Rule 5110, based on the FINRA Staff’s interpretation of such rule: (a) the Company’s Units Private Placement conducted between May 2021Europe and August 2022, (b) the My Health Logic acquisition, (c) a consulting agreement that the Company entered into with Mr. Richmond in September 2020, and (d) a stock option exercisable for shares of common stock received by Mr. Richmond from one of the Company’s former executives in March 2022. Consequently, each of Univest and Mr. Richmond, pursuant to a letter agreement entered into with the Company (the “October 2022 Letter Agreement”), has agreed to forego their rights, to an aggregate of shares of common stock beneficially owned by them collectively (including shares of common stock and shares of common stock issuable upon exercise and conversion of warrants, convertible notes and a stock option), which were issued pursuant to the transactions listed above, not accept the receipt of the aforementioned securities or undo or dispose of the aforementioned securities. Pursuant to the October 2022 Letter Agreement, the parties thereto agreed that the cancellation or disposal of the aforementioned securities shall be without recourse by either Univest or Mr. Richmond.
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This discussion covers the three months and nine months ended September 30, 20222023 and the subsequent period up to the date of issuance of this Quarterly Report on Form 10-Q. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited interim financial statements and notes thereto included in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 20212022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2021 (“20212022 (the “2022 Form 10-K”).
FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended.amended (the “Exchange Act”). Forward-looking statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, research and development plans and costs, the impact of COVID-19, the timing and likelihood of regulatory filings and approvals, commercialization plans, pricing and reimbursement, the potential to develop future product candidates, the timing and likelihood of success of the plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in the Part II, Item 1A under the heading “Risk Factors.“Risk Factors.” The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
TRADEMARKS, TRADE NAMES AND SERVICE MARKS
We use various trademarks, trade names and service marks in our business. For convenience or readability, we may not include the ℠, ® or ™ symbols, but such omission is not meant to indicate that we would not protect our intellectual property rights to the fullest extent allowed by law. Any other trademarks, trade names or service marks referred to in this report are the property of their respective owners.
OVERVIEW
Marizyme is a multi-technology biomedicalmedical technology company dedicatedseeking to change the acceleratedlandscape of cardiac care by delivering innovative solutions for coronary artery bypass, or CABG, surgery.
We are focused on commercializing or developing three medical technologies and related products – DuraGraft®, MATLOC® and MAR-FG-001. DuraGraft is a first-in- class De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during CABG surgeries. MATLOC is a point-of-care, lab-on-chip digital screening and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment. MAR-FG-001 is a technology in development for use in fat grafting procedures formulated as a tumescent solution base for protecting adipose tissue during adipose tissue harvesting and storage. DuraGraft, MATLOC and MAR-FG-001 are expected to serve an unmet significant market need in several areas, including, cardiac surgery, CKD assessment, and fat grafting.
| 23 |
Since October 2023, DuraGraft has been authorized for marketing by the U.S. Food and Drug Administration, or FDA, for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries in the United States, subject to applicable risks, mitigation requirements, and control provisions. Since August 2014, DuraGraft has also had the CE marking required to be sold in the EEA, and DuraGraft has therefore been assessed as meeting the EEA safety, health, and environmental protection requirements.
We intend to continue the advancement of our other two primary product technologies, MATLOC and MAR-FG-001. Our MATLOC CKD point-of-care device is being developed toward a functional prototype, mainly through the development of its lab-on-chip technology under a Sponsored Research Agreement, or SRA. An SRA is an agreement (which may be classified as a grant, contract or cooperative agreement) under which one party (the “Sponsor”) provides funding to a second party to support the performance of a specified research project or related activity. The Sponsor may be a foundation, government agency, for-profit entity, research institute, or another university. We will also continue to ready MAR-FG-001 for viability for development and commercializationmanufacturing. We intend to fully develop and market MAR-FG-001 in the U.S. for fat grafting for procedures such as plastic and cosmetic surgery.
In the near term, we expect to generate revenue primarily from the sale of DuraGraft through the expansion of our international marketing efforts by our distribution partners in Europe and in other countries that accept CE marking.
We intend to commercialize DuraGraft in the U.S. primarily through hospital integrated networks using our own direct sales force. We anticipate that once we commence marketing and sales operations for DuraGraft in the U.S., we will be able to generate sustainable revenue growth, accelerate the development of a functional MATLOC device prototype, and expedite the development of MAR-FG-001 into medical device technologies that improve patient health outcomes.products.
Key elements of our strategy include:
| ● | ||
| ● | Develop MATLOC technology and related products. We intend to continue the development of MATLOC toward a functional device prototype. |
We have incurred losses for each period from inception.
| ● | Develop MAR-FG-001 fat grafting technology and related products. We intend to continue the development of MAR-FG-001 to validate its protective abilities and its improvements to the retention of fat volume. |
| ● | Acquire more life science assets. We intend to continue to expand our product portfolio through the identification and acquisition of additional life science assets. |
| 24 |
Our net loss was approximately $1.6 $32.5 million and $14.6$55.6 million for the three and nine months ended September 30, 2023, respectively (September 30, 2022 respectively ($1.6- $1.6 million and $5.5$14.6 million, forrespectively). During the three and nine monthmonths ended September 30, 2021, respectively). 2023 and 2022, we used approximately $3.5 millionand $9.3 millionin operating activities, respectively, and financing activities provided approximately $3.4 millionand $6.4 million, respectively. We expect to incur significant expenses and operating losses over the next several years. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity offerings, debt financings, government or other third-party funding, collaborations and licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would impact our going concern and would have a negative impact on our financial condition and our ability to pursue our business strategy and continue as a going concern. We will need to generate significant revenues to achieve profitability, and we may never do so.
Our Products
DuraGraft®Impact of COVID-19 Pandemic
Through our acquisitionThe Company has been impacted by the COVID-19 pandemic and related supply chain shortages and other economic conditions, and some of its earlier plans to diversify and expand its operations were delayed as a result. Moreover, the impact of the Somah assets in July 2020,COVID-19 pandemic on the Company’s supply chain and its ability to produce DuraGraft inventory was a primary reason that we acquired key intellectual products based on a patent protected cytoprotective platform technology designed to reduce ischemic injury to organsdid not generate substantial revenue from sales of DuraGraft during 2021 and tissues in grafting and transplantation surgeries. These assets include DuraGraft, a one-time intraoperative vascular graft treatment, that is able to protect endothelial cells from ischemic damage and reperfusion injury, and reduce complications associated with Vein Graft Failure, or VGF, post-CABG, thereby reducing major adverse cardiac events such as repeat revascularization and myocardial infarction, reducing incidence and complications of graft failure, and improving clinical outcomes.2022.
The Company’s inventory production of DuraGraft is an endothelial damage inhibitor, or EDI, indicated for cardiac bypass, peripheral bypass,returned to its pre-pandemic level at the end of the second quarter of 2022. There can be no assurance that future supply chain disruptions and other vascular surgeries. It carries CE marking and is approved for marketing in 18 countries worldwide on three continents including, but not limited to, the European Union countries, such as Spain, Austria, and Germany, Switzerland, Philippines, Chile, and Turkey. Somah had also been focused on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries and other indications in which ischemic injury can cause disease. Now, underCOVID-19 outbreaks will not adversely impact our ownership, multiple products derived from the cytoprotective platform technology for several indications are under various stages of development.
According to market analysis reports, the size of the coronary artery bypass graft (“CABG”) procedures market globally was approximately $16.7 billion as of 2020 (Expert Markets Research, 2020). This market is forecast to increase at a compound annual growth rate (“CAGR”) of 2.5% between 2021 and 2026 (Expert Markets Research, 2020). Globally, it is estimated that approximately 800,000 CABG procedures are performed each year (Grand View Research, March 2017), with procedures performed in the U.S. being a substantial percentage of the total global procedures performed. In the U.S., it is estimated that approximately 340,000 CABG surgeries are performed each year. The number of CABG procedures performed is predicted to decline at a rate of approximately 0.8% per year to less than 330,000 annually by 2026, primarily due to medical and technological advances in the use of percutaneous coronary intervention, also known as “angioplasty” (idata Research, September 2018).revenues.
In 2020,addition, the U.S. peripheral vascular device market size was valued at $7.1 billion, with over 8.26 million peripheral vascular procedures performed each year with an expected market sizeCompany is dependent upon certain contract manufacturers and suppliers and their ability to reliably and efficiently fulfill its orders is critical to the Company’s business success. The COVID-19 pandemic has impacted and may continue to impact certain of $10.4 billion by 2026. The vascular device market size globally was valued at $11.9 billion in 2020 with more than 16 million yearly peripheral vascular procedures performed. The market size is expectedthe Company’s manufacturers and suppliers. As a result, the Company has faced and may continue to increase at a CAGR of 5.2%face delays or difficulty sourcing certain products, which could negatively affect the Company’s business and reach $16.9 billion in 2026. (idata Research, 2020).financial results.
For 2022,While it is not possible at this time to estimate the total impact that COVID-19 could have on our main business priority is applying for FDA clearance of DuraGraft for CABG procedures through a De Novo classification request. We also plan to finalize the development of fat grafting procedures using DuraGraft for plastic surgery procedures in the U.S. It is reported that 22.4 million such surgeries take place annuallyfuture, the continued spread of COVID-19 and variants of the virus, the rate of vaccinations regionally and globally and the measures taken by the government authorities, and any future epidemic disease outbreaks, could: Disrupt the supply chain and the manufacture or shipment of products and supplies for use by us in our research activities and by strategic partners for their distribution and sales activities; delay, limit or prevent us in our research activities and strategic partners in their distribution and sales activities; impede our negotiations with strategic partners; impede testing, monitoring, data collection and analysis and other related activities by us; interrupt or delay the U.S. (American Societyoperations of Plastic Surgeons, 2020).
Following the FDA or other regulatory authorities, which may impact review and approval timelines for initiation of DuraGraft,clinical trials or marketing; or impede the launch or commercialization of any approved products; any of which we expect to obtain in 2023, we will seek to commercialize DuraGraft in the U.S. through the assistance ofcould delay our strategic partnership plans, increase our operating costs, and have a strategic partner who will be responsible for marketing and sales. We will continue our DuraGraft marketing efforts in Europe relyingmaterial adverse effect on our DuraGraft CE markingbusiness, financial condition and our distribution partners. We also intend to develop additional applications for the U.S. marketplace including, but not limited to, fat grafting for plastic surgery. The CE marking signifies that DuraGraft may be sold in the EEA and that DuraGraft has been assessed as meeting safety, health, and environmental protection requirements. We intend to strive for rapid revenue growth using multiple strategic partners and revenue channels. We expect that we will market DuraGraft internationally, through multiple distribution partners with a focus on sales to cardiac surgeons and cardiologists. We are currently working with local distributorsresults of cardiovascular disease-related products, in accordance with local regulatory requirements, to sell and increase the market share of DuraGraft in Spain, Austria, Switzerland, Philippines, Germany, Chile, and Turkey. In the U.S., we intend to enter into a commercialization arrangement with a strategic partner who will be responsible for the marketing and sales of DuraGraft. If we are not able to find an appropriate strategic partner, we will have to build our own marketing and sales capabilities which we expect would be time consuming and costly.operations.
MATLOC 1Principal Factors Affecting Our Financial Performance
Our operating results are primarily affected by the following factors:
On December 22, 2021, we acquired My Health Logic, its lab-on-chip technology platform and its patient-centric, digital point-of-care screening device, MATLOC 1.
| ● | our ability to generate revenue from sales of our products; |
The excitement over microfluidics, also known as lab-on-a-chip technology, lies in its potential for producing revolutionary, timely, accessible, and practical point-of-care devices; devices that are patient-centric (one-to-many, rather than doctor centric, one-to-one) and support self-care and independence. Microfluidics is a technology for analyzing small volumes of fluids, with the potential to miniaturize complex laboratory procedures onto a small microchip, hence the term “lab-on-chip”.
| ● | our ability to obtain FDA approval for our products; |
| ● | our ability to access additional capital and the size and timing of subsequent financings, if any; |
| ● | our ability to become listed on a national securities exchange; |
| ● | the costs of acquiring and utilizing data, technology, and/or intellectual property to successfully reach our goals and to remain competitive; |
| ● | personnel and facilities costs in any region in which we seek to introduce and market our products; |
| ● | the costs of sales, marketing, and customer acquisition; |
| ● | the average price for our products that will be paid by consumers; |
| ● | the number of our products ordered per quarter; |
Marizyme’s lab-on-chip technology is currently being developed for screening and diagnosis related to the three leading biomarkers for chronic kidney disease (CKD), a disease estimated to affect 37 million Americans – or one out of every seven people (National Kidney Foundation, 2019). If left untreated, many patients will advance to end stage renal disease (ESRD), often leading to kidney transplant, renal failure, or dialysis. Since 90% of those with CKD do not know they have it, the risk of progression in the disease is high and this creates massive burdens for CKD patients and healthcare systems (National Kidney Foundation, 2019). CKD and ESRD costs the U.S. public healthcare systems hundreds of billions of dollars a year. In 2018 Medicare alone spent $130 billion on CKD and ESRD-related costs (National Kidney Foundation, 2019). With the increase of diabetics and hypertension cases in the U.S., which make up roughly two-thirds of all CKD patients (National Kidney Foundation, 2022), CKD related healthcare costs are expected to increase significantly. Compounding this development is the fact that less than 50% of diabetic patients, the highest at-risk group, are annually screened or tested for CKD (Mayo Clinic Proceedings, 2021). This creates an unmet need for point-of-care technologies that facilitate CKD screening and diagnosis, which further facilitates earlier screening and diagnosis and detection to slow down or eliminate the CKD progression. By combining lab-on-chip technology with Marizyme’s MATLOC 1 device, it will be able to quantitatively read the two urine biomarkers, albumin and creatine, necessary for effective CKD screening at point-of-care with results available instantly on a patient’s smartphone.
| ● | costs to manufacture our products; |
MATLOC 2, the Company’s next-generation point-of-care device in development, is designed to provide a fully integrated, quantitative diagnostic assessment of estimated glomerular filtration rate, or eGFR, using a blood-based biomarker. eGFR is a key measure of kidney function health and/or stage of kidney disease and our MATLOC 2 device is designed to provide a fully integrated, complete diagnostic assessment for CKD, potentially eliminating the need for lab visits and in-person assessment.
| ● | the costs of compliance with any unforeseen regulatory obstacles or governmental mandates in any states or countries in which we seek to operate; and |
The COVID-19 pandemic has accelerated the ongoing transformation in healthcare. Connected consumer electronic devices are enabling 24/7 home-based digital healthcare. We believe that consumers have the desire and are now becoming empowered to manage their own healthcare and that they will seek to utilize our point-of-care MATLOC 1 device.
With our lab-on-chip technology and MATLOC 1 device in development, we are striving to achieve earlier detection and slowing of the progression of CKD, allowing patients and healthcare systems to reduce the enormous costs of kidney failure, transplant, and/or dialysis. After completing the technology for CKD assessment, we plan to explore the commercial potential of other biomarkers for chronic diseases to be measured at point-of-care.
MATLOC 1, upon FDA approval, which we anticipate but cannot guarantee, is expected to be marketed and sold through an experienced medical device distribution partner network with a focus on nephrologists in hospitals, ambulatory surgery centers and private practices, to better assess patients and slow the progression of CKD.
| ● | the costs of any additional clinical studies which are deemed necessary for us to remain viable and competitive in any region of the world. |
KrillaseSmaller Reporting Company
Through our acquisition of ACB Holding AB in 2018, we acquired the Krillase technology, a protease therapeutic platform originally researched and evaluated in the European Union that has the potential for use in the treatment of chronic wounds and burns, and other clinical applications.
Krillase, derived from Antarctic krill, shrimp-like crustaceans, is a combination of endo- and exopeptidases that safely and efficiently breaks down organic material. As a “biochemical knife,” Krillase can potentially break down organic matter, such as necrotic tissue, thrombogenic material, and biofilms produced by microorganisms. As such, it may be useful in the mitigation or treatment of multiple disease states in humans. For example, Krillase may promote faster healing, support the grafting of skin for the treatment of chronic wounds and burns, and reduce bacterial biofilms associated with poor oral health in humans and animals.
We are currently focused on developing a Krillase-based product for“smaller reporting company” as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the dissolvinglast day of plaque and biofilms on teeth for the pet health dental market. In addition, our Krillase platform team is planning a pet health study, and we expect thatfiscal year in which (1) the results of this study may enable us to introduce our Krillase products into the pet health market in the United States. We believe that the U.S. pet health market presents a substantial opportunity for the marketingvalue of our Krillase products. We expect to establish the first stream of revenue from the sale of Krillase-based pet health products in 2023.
Our strategic plan for Krillase is, first, to leverage and maximize near-term revenue generating opportunities with Krillase products for commercialshares held by non-affiliates equals or clinical applications with low regulatory risk, suchexceeds $250 million as in the pet health market, and second, to develop products for applications of the Krillase platform that address unmet medical needsprior June 30th, or address medical(2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market needs better than existing products in the marketplace, in clinical applications with higher regulatory risk but significant commercial potential.
Our Competitive Strengths
We believe that the following competitive strengths will enable us to compete effectively:
Our Growth Strategies
We will strive to grow our business by pursuing the following key growth strategies:
The strategic plans described above will require capital. We expect to raise a substantial portion of the required capital in our planned future offerings. There can be no assurances, however, that we will be able to raise the capital that we need to execute our plans or that capital, whether through securities offerings, either private or public, will be available to us on acceptable terms, if at all. An inability to raise sufficient funds could cause us to scale back our development and growth plans or discontinue them altogether.
KEY HIGHLIGHTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBERprior June 30 2022
Financing
In 2021 and 2022, the Company offered units (the “Units Offering”) comprised of convertible notes and warrants, with the intent to raise up to $17,000,000 on a rolling basis. In late 2021, due to the Company’s continuous growth and need for additional capital to sustain its operations and progress towards its goals, the Company amended certain terms and conditions of the Units Offering. As a result:
In aggregate, the Company received $14.8 million in proceeds from the units private placement th. The proceeds from the Units Offering were used to settle certain debt obligations and will be used to sustain the Company’s growth and meet its capital obligations.
Reverse Stock Split
On August 1, 2022, the Board of Directors (the “Board”) of Marizyme approved a reverse stock split of the Company’s authorized and outstanding common stock at a ratio of 1-for-4. On August 3, 2022, the Company effected the reverse stock split by filing a Certificate of Change with the Secretary of State of the State of Nevada. As a result, the total number of shares of common stock held by each stockholder was converted automatically into the number of whole shares of common stock equal to the number of issued and outstanding shares of common stock held by such stockholder immediately prior to the reverse stock split, divided by four, subject to rounding of fractional shares. The Company expects that the reverse stock split will be reflected in the trading price of the common stock after the Financial Industry Regulatory Authority, Inc. (“FINRA”) completes its processing of the reverse stock split, which is expected to be the date on which the common stock is listed on the Nasdaq Capital Market tier operated by Nasdaq in the event that the Company’s listing application to Nasdaq is approved.
As a result of the reverse stock split, there are approximately 10,207,212 shares of common stock outstanding, not including the shares of common stock included in the units that the Company expects to issue in this public offering or upon any exercise of the Over-Allotment Option or of any warrants included in the units issued to investors or of the representative’s warrant. No fractional shares have been or will be issued, and no cash or other consideration has been or will be paid. Instead, the Company issued one whole share of the post-reverse stock split common stock to any stockholder who otherwise would have received a fractional share as a result of the reverse stock split. The Company’s existing shareholders’ percentage ownership interests in the Company remains the same following the reverse stock split (subject to rounding of fractional shares).
As of November 14, 2022, the approval from Nasdaq is still pending and FINRA has not yet completed the processing of the reverse stock split for purposes of the trading price of the common stock.
Operational
In 2021 Marizyme undertook a corporate restructuring, whereby the key officers, directors, and management team changed in order to accelerate Company’s progress toward meeting its key objectives and deliver on its strategy. In the nine months ended September 30, 2022, the executive and management team was focused on meeting and delivering on the Company’s objectives to commercialize its products and advance in its search for more life science assets. Additionally, the Board of Directors of the Company was increased to seven members and a new Chair of the Audit Committee was elected.
FINANCIAL OPERATIONS REVIEW
ComponentComponents of Results of Operations
Revenue
Revenue represents gross product sales less service fees and product returns. For our Distribution Partnerdistribution partner channel, we recognize revenue for product sales at the time of delivery of the product to our Distribution Partner.distribution partner. As our products have an expiration date, if a product expires, we will replace the product at no charge. Currently, all of our revenue is generated from the sale of DuraGraft in European and Asian markets where the product hashad the required regulatory approvals.approvals during the three and months ended September 30, 2023 and 2022..
Direct Cost of RevenueGoods Sold
Direct costsCost of revenuegoods sold include primarily product costs, which include all costs directly related to the purchase of raw materials, charges from our contract manufacturing organizations, and manufacturing overhead costs, as well as shipping and distribution charges. Direct costsCost of revenuegoods sold also includeincludes losses from excess, slow-moving or obsolete inventory and inventory purchase commitments, if any.
Professional Fees
Professional fees include legal fees relating to intellectual property development, due diligence and corporate matters, and consulting fees for accounting, finance, and valuation services. Professional fees paid to a certain related party relate to certain consulting services - see Note 9 to the financial statements accompanying this report for further related party disclosures. We anticipate increasedservices. Increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with SEC requirements and with securities exchange rules in future periods are likely to occur, including likely increases in costs of compliance with SEC regulations of public companies in general any costs incurred from corporate actions and filings that may be required in order for the Company’s listing application with The Nasdaq Stock Market LLC (“Nasdaq”) to list the Company’s common stock on the Nasdaq Capital Market tier of Nasdaq to be approved, and, SECshould such listing application be approved, costs of compliance with Nasdaq’s continuing listing requirements.
| 26 |
Salaries and Stock-Based Compensation
Salaries consistsconsist of compensation and related personnel costs. Stock-based compensation represents the fair value of equity-settled share awards on stock options and restricted share awards granted by the Company to its employees, officers, directors, and consultants. The fair value of awards is calculated using the Black-Scholes option pricing model, which considers the following factors: exercise price, current market price of the underlying shares, expected life, risk-free interest rate, expected volatility, dividend yield, and forfeiture rate.
Research and Development
All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, forthose individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of Duragraft,DuraGraft, and costs related to manufacturing DuragraftDuraGraft for clinical trials. The Company has entered into various research and development contracts with various organizations and other companies.
Depreciation and Amortization
Intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Intangible assets acquired as a result of an acquisition or in a business combination are measured at fair value at the acquisition date. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the estimated useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis.
Royalty Expenses
In connection with the Somahlution Acquisition (as defined in “—Liquidity and Capital Resources – Funding Requirements and Other Liquidity Matters – Exercise of Somahlution Warrants with Reduced Exercise Price”), the Company entered into the Somahlution Agreement (as defined in “—Liquidity and Capital Resources – Funding Requirements and Other Liquidity Matters – Exercise of Somahlution Warrants with Reduced Exercise Price”), under which the Company became legally obligated to pay royalties on all net sales of certain products. Royalty expenses consists of royalty payable accrued on net sales of DuraGraft product within and outside of the U.S.
Other General and Administrative Expenses
Other general and administrative expenses consist principally of marketing and selling expenses, facility costs, administrative and office expenses, director and officer insurance premiums, and investor relations costs associated with operating a public company.
Other Income (Expenses)
Other income (expenses) consistsand expenses consist of mark-to-market adjustments on contingent liabilities assumed on the acquisition of Somahall of the assets of Somahlution, Inc., Somahlution, LLC, and Somaceutica LLC (collectively, “Somahlution”), including our DuraGraft-related assets (the “Somahlution Assets”) and interest and accretion expenses related to our convertible notes issued pursuant to the units private placement.Convertible Notes.
| 27 |
RESULTS OF OPERATIONS
Comparison of the Three Months Ended September 30, 20222023 and 20212022
The following table summarizes our results of operations for the three months ended September 30, 20222023 and 2021:2022:
| Three Months Ended September 30, | ||||||||||||
| 2022 | 2021 | Change | ||||||||||
| Revenue | $ | 76,012 | $ | 37,215 | $ | 38,797 | ||||||
| Operating expenses: | ||||||||||||
| Direct costs of revenue | 15,503 | 18,356 | (2,853 | ) | ||||||||
| Professional fees (includes related party amounts of $155,000 and $90,000, respectively) | 303,574 | 460,378 | (156,804 | ) | ||||||||
| Salary expenses | 330,221 | 517,192 | (186,971 | ) | ||||||||
| Research and development | 708,220 | 241,748 | 466,472 | |||||||||
| Stock-based compensation | 271,517 | 64,074 | 207,443 | |||||||||
| Depreciation and amortization | 210,361 | 1,425 | 208,936 | |||||||||
| Other general and administrative expenses | 469,656 | 489,820 | (20,164 | ) | ||||||||
| Total operating expenses | 2,309,052 | 1,792,993 | 516,059 | |||||||||
| Total operating loss | $ | (2,233,040 | ) | $ | (1,755,778 | ) | $ | (477,262 | ) | |||
| Other income (expenses): | ||||||||||||
| Interest and accretion expense | (810,598 | ) | (70,221 | ) | (737,960 | ) | ||||||
| Change in fair value of contingent liabilities | 1,491,000 | 194,000 | 1,297,000 | |||||||||
| Net loss | $ | (1,552,638 | ) | $ | (1,631,999 | ) | $ | 81,778 | ||||
| Three Months Ended September 30, | ||||||||||||
| 2023 | 2022 | Change | ||||||||||
| Revenue | $ | 181,535 | $ | 76,012 | $ | 105,523 | ||||||
| Cost of goods sold | 50,989 | 15,503 | 35,486 | |||||||||
| Gross profit | 130,546 | 60,509 | 70,037 | |||||||||
| Operating expenses: | ||||||||||||
| Direct costs of revenue | ||||||||||||
| Professional fees | 921,552 | 303,574 | 617,978 | |||||||||
| Salary expenses | 329,564 | 330,221 | (657 | ) | ||||||||
| Research and development | 492,235 | 708,220 | (215,985 | ) | ||||||||
| Stock-based compensation | 86,132 | 271,517 | (185,385 | ) | ||||||||
| Depreciation and amortization | 210,293 | 210,361 | (68 | ) | ||||||||
| Royalty expense | 13,014 | - | 13,014 | |||||||||
| Other general and administrative expenses | 2,934,966 | 469,656 | 2,465,310 | |||||||||
| Total operating expenses | 4,987,756 | 2,293,549 | 2,694,207 | |||||||||
| Total operating loss | $ | (4,857,210 | ) | $ | (2,233,040 | ) | $ | (2,624,170 | ) | |||
| Other income (expenses): | ||||||||||||
| Interest and accretion expense | (7,405,668 | ) | (810,598 | ) | (6,595,070 | ) | ||||||
| Change in fair value of contingent liabilities | (1,678,000 | ) | 1,491,000 | (3,169,000 | ) | |||||||
| Change in fair value of derivative liabilities | (14,454,397 | ) | - | (14,454,397 | ) | |||||||
| Loss on debt extinguishment | (80,001 | ) | - | (80,001 | ) | |||||||
| Loss on issuance of debt | (3,974,993 | ) | - | (3,974,993 | ) | |||||||
| Net loss | $ | (32,450,269 | ) | $ | (1,552,638 | ) | $ | (30,897,631 | ) | |||
Revenue
We recognized revenue of approximately $0.18 million for the three months ended September 30, 2023 compared to $0.08 million for the three months ended September 30, 2022. In 2022, comparedthe Company experienced a lack of significant revenue due to the impact of the COVID-19 pandemic on its supply chain and the production of DuraGraft inventory. However, with the Company’s inventory production returning to pre-pandemic levels by the end of the second quarter of 2022 and subsequent sales resumption, there was a notable increase in revenue period over period.
Cost of Goods Sold
Cost of goods sold increased by approximately $0.03 million or 228.9% to approximately $0.04$0.05 million for the three months ended September 30, 2021. The increase in revenues was due2023 compared to the impact of COVID-19 on the Company’s supply chain in fiscal 2021 and its ability to produce Duragraft inventory during 2021 and the resumption of production of the Company’s DuraGraft inventory and sales in Q2 2022.
Direct Costs of Revenue
The higher direct costs of revenue in the comparative Q3 2021 quarter was predominantly due to the COVID-19 interruptions to the Company’s supply chain and limited access to raw materialsapproximately $0.02 million for DuraGraft product. During the three months ended September 30, 2022, our executive and management teams’ efforts2022. The increase was due to re-establish the Company’s business relationships with its trusted manufacturing and distribution partners, and the loosening of COVID-19 restrictions, led to a decrease in direct costs of revenue.increased sales period over period.
Professional Fees
Professional fees decreasedincreased by approximately $0.2$0.6 million or 34%203.6% to approximately $0.9 million for the three months ended September 30, 2023 compared to approximately $0.3 million for the three months ended September 30, 2022. The increase was due to legal and placement agent fees related to the Company’s Units Private Placement (as defined in Q3 2022“—Liquidity and Capital Resources – Funding Requirements and Other Liquidity Matters – Issuance of Replacement Securities”), the OID Units Private Placement (as defined in “—Liquidity and Capital Resources – Funding Requirements and Other Liquidity Matters – Third Closing of OID Units Private Placement”), and consulting services expenses for DuraGraft FDA regulatory support during the quarter ended September 30, 2023 compared to approximately $0.5 million in Q3 2021. The decrease relates to higher professional fees incurred in the prior comparative period due to the acquisition of the Somah assets.quarter ended September 30, 2022.
Salary Expenses
Salary expenses in Q3 2022 werefor the three months ending September 30, 2023, amounted to approximately $0.3$0.33 million, an approximately $0.2 million or 36% decreasereflecting minimal change from the comparative period. The decreasecorresponding period in 2022, which also stood at $0.33 million. Salary expenses experienced a slight reduction during the cost is attributablequarter ending September 30, 2023, in comparison to the restructuringsame quarter in 2022. This decrease is attributed to the prior comparative period asstrategic effort to streamline the Company restructured its executive and management teams in 2021.Company’s operations while maintaining employee salaries.
Research and Development
Research and development expenses in Q3 2022,for the three months ended September 30, 2023 were approximately $0.5 million, an approximately $0.2 million or 30.5% decrease from approximately $0.7 million an approximately $0.5 million or 193% increase fromfor the comparative period. The increasethree months ended September 30, 2022. This reduction in research and development expenses can be mainlyis primarily attributed to the Company’s acquisitionsuspension of a European study on DuraGraft as well the Company’s decision to suspend expenditures related to FDA approvals for MATLOC 1and Krillase-related assets in late 2021during the quarter ending September 30, 2023.
The Company previously sought to develop and its focuscommercialize FDA-approved products based on development and advancement of DuraGraft,its Krillase and MATLOC 1 towards commercialization.assets simultaneously with its DuraGraft products. Since the first quarter of 2023, the Company has prioritized the completion of regulatory processes to obtain FDA approval for the commercialization of DuraGraft in the United States and the development of a functional MATLOC device prototype and MAR-FG-001-based viable products. The Company intends to maintain the Krillase assets for potential future development and commercialization or disposition. Any determination as to these matters would be based on a number of factors. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Principal Factors Affecting Our Financial Performance” for a summary of factors that we may consider in this respect. There is no assurance that any of the Company’s intellectual property assets will ever be developed and fully commercialized and generate significant revenues or will ever attract significant interest from potential buyers or investors. See “Item 1A. Risk Factors – Risks Related to Our Business – We may not be able to monetize intangible assets, which may result in the need to record an impairment charge.” in the 2022 Form 10-K.
| 28 |
Stock-Based Compensation
Stock-based compensation increaseddecreased by approximately $0.2 million or 68.3% to approximately $0.09 million for the three months ended September 30, 2023 from approximately $0.06$0.27 million to approximately $0.27 millionfor the three months ended September 30, 2022. A significant portion of options completed their vesting period during the nine months ended September 30, 2022 and no options were granted during the nine months ended September 30, 2023, which caused the decrease in stock-based compensation during the three months ended September 30, 2021 and 2022, respectively, a $0.21 million or 324% increase. The increase in stock-based compensation can be explained by am additional 400,000 stock options granted in 2022 and 350,000 restricted share awards granted in late 2021, which were fair valued significantly higher compared to the stock options granted and outstanding in the comparative period. This was due to a 58% increase in the Company’s stock price period over period to $1.90 as of September 30, 2022 from $1.20 as of September 30, 2021.2023.
Depreciation and Amortization
Depreciation and amortization increasedremained relatively constant at approximately $0.21$0.2 million or 324% in Q3for each of the three months ended September 30, 2023 and 2022. The increase was due to the acquisition of My Health Logic in December 2021 and itsCompany did not acquire any new tangible or intangible capital assets and acquisitionduring either of these periods.
Royalty Expense
For the three months ended September 30, 2023, the Company recorded an aggregate of approximately $0.01 million in royalty expense, most of which was accrued on sales of DuraGraft sales outside of the Somah assets in July 2020 where key intellectual productsU.S. No royalties were acquired.accrued for the three months ended September 30, 2022 as minimal sales of DuraGraft occurred during the period.
Other General and Administrative Expenses
Other general and administrative expenses decreasedincreased approximately $0.02$2.5 million or 4%524.9% to approximately $0.47$2.9 million in Q3for the three months ended September 30, 2023 compared to $0.5 million for the three months ended September 30, 2022. The majority of the expenses in Q3 2022 wereincrease was due to the Company’s lower non-legal fees related to the filingvaluation of an amendment to a Registration Statement on Form S-1Replacement Placement Agent Warrants (as defined in “—Funding Requirements and Other Liquidity Matters – Issuance of Replacement Securities”) and OID Units Placement Agent Warrants (as defined in “—Funding Requirements and Other Liquidity Matters – Issuance of OID Units Placement Agent Warrants”)issued in the period and preparation for the Company’s public offering compared to the higher general and administrative expenses in Q3 2021 from higher non-legal fees related to the acquisition of the Somah entities.three months ended September 30, 2023.
Other Income (Expenses)
In Q3 2022,For the three months ended September 30, 2023, the Company incurred approximately $0.8$7.4 million of interest and accretion costs compared to approximately $0.8 million for the three months ended September 30, 2022, an increase of 813.6%. The interest and accretion costs were associated with convertible notescertain securities issued at discount as partrelating to the Units Private Placement and the OID Units Private Placement, compared to $0.8 million of its units private placement interest and accretion costs recorded in the third quarter of 2022 on the Company’s 10% Secured Convertible Promissory Notes (the “Convertible Notes”).
Additionally, the Company recognized $1.5$1.7 million of fair value gainloss from mark-to-market adjustments on the contingent liabilities assumed on the acquisition of the Somah assetsSomahlution Assets due to the change of the fair value of the contingent consideration.consideration compared to $1.5 million of fair value gain, a decrease of $3.2 million from mark-to-market adjustment on the contingent liabilities in the comparative quarter ended September 30, 2022.
The Company recognized a $14.5 million increase in fair value of the detachable warrants issued in the OID Units Private Placement transactions during the nine months ended September 30, 2023. No such warrants were issued in 2022.
The Company recordeda loss of $4.0 million on issuance of 15% OID Convertible Notes due to the fair value of Class E and F Warrants (as defined in “—Liquidity and Capital Resources – Funding Requirements and Other Liquidity Matters – OID Units Private Placement – First Closing of OID Units Private Placement”)exceeding the value of the debt principal.
Comparison of the Nine Months Ended September 30, 20222023 and 20212022
The following table summarizes our results of operations for the nine months ended September 30, 20222023 and 2021:2022:
| Nine Months Ended September 30, | ||||||||||||
| 2022 | 2021 | Change | ||||||||||
| Revenue | $ | 137,821 | $ | 271,952 | $ | (134,131 | ) | |||||
| Operating expenses: | ||||||||||||
| Direct costs of revenue | 26,528 | 168,419 | (141,891 | ) | ||||||||
| Professional fees (includes related party amounts of $422,000 and $180,000, respectively) | 1,721,479 | 1,445,004 | 276,475 | |||||||||
| Salary expenses | 2,147,967 | 2,084,430 | 63,537 | |||||||||
| Research and development | 3,297,986 | 877,936 | 2,420,050 | |||||||||
| Stock-based compensation | 1,664,191 | 626,449 | 1,037,742 | |||||||||
| Depreciation and amortization | 631,083 | 5,849 | 625,234 | |||||||||
| Other general and administrative expenses | 1,478,726 | 944,248 | 534,478 | |||||||||
| Total operating expenses | 10,967,960 | 6,152,335 | 4,815,625 | |||||||||
| Total operating loss | $ | (10,830,139 | ) | $ | (5,880,383 | ) | $ | (4,949,756 | ) | |||
| Other income (expenses): | ||||||||||||
| Interest and accretion expense | (1,640,368 | ) | (74,410 | ) | (1,563,541 | ) | ||||||
| Change in fair value of contingent liabilities | (2,131,000 | ) | 472,000 | (2,603,000 | ) | |||||||
| Net loss | $ | (14,601,507 | ) | $ | (5,482,793 | ) | $ | (9,116,297 | ) | |||
| Nine Months Ended September 30, | ||||||||||||
| 2023 | 2022 | Change | ||||||||||
| Revenue | $ | 495,248 | $ | 137,821 | $ | 357,427 | ||||||
| Cost of goods sold | 139,875 | 26,528 | 113,347 | |||||||||
| Gross profit | 355,373 | 111,293 | 244,080 | |||||||||
| Operating expenses: | ||||||||||||
| Direct costs of revenue | ||||||||||||
| Professional fees | 1,818,202 | 1,721,479 | 96,723 | |||||||||
| Salary expenses | 931,536 | 2,147,967 | (1,216,431 | ) | ||||||||
| Research and development | 1,789,625 | 3,297,986 | (1,508,361 | ) | ||||||||
| Stock-based compensation | 457,860 | 1,664,191 | (1,206,331 | ) | ||||||||
| Depreciation and amortization | 630,924 | 631,083 | (159 | ) | ||||||||
| Royalty expense | 211,262 | - | 211,262 | |||||||||
| Other general and administrative expenses | 6,310,039 | 1,478,726 | 4,831,313 | |||||||||
| Total operating expenses | 12,149,448 | 10,941,432 | 1,208,016 | |||||||||
| Total operating loss | $ | (11,794,075 | ) | $ | (10,830,139 | ) | $ | (963,936 | ) | |||
| Other income (expenses): | ||||||||||||
| Interest and accretion expense | (22,527,538 | ) | (1,640,368 | ) | (20,887,170 | ) | ||||||
| Change in fair value of contingent liabilities | 312,000 | (2,131,000 | ) | 2,443,000 | ||||||||
| Change in fair value of derivative liabilities | (14,454,397 | ) | - | (14,454,397 | ) | |||||||
| Loss on debt extinguishment | (764,683 | ) | - | (764,683 | ) | |||||||
| Loss on issuance of debt | (6,352,562 | ) | - | (6,352,562 | ) | |||||||
| Net loss | $ | (55,581,255 | ) | $ | (14,601,507 | ) | $ | (40,979,748 | ) | |||
| 29 |
Revenue
We recognized revenue of approximately $0.1$0.50 million for the nine months ended September 30, 20222023 compared to approximately $0.3 million for the nine months ended September 30, 2021. No revenue was generated in Q1 2022 due to the impact of COVID-19 on the Company’s supply chain in fiscal 2021 and its ability to produce DuraGraft inventory. As the result of the Company’s executive and management teams’ efforts to re-establish the Company’s business relationships with its trusted manufacturing and distribution partners, the production of DuraGraft inventory and sales resumed in Q2 2022 and continued into Q3 2022.
Direct Costs of Revenue
Direct costs of revenue decreased by approximately $0.1 million or 84% to approximately $0.03$0.14 million for the nine months ended September 30, 2022. This was predominantlyDuring the nine months ending September 30, 2022, the Company experienced a lack of significant revenue due to fewer unitsthe impact of the COVID-19 pandemic on its supply chain and the production of DuraGraft product producedinventory. However, with the Company’s inventory production returning to pre-pandemic levels by the end of the second quarter of 2022 and subsequent sales resumption, there was a notable increase in revenue period over period.
Cost of Goods Sold
Cost of goods sold increased by approximately $0.11 million or 427.3% to approximately $0.14 million in the currentnine months ended September 30, 2023 compared to approximately $0.03 million in the nine months ended September 30, 2022. The increase was due to increased sales period because of the shortage of raw materials as a result of COVID-19.over period.
Professional Fees
Professional fees increased by approximately $0.3$0.10 million or 19%5.6% to approximately $1.8 million for the nine months ended September 30, 2023 compared to approximately $1.7 million for the nine months ended September 30, 2022 compared to approximately $1.4 million for the comparative2022. Period over period, ended September 30, 2021. The increase in professional fees can be attributed to legal support with preparation and filing of the Company’s amendment to its Registration Statement on Form S-1 with the SEC, audit fees in connection with the audit of the 2021 Form 10-K, and compensation costs incurred in connection with closings of the Company’s units private placement financing. Related party professional fees increased by approximately $0.2 million or 134% to approximately $0.4 million from approximately $0.2 million during the third quarter of 2022 compared to the third quarter of 2021 because the Company retained additionalsaw a reduction in legal and placement agent fees, however this decrease was offset by increased spending on consulting services in order to advance development of its medical technologies.for DuraGraft FDA regulatory and clinical support.
Salary Expenses
Salary expenses for the nine months ended September 30, 2022,2023 were approximately $0.9 million, an approximately $1.2 million or 56.6% decrease from approximately $2.1 million an approximately $0.1 million or 3% increase fromfor the comparative period.nine months ended September 30, 2022. The increase in the salary cost isdecrease was attributable to reductions in employee salaries as part of efforts to streamline the restructuring and growth of the organization as the Company continues to expand into new markets and work towards commercialization of DuraGraft in the United States.Company’s operations.
Research and Development
Research and development expenses for the nine months ended September 30, 20222023 were approximately $1.8 million, an approximately $1.5 million or 45.7% decrease from approximately $3.3 million an approximately $2.4 million or 276% increase fromfor the comparative period. The increasenine months ended September 30, 2022. This reduction in research and development expenses can be mainlyis primarily attributed to the Company’s acquisitionsuspension of a European study on DuraGraft as well the Company’s decision to suspend expenditures related to FDA approvals for MATLOC 1and Krillase-related assets in late 2021during the quarter ending September 30, 2023.
The Company previously sought to develop and its focuscommercialize FDA-approved products based on development and advancement of DuraGraft,its Krillase and MATLOC 1 towards commercialization.assets simultaneously with its DuraGraft products. Since the first quarter of 2023, the Company has prioritized the completion of regulatory processes to obtain FDA approval for the commercialization of DuraGraft in the United States and the development of a functional MATLOC device prototype and MAR-FG-001-based viable products. The Company intends to maintain the Krillase assets for potential future development and commercialization or disposition. Any determination as to these matters would be based on a number of factors. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Principal Factors Affecting Our Financial Performance” for a summary of factors that we may consider in this respect. There is no assurance that any of the Company’s intellectual property assets will ever be developed and fully commercialized and generate significant revenues or will ever attract significant interest from potential buyers or investors. See “Item 1A. Risk Factors – Risk Factors – Risks Related to Our Business – We may not be able to monetize intangible assets, which may result in the need to record an impairment charge.” in the 2022 Report.
| 30 |
Stock-Based Compensation
Stock-based compensation decreased by approximately $1.2 million to approximately $0.5 million for the nine months ended September 30, 2023 from approximately $1.7 million for the nine months ended September 30, 2022, increased by approximately $1.0 million or 166% to approximately $1.7 million if compared towhich represents a 72.5% decrease period over period. A significant portion of options completed their vesting period during the nine months ended September 30, 2021. The increase2022 and no options were granted during the nine months ended September 30, 2023, which caused the decrease in stock-based compensation can be explained by an additional 400,000 stock options granted in 2022 and 350,000 restricted share awards granted in late 2021, which were fair valued significantly higher compared to the stock options granted and outstanding in the comparative period. This was due to a 58% increase in the Company’s stock price period over period to $1.90 as of September 30, 2022 from $1.20 as of September 30, 2021.period.
Depreciation and Amortization
Depreciation and amortization increasedremained relatively constant at approximately $0.6 million or 10,690% in Q3for each of the nine months ended September 30, 2023 and 2022. The increase was due to the acquisition of My Health Logic in December 2021 and itsCompany did not acquire any new tangible or intangible capital assets and acquisitionduring either of the Somah assets in July 2020 where key intellectual products were acquired.these periods.
Royalty Expense
For the nine months ended September 30, 2023, the Company recorded an aggregate of approximately $0.2 million in royalty expense - $0.05 million in royalties payable was incurred on sales of DuraGraft outside of the U.S.; the remaining $0.15 million in royalty expense was recorded as a 50% reduction of the prepaid royalty balance owed to the former beneficial owners of Somahlution. No royalties were accrued for the nine months ended September 30, 2022 as minimal sales of DuraGraft occurred during the nine months ended September 30, 2022.
Other General and Administrative Expenses
Other general and administrative expenses increased by approximately $0.5$4.8 million, or 57%326.7%, to approximately $6.3 million for the nine months ended September 30, 2023 compared to approximately $1.5 million for the nine months ended September 30, 2022. Approximately $0.5 million of the increase can be attributed to the deferred offering costs expensed as a result of adjustments to the Convertible Notes and $0.7 million of the deferred offering costs that were expensed due to the Company’s withdrawal of its registration statement for a public offering in April 2023. Additionally, $1.3 million of other general and administrative expenses can be attributed to the valuation of Class E and F Warrants issued on May 22, 2023 in connection with the First OID Units Closing pursuant to the terms of the Hexin Promissory Note. In addition, approximately $2.6 million of the increase can be attributed to the valuation of Replacement Placement Agent Warrants and OID Units Placement Agent Warrants issued in the nine months ended September 30, 2022. The increase was due to the Company’s non-legal fees related to the filing of an amendment to a Registration Statement on Form S-1, preparation for the Company’s public offering, increased rent due to the lease of additional office and laboratory space, and expenses associated with running a public company, during the nine-month period ended September 30, 2022. Due to the planned continued buildout of administrative and commercial functions we expect general and administrative expenses to increase in future periods.2023
Other Income (Expenses)
DuringFor the nine months ended September 30, 2022,2023, the Company incurred approximately $1.6$22.5 million of interest and accretion costs associated with convertible notescertain securities issued at discount as partrelating to the Units Private Placement and the OID Units Private Placement, compared to $1.6 million of interest and accretion costs recorded for the nine months ended September 30, 2022 on the Convertible Notes. Additionally, due to the non-repayment of the Company’s units private placement. initial principal amount of $1.0 million under an unsecured promissory note to Walleye Opportunities Master Fund Ltd. (“Walleye”) for $1,000,000 with a maturity date of May 7, 2023 (the “Walleye Promissory Note”) by its maturity date of May 7, 2023, the Company also defaulted under the Convertible Notes on the same date, resulting in a default amount of $7.4 million accreted to the principal of the Convertible Notes. This represents an approximately $20.9 million or 1,273.3% increase over the nine months ended September 30, 2022.
Additionally, the Company recognized approximately $2.1$0.3 million of fair value lossgain from mark-to-market adjustments on the contingent liabilities assumed on the acquisition of Somahthe Somahlution Assets due to the change of the fair value of the contingent consideration.consideration compared to $2.1 million of fair value loss, an increase of $2.4 million from mark-to-market adjustment on the contingent liability for the nine months ended September 30, 2022.
The Company recognized a $14.5 million increase in fair value of the detachable warrants issued in the OID Convertible Notes transactions during the nine months ended September 30, 2023. No such warrants were issued in the nine months ended September 30, 2022.
For the nine months ended September 30, 2023, due to the substantial reduction of the conversion price of the Convertible Notes in April 2023, the Company recorded a loss of approximately $0.76 million on the extinguishment of the Convertible Notes. The Company also recorded a loss of $6.3 million on issuance of OID Convertible Notes due to the fair value of Class E and F Warrants exceeding the value of the debt principal.
LIQUIDITY AND CAPITAL RESOURCES
To date, we have incurred significant net losses and negative cash flows from operations. As of September 30, 2022,2023, we had available cash of approximately $1.2$0.5 million and accumulated deficit of approximately $62$136.2 million. We fundhave funded our operations throughprimarily from capital raises.
| 31 |
Recent Developments
FDA De Novo Grant Issued for DuraGraft
On October 4, 2023, DuraGraft was classified as a Class II device and authorized for marketing by the FDA for use and marketing as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries, subject to applicable risks, mitigation requirements, and control provisions. The FDA granted this classification and authorization in response to our application under the De Novo request process of the Food, Drug, and Cosmetic Act (“FD&C Act”). As a Class II device, DuraGraft is subject to special controls to provide reasonable assurance of the safety and effectiveness of the device type. The FDA identified the following risks and mitigation measures: risk of adverse tissue reaction requiring mitigation through biocompatibility evaluation; risk of damage to vascular grafts leading to major adverse cardiac events or vascular injury requiring mitigation through clinical performance data, non-clinical performance testing, shelf life testing, and labeling; risk of particulate matter contamination leading to vascular occlusion, coronary artery embolization and occlusion, phlebitis, infarction, and death requiring mitigation through clinical performance data, non-clinical performance testing, shelf life testing, and labeling; and risk of infection requiring mitigation through sterilization validation.
Units Private Placement
During the nine months ended September 30, 2022, the Company issued 4,180,071 units in its units private placement for the gross proceeds of approximately $7.3 million. Of the total 4,180,071 units issued: (i) 159,245 units were issued to settle notes payable assumed on acquisition of My Health Logic, (ii) 22,857 units were issued to settle accounts payable, and 171,428 units were issued in exchange for services renderedIn addition to the Companygeneral controls of the FD&C Act, use of DuraGraft is subject to the following special controls: (1) Clinical data must evaluate adverse events associated with clinical use of the device. Devices indicated for vascular grafts for coronary artery bypass graft surgeries must include an evaluation of the incidence of major adverse cardiac events, vein graft occlusion, and mortality. (2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Maintenance of cell viability and structural integrity of vascular conduits during storage at the labeled temperature and storage duration; and (ii) Evaluation of visible and non-visible particulates in the nine months ended September 30, 2022.final mixed solution. (3) Shelf life testing must demonstrate the stability of the device’s chemical components over the identified shelf life. (4) The remaining proceeds from this offering willdevice must be useddemonstrated to sustainbe biocompatible. (5) Performance data must demonstrate the Company’s growthsterility of the device. (6) Labeling must include: (i) The maximum storage duration for vascular autografts in the solution; (ii) A description of all additives or supplements that are added at the point of care; (iii) The need for visual inspection of the solution for particulate matter prior to use; (iv) A statement regarding the duration of stability of the final solution after preparation; (v) A summary of the non-clinical performance testing that supports use of the device as a flushing and meet its capital obligations.storage solution for vascular autografts; and (vi) A summary of the clinical data that supports use of the device as a flushing and storage solution for vascular autografts. In addition, DuraGraft is a prescription device and must comply with 21 CFR 801.109. DuraGraft must also comply with applicable requirements under the FD&C Act, including registration and listing, labeling, medical device reporting (reporting of medical device-related adverse events) for devices or postmarketing safety reporting for combination products, good manufacturing practice requirements as set forth in the quality systems regulation for devices or current good manufacturing practices for combination products, and if applicable, the electronic product radiation control provisions.
In connection with the FDA’s review of our De Novo request, the FDA did not exempt DuraGraft as a Class II device from the premarket notification requirements under section 510(k) of the FD&C Act. Future products that use DuraGraft as a predicate device for vascular graft storage and flushing solutions used during CABG surgery may be required to comply with premarket notification requirements under Section 510(k) of the FD&C Act.
Public OfferingLetter Agreement to Amend Convertible Notes to Permit Conversion of Mandatory Default Amount
On February 14, 2021, Marizyme filedOctober 3, 2023, under a Registration Statement on Form S-1 to raise up to $17,250,000. As atletter agreement between Univest Securities, LLC (“Univest”), as unitholder representative for the end of Q3 2022, the final prospectus had not yet been filed and the final amount of the offering will be dependent on market conditions. The proceeds from the offering will be usedinvestors in a private placement by the Company (i)of units consisting of the Convertible Notes and the Class C Warrants during the fiscal years ended December 31, 2021 and 2022 (the “Units Private Placement”), and the Company (the “Convertible Notes Letter Agreement”), the definition of the amount that must be paid upon the first uncured or uncurable default under the Convertible Notes was amended to develop its DuraGraft, MATLOC,equal 135% of the outstanding principal plus accrued interest as of the date on which the first event of default occurred under the Convertible Notes (the “Mandatory Default Amount”), and Krillase platforms; (ii) to commercializepermit the conversion of the Mandatory Default Amount into shares of common stock at the applicable conversion price. As a result, at the current conversion price of $0.10 per share, the outstanding Convertible Notes became convertible into an aggregate of 221,939,338 shares of common stock. The Convertible Notes Letter Agreement also amended the Convertible Notes to provide that a full conversion of the Mandatory Default Amount would also fully extinguish any outstanding principal and produce its products,accrued and (iii)unpaid interest; that non-voluntary conversion of the Mandatory Default Amount (which would also extinguish any outstanding principal and accrued and unpaid interest as noted above) under all of the Convertible Notes will occur only if at any time following the 60-day anniversary of the final closing date or termination of the Units Private Placement, and provided there is an effective registration statement permitting the issuance or resale of the shares of common stock into which the Convertible Notes may be converted, (A) the common stock is listed on a senior national securities exchange, (B) the daily volume-weighted average price for general working capitalthe prior twenty (20) consecutive trading days is $6.00 or more (adjusted for splits and other corporate purposes. Management anticipatessimilar distributions) and (C) the daily trading volume is at least $1,000,000 during such 20-day period; and that, for all Convertible Notes, upon the occurrence of an equity financing with a gross aggregate amount of securities sold of not less than $10,000,000, provided that the offeringCompany is listed on a trading market that is a senior exchange such as Nasdaq or the New York Stock Exchange (the “NYSE”), the conversion price of the Convertible Notes will closebe adjusted to the price per share equal to 75% of the price per equity security in Q4such financing (a “Qualified Financing”).
In connection with the Convertible Notes Letter Agreement, additional Replacement Placement Agent Warrants were issued to Univest and Mr. Richmond on October 3, 2023 to purchase 15,244,839 and 22,867,250 shares of common stock, respectively, which together with their previous Replacement Placement Agent Warrants issued to purchase 4,048,762 and 6,073,182 shares of common stock, respectively, totaled 8% in aggregate of the shares issuable upon conversion of the Convertible Notes, including the Mandatory Default Amount, and the Class C Warrants, in accordance with the 2021 Placement Agency Agreement (as defined in “—Funding Requirements and Other Liquidity Matters – Issuance of Replacement Securities”). The Replacement Placement Agent Warrants are exercisable, in whole or in part, until October 3, 2028 by payment of cash or on a cashless net exercise basis, and contain certain antidilution provisions and exercise price adjustment provisions that are substantially identical to equivalent provisions of the Class C Warrants; are currently exercisable for $0.10 per share; and the holders of such warrants have the rights set forth in the unit purchase agreement dated as of August 12, 2022 with respect to the Convertible Notes and Class C Warrants that were issued in August 2022.
Funding Requirements and Other Liquidity Matters
Marizyme expectsWe expect to continue to incur expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase as a result of the following operational and business development efforts:
| ● | Increase our expertise and knowledge through hiring and retaining qualified operational, financial and management personnel, who | |
| ● | Increase in research and development and legal | |
| ● | Expand our product portfolio through the identification and acquisition of additional life science | |
| ● | Seek to increase awareness about our products to boost sales and |
Until such time, if ever, as we can generate substantial product revenues to support our cost structure, the Company will continue to haveneed to raise funds beyond its current working capital balance in order to finance future development of products, potential acquisitions, and meet its debt obligations until such time as future profitable revenues are achieved.
| 33 |
We expect to finance our cash needs through a combination of private and public equity offerings, debt financings, government or other third-party funding, and collaborations, arrangements or acquisitions. On February 14, 2022, we filed a registration statement on Form S-1, subsequently amended, relating to a proposed underwritten public offering for gross proceeds of approximately $8 million from the issuance of units each of which would consist of a share of common stock and two warrants to purchase one share of common stock. On April 21, 2023, prior to the effectiveness of the registration statement, we filed an application with the Securities and Exchange Commission (the “SEC”) for the withdrawal of the registration statement, including all amendments and exhibits to the registration statement. The application for withdrawal was filed to withdraw the registration statement because the Company no longer intended to pursue the proposed public offering. Pursuant to Rule 477 under the Securities Act, the application was deemed granted at the time the application was filed, because it was filed before the effective date of the registration statement, and the SEC did not notify us that the application for withdrawal would not be granted within 15 calendar days after er had filed the application.
We have not withdrawn the listing application that we submitted to list our common stock on the Nasdaq Capital Market tier of Nasdaq in connection with the proposed public offering, and continue to seek such listing of our common stock. We believe that such a listing may be an important factor in the Company’s efforts to gain sufficient financing to fund its operations in the short-term and long-term. There is no guarantee or assurance that our common stock will be approved for listing on the Nasdaq Capital Market. If we are unable to list our common stock on the Nasdaq Capital Market or other national securities exchange, we may experience heightened difficulty in raising sufficient funding to meet our capital and cash requirements over the 12 months following the date of this report and any period beyond that date. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interest of our stockholders may be materially diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rightsthe interests of our common stockholders. Debt financing and preferred equity financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. Securing additional financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management’s ability to oversee the development or acquisition of product.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. These factors raise substantial doubt about the Company’s ability to continue as a going concern. See “—Going Concern” below.
Cash Flows
| Nine months ended September 30, | ||||||||||||
| 2023 | 2022 | $ Change | ||||||||||
| Net Cash provided by/(used in): | ||||||||||||
| Operating activities | $ | (3,470,887 | ) | $ | (9,266,036 | ) | $ | 5,795,149 | ||||
| Financing activities | 3,434,966 | 6,375,945 | (2,940,979 | ) | ||||||||
| Net change in cash | $ | (35,921 | ) | $ | (2,890,091 | ) | $ | 2,854,170 | ||||
The following table sets forth a summary of the net cash flow activity for each of the periods indicated:
| 34 |
| Nine Months Ended September 30, | ||||||||||||
| 2022 | 2021 | $ Change | ||||||||||
| Net cash provided by/(used in): | ||||||||||||
| Operating activities | $ | (9,266,036 | ) | $ | (4,313,038 | ) | $ | (4,952,998 | ) | |||
| Financing activities | 6,375,945 | 1,426,949 | 4,948,996 | |||||||||
| Net change in cash | $ | (2,890,091 | ) | $ | (2,886,089 | ) | $ | (4,002 | ) | |||
Operating Activities
Net cash used in operating activities was approximately $9.3$3.5 million and approximately $4.3$9.3 million infor the nine months ended September 30, 20222023 and 2021,2022, respectively. The net cash used in operating activities duringfor the nine months ended September 30, 2023 was due to approximately $1.8 million spent on research and development, approximately $0.9 million spent on salaries and related compensation expenses, and approximately $1.8 million spent on professional fees. The net cash used in operating activities for the nine months ended September 30, 2022 was due to approximately $3.3 million spent on research and development, approximately $1.7 million spent on professional fees approximatelyand $2.1 million spent on salaries and related compensation expenses, and approximately $3.3$1.5 million spent on other general and administrative expenses. The decrease in net cash used in operating activities in the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 was primarily due to the decrease in the Company’s research and development activities . The net change in operating assets and liabilities primarily related to approximately $0.4 million spent on the manufacturing of DuraGraft product in the period and an approximately $1.8 million increase in accounts payable, accrued expenses and amounts due to related parties in support of the growth of our research and developmentsalaries and other operating activities.compensation.
Financing Activities
Net cash provided by financing activities for the nine months ended September 30, 2023 was approximately $3.4 million, of which approximately $2.3 million was due to funds raised from the financing. An additional $1.0 million of funds was raised from the issuance of the Walleye Promissory Note and approximately $0.3 million was received from the exercise of the Somahlution Warrants. During the nine months ended September 30, 2023 the Company also repaid approximately $0.2 million in notes payable.
Net cash provided by financing activities for the nine months ended September 30, 2022 was approximately $6.4 million, and was primarily due to approximately $6.5 million of funds raised from the issuance of convertible promissory notes in the Company’s units private placement, net of issuance costs. During the nine months ended September 30, 2022, theConvertible Notes. The Company also repaid notes payablesettled an aggregate of approximately $0.1 million in notes payable as part of the units private placement issuances and repaid approximately $0.1 million in notes payable assumed on the acquisition of My Health Logic.
Contractual Obligations and Commitments
Other than disclosed below, there were no material changes outside the ordinary course of our businessUnits Private Placement during the nine months ended September 30, 2022.
Issuance of Replacement Securities
As previously reported in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed on March 31, 2022 and the 2022 Form 10-K, in May 2021, the Company entered into an exclusive Placement Agency Agreement, subsequently modified on December 21, 2021 (the “2021 Placement Agency Agreement”) with Univest pursuant to which Univest agreed to act as the Company’s exclusive placement agent for a private placement (the “Units Private Placement”) of up to $18,000,000 in units which, subsequent to certain modifications of the terms of such private placement, consisted of the Convertible Notes, initially convertible into shares of common stock at a conversion price of $1.75 per share, subject to adjustment, and Class C Warrants, initially exercisable for shares of common stock at an exercise price of $2.25 per share, subject to adjustment. On January 24, 2022, the Company issued each of Univest and its designee, Bradley Richmond (“Mr. Richmond”), as a registered representative of Univest entitled to a portion of Univest’s compensation due to his employment terms, a Convertible Note in the principal amount of $120,000 and $180,000, respectively (collectively, the “Placement Agent Convertible Notes”), and a Class C Warrant for the purchase of 137,142 and 205,714 shares of common stock, subject to adjustment, respectively (collectively, the “Placement Agent Class C Warrants”), in exchange for Univest’s and Mr. Richmond’s services provided to the Company in connection with the Company’s acquisition of My Health Logic Inc. (“My Health Logic”). In addition, as previously reported in the 2022 Report, on June 26, 2022, pursuant to the 2021 Placement Agency Agreement, in anticipation of the final closing of the Units Private Placement, in exchange for $100, the Company issued Univest a warrant for the purchase of 231,239 shares of common stock, and a warrant to Mr. Richmond, as a registered representative of Univest who is entitled to a portion of Univest’s compensation due to his employment terms, for the purchase of 347,039 shares of common stock (the “2022 Placement Agent Warrants”), each of which was initially exercisable at $1.75 per share, subject to adjustment.
Separately, on January 26, 2022 and February 14, 2022, the Company granted Mr. Richmond two warrants (the “Consultant Warrants”) to purchase up to 150,000 shares of common stock at an exercise price of $0.01 per share as compensation for certain services. Mr. Richmond fully exercised both of the Consultant Warrants for 300,000 shares of common stock in March 2022 (the “Consultant Shares” and together with the Placement Agent Convertible Notes, the Placement Agent Class C Warrants, and the 2022 Placement Agent Warrants, the “Cancelled Securities”).
On February 14, 2022, the Company filed a registration statement on Form S-1, which was subsequently amended on certain dates, relating to the Company’s proposed underwritten public offering for gross proceeds of approximately $8 million. Univest was named as the representative of the underwriters of the offering. As previously reported in the 2022 Report, the staff (“FINRA Staff”) of the Corporate Financing Department of the Financial Industry Regulatory Authority, Inc. (“FINRA”) determined that the sales of the Placement Agent Convertible Notes, the Placement Agent Class C Warrants, the 2022 Placement Agent Warrants, the Consultant Shares, as well as a grant of a stock option to Mr. Richmond constituted underwriting compensation in connection with the Company’s proposed public offering pursuant to FINRA Rule 5110, based on the FINRA Staff’s interpretation of such rule. Consequently, each of Univest and Mr. Richmond, pursuant to a letter agreement entered into with the Company, dated October 28, 2022, addressed and submitted to the FINRA Staff (the “October 2022 Letter Agreement”), agreed to forego their applicable rights to these securities. Pursuant to the October 2022 Letter Agreement, the parties thereto agreed that the cancellation or disposal of the aforementioned securities shall be without recourse by either Univest or Mr. Richmond. Accordingly, the Placement Agent Convertible Notes, the Placement Agent Class C Warrants, the 2022 Placement Agent Warrants, and the Consultant Shares were subsequently cancelled, and the Company and Mr. Richmond agreed to the transfer of his stock option to a Company designee who is unaffiliated with Mr. Richmond.
| 35 |
The Convertible Notes including the Placement Agent Convertible Notes prior to their cancellation, Class C Warrants including the Placement Agent Class C Warrants prior to their cancellation, and the 2022 Placement Agent Warrants contained certain adjustment provisions as described below under “—Funding Requirements and Other Liquidity Matters – Adjustments to Conversion Price of Convertible Notes and Exercise Price of Class C Warrants and Number of Underlying Shares”, except that the terms of the January 2023 Letter Agreement (as defined and described in that section) did not expressly apply to the Placement Agent Class C Warrants or the 2022 Placement Agent Warrants, which had previously been cancelled as described above.
In April 2023, as a result of the events described below under “—Funding Requirements and Other Liquidity Matters – Exercise of Somahlution Warrants at Reduced Exercise Price”, and pursuant to the adjustment provisions described below under “—Funding Requirements and Other Liquidity Matters – Adjustments to Conversion Price of Convertible Notes and Exercise Price of Class C Warrants and Number of Underlying Shares”, the conversion price of the Convertible Notes and the exercise price of the Class C Warrants were both adjusted to $0.10 per share of common stock. As a result of these adjustment provisions and the conversion or exercise terms of the Convertible Notes and Class C Warrants, the aggregate number of shares into which the Convertible Notes may be converted or the Class C Warrants may be exercised to purchase adjusted upwards proportionately.
On April 21, 2023, prior to the effectiveness of the registration statement for its proposed public offering, the Company filed an application with the SEC for the withdrawal of the registration statement, including all amendments and exhibits to the registration statement. The application for withdrawal stated that the Company did not intend to pursue the contemplated public offering at that time. Pursuant to Rule 477 under the Securities Act, the application was deemed granted at the time the application was filed, because it was filed before the effective date of the registration statement, and the SEC did not notify the Company that the application for withdrawal would not be granted within 15 calendar days after the Company had filed the application.
On June 22, 2023, Univest and Mr. Richmond requested through counsel that the Company either reissue the Cancelled Securities or issue them new securities with equivalent terms and conditions, in light of the fact that the Company was not proceeding with the public offering. On July 16, 2023, Univest and Mr. Richmond communicated through counsel that they believed that the Cancelled Securities should be reissued as if they were never canceled, meaning that they should have all of the adjusted terms that may have applied to the Cancelled Securities had they not been cancelled.
Pursuant to these requests, on July 25, 2023 and September 29, 2023, the Company approved the grant of the following securities to Univest and Mr. Richmond: (i) Convertible Notes (the “Replacement Convertible Notes”) with terms and conditions equivalent to or at least as favorable as those that would have applied to each of the respective Placement Agent Convertible Notes, such that, among other adjustments, the principal and any accrued interest under the Replacement Convertible Notes is convertible into shares of common stock at $0.10 per share, subject to adjustment, reflecting adjustments to their terms equivalent to those that applied to the Convertible Notes as a result of the Somahlution Warrants Exercise, and with principal increased to reflect the amount of interest that would have been incurred under the respective Placement Agent Convertible Notes up to the date of issuance, such that the adjusted principal under the Replacement Convertible Notes is $137,983.56 and $206,975.34, respectively, being the original principal under the Placement Agent Convertible Notes plus pre-issuance interest that would have accrued since the date of the issuance of the Placement Agent Convertible Notes as of July 25, 2023, maturing on July 25, 2025, and that, taking into account the Convertible Notes’ amended Mandatory Default Amount provisions as described in “—Recent Developments – Letter Agreement to Amend Convertible Notes to Permit Conversion of Mandatory Default Amount” and the default under the Convertible Notes that occurred as a result of their cross-default provisions as described in “—Funding Requirements and Other Liquidity Matters – Cross-Default Under Convertible Notes”, approximately $182,772 and $274,157 is due, respectively, and up to 1,827,715 and 2,741,573 shares of common stock are issuable upon conversion thereof, subject to adjustment and applicable beneficial ownership limitations and other limitations or restrictions, and having an approximate dollar value of $182,772 and $274,157, respectively; (ii) Class C Warrants (the “Replacement Class C Warrants”) with terms and conditions equivalent to or at least as favorable as those that would have applied to each of the respective Placement Agent Class C Warrants, reflecting adjustments to their terms equivalent to those that applied to the Class C Warrants as a result of the Somahlution Warrants Exercise such that the exercise price per share of the Replacement Class C Warrants is $0.10 per share, subject to adjustment, and the number of shares of common stock issuable upon exercise of each of the Replacement Class C Warrants reflecting a proportional increase relative to the number of shares issuable under the respective Placement Agent Class C Warrants equivalent to the difference between the exercise price per share of the Placement Agent Class C Warrants and the exercise price of such Replacement Class C Warrants, such that up to 3,548,148 and 5,322,223 shares of common stock, respectively, are issuable upon exercise thereof, subject to adjustment, without regard to any beneficial ownership limitations and other limitations or restrictions; (iii) Placement Agent Warrants (the “Replacement Placement Agent Warrants”) with terms and conditions equivalent to or at least as favorable as those that would have applied to those that applied to each of the respective 2022 Placement Agent Warrants, reflecting adjustments to their terms equivalent to those that applied to the Class C Warrants as a result of the Somahlution Warrants Exercise such that the exercise price per share of the Replacement Placement Agent Warrants is $0.10 per share, subject to adjustment, and the number of shares of common stock issuable upon exercise of each of the Replacement Placement Agent Warrants reflecting a proportional increase relative to the number of shares issuable under the respective 2022 Placement Agent Warrants equivalent to the difference between the exercise price per share of the 2022 Placement Agent Warrants and the exercise price of the Replacement Placement Agent Warrants, such that up to 19,293,621 and 28,940,432 shares of common stock, respectively, are issuable upon exercise thereof, subject to adjustment and applicable beneficial ownership limitations and other limitations or restrictions; and (iv) 300,000 shares of common stock to Mr. Richmond, being the same number of shares as the Consultant Shares (the “Replacement Consultant Shares” and together with the Replacement Convertible Notes, the Replacement Class C Warrants, and Replacement Placement Agent Warrants, the “Replacement Placement Agent and Consultant Securities”). In connection with these grants, each of Univest and Mr. Richmond agreed to waivers of any registration rights that would have been applicable to each of the Replacement Convertible Notes, the Replacement Class C Warrants, and the Replacement Placement Agent Warrants.
| 36 |
In May 2023, the event described under “—Funding Requirements and Other Liquidity Matters – Default Under Promissory Note” and “—Funding Requirements and Other Liquidity Matters – Cross-Default Under Convertible Notes” occurred. Assuming that the event described would have triggered the cross-default provision in the Placement Agent Convertible Notes if they had not been cancelled, and assuming that each of the Replacement Placement Agent Convertible Notes are also subject to immediate payment of the applicable Mandatory Default Amount, the aggregate Mandatory Default Amount that may be due under the Replacement Placement Agent Convertible Notes would be $456,929, or approximately $0.1 million more than would otherwise have been due under the Placement Agent Convertible Notes on the date of the default had they been outstanding on that date.
Under the unit purchase agreement entered into on May 27, 2021 with certain holders of several of the Convertible Notes, each of the Company’s subsidiaries entered into a guaranty to guarantee the repayment of the Company’s obligations under the Convertible Notes, and the Company and its subsidiaries entered into security agreements granting security interests in all of their respective assets for up to the dollar value owed under the respective Convertible Notes. The respective Convertible Notes were issued for aggregate principal of approximately $1.2 million. Under each unit purchase agreement entered into with respect to subsequent issuances of the Convertible Notes, including the unit purchase agreement entered into with each of Univest and Mr. Richmond in connection with the issuance of the Placement Agent Convertible Notes, the Company and its subsidiaries were obligated to enter into similar security agreements and guaranties, but did not do so.
Univest and Mr. Richmond have not exercised any remedies applicable to the Replacement Convertible Notes or given notice of any intention to do so as of the date of this report. In the event that the balance owed under the Replacement Convertible Notes, including the respective Mandatory Default Amount, is not repaid upon demand, Univest and Mr. Richmond may seek to take possession of some or all of the Company’s and its subsidiaries’ assets, force the Company and its subsidiaries into bankruptcy proceeds, or seek other legal remedies against the Company and its subsidiaries. In such event, the Company’s business, operating results and financial condition may be materially adversely affected.
Special Stockholders Meeting, Changes in Authorized Shares, and Approval of Voting Rights for Certain Debtholders
On May 15, 2023, the Company made a state filing which provided for the increase of the Company’s authorized common stock from 20,000,000 shares to 300,000,000 shares and the corresponding change of every one (1) share of the Company’s issued and outstanding common stock to fifteen (15) shares, such that there were 300,000,000 authorized shares of common stock with no proportional change to the outstanding shares of common stock, which totaled 43,420,350 shares as of May 15, 2023.
On August 9, 2023, a special meeting of stockholders (the “Special Stockholders Meeting”) was held to consider and vote on the following proposals: (i) to approve an amendment to the Company’s articles of incorporation, as amended to date, to increase the total number of shares of authorized common stock from 300,000,000 to 2,000,000,000 (the “Capital Event Amendment”), and (ii) to approve an amendment to the Company’s articles of incorporation, as amended to date, to provide that holders of any of the Company’s bonds, debentures or other obligations of the Company may have, at the option of the board of directors of the Company, any of the rights of a stockholder of the Company, and that the holders of the Convertible Notes issued between December 21, 2021 and August 12, 2022, shall be entitled, from the date of the filing with the Nevada Secretary of State providing such amendment, to vote with the shares of the Company’s common stock, on an as-converted to common stock basis without actually having converted the Convertible Notes to shares of the Company’s common stock, with respect to all corporate matters of the Company on which the holders of common stock are entitled to vote, as provided in of the Convertible Notes (the “Voting Rights Amendment”). Approval of each proposal required a “quorum” at the meeting consisting of a majority (more than 50%) of the outstanding voting shares as of the record date, present in person or represented by proxy, and the affirmative “for” vote of the holders of a majority of the shares represented at the meeting, in person or by proxy, and entitled to vote.
At the Special Stockholders Meeting, a quorum was attained, and each of the proposals described above was approved by the required number of votes of the Company’s stockholders. On August 15, 2023, the board of directors of the Company approved resolutions authorizing each of the holders of the Convertible Notes to vote with the shares of common stock, on an as-converted to common stock basis, with respect to all corporate matters of the Company on which the holders of common stock are entitled to vote, subject to any applicable beneficial ownership limitations, upon the effectiveness of the Certificate of Amendment Pursuant to NRS 78.380 & 78.390 to be filed with the Nevada Secretary of State providing for the Capital Event Amendment and the Voting Rights Amendment (the “Certificate of Amendment”). On August 16, 2023, the Company filed the Certificate of Amendment with the Nevada Secretary of State providing for the Capital Event Amendment and the Voting Rights Amendment, and the Certificate of Amendment became effective upon filing. Accordingly, upon the filing of the Certificate of Amendment, (i) the Company’s authorized shares of common stock were increased from 300,000,000 to 2,000,000,000 with no corresponding change in the number of issued and outstanding shares of common stock; (ii) the Company’s board of directors may grant any of the rights of stockholders to any of the holders of any of the Company’s bonds, debentures or other obligations; and (iii) all of the holders of the Convertible Notes became entitled to vote with the shares of the Company’s common stock, on an as-converted to common stock basis without actually having converted the Convertible Notes to shares of the Company’s common stock, with respect to all corporate matters of the Company on which the holders of common stock are entitled to vote, as provided in the Convertible Notes.
| 37 |
As a result of the filing of the Certificate of Amendment, the voting rights of the holders of the Company’s common stock may be deemed to be proportionately reduced to the extent that the voting rights granted to the holders of the Convertible Notes by the Certificate of Amendment may be exercised at a meeting or with respect to other applicable actions of the stockholders of the Company. As of the date of this report, the holders of these voting rights have the right to cast up to 214,709,068 votes, compared to 46,666,760 votes by the holders of shares of the outstanding common stock. These voting rights remain subject to beneficial ownership limitations, including that holders of Convertible Notes may vote the amount of shares of common stock that that they may convert their Convertible Notes into subject to the applicable beneficial ownership percentage limitation.
OID Units Private Placement
First Closing of OID Units Private Placement
On May 12, 2023, the Company conducted the first closing (the “First OID Units Closing”) of a private placement (the “OID Units Private Placement”) of up to $10,000,000 for an aggregate of up to 100,000,000 units (“OID Units”), under a unit purchase agreement (each, an “OID Units Purchase Agreement”). Each investor represented that it is an “accredited investor” as such term is defined by Rule 501(a) of the Securities Act. Each issuance of OID Units to an investor in the OID Units Private Placement consists of (i) an OID Convertible Note, convertible into shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment, (ii) a Class E Warrant for the purchase of 125% of the shares of common stock into which the OID Convertible Note may be converted at $0.10 per share, subject to adjustment, and (iii) a Class F Warrant for the purchase of 125% of the shares of common stock into which the OID Convertible Note may be converted at $0.20 per share, subject to adjustment (together with the Class E Warrants, the “Class E and F Warrants”). Under the OID Units Purchase Agreement, the minimum investment permitted is $1,000. The Company retained Univest as its exclusive placement agent in connection with the sale of the OID Units pursuant to the OID Units Purchase Agreement under a Placement Agency Agreement, dated April 27, 2023 (the “April 2023 PAA”). In addition to the rights set forth in each OID Units Purchase Agreement, the OID Convertible Notes, and the Class E and F Warrants, each investor party to each OID Units Purchase Agreement and each holder of one of the OID Convertible Notes, the Class E Warrants, or the Class F Warrants will have rights under the respective Registration Rights Agreement with the Company (each, “OID Units Registration Rights Agreement”), as described below.
In connection with the First OID Units Closing, on May 12, 2023, Walleye entered into an OID Units Purchase Agreement dated as of such date, paid a subscription amount of $1,000,000, and the Company issued 11,764,710 OID Units consisting of (i) an OID Convertible Note in the principal amount of $1,176,471, convertible into 11,764,710 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment, (ii) a Class E Warrant for the purchase of 14,705,880 shares of common stock at $0.10 per share, subject to adjustment, and (iii) a Class F Warrant for the purchase of 14,705,880 shares of common stock at $0.20 per share, subject to adjustment. In connection with the First OID Units Closing, pursuant to the April 2023 PAA and the OID Units Purchase Agreement, the Company received net proceeds of $870,000 after deducting Univest’s 8% fee and $50,000 for reimbursement of Univest’s legal fees and expenses. See below for additional related discussion.
Second Closing of OID Units Private Placement
On May 30, 2023, the Company conducted the second closing (the “Second OID Units Closing”) of the OID Units Private Placement. Each investor represented that it is an “accredited investor” as such term is defined by Rule 501(a) of the Securities Act. In connection with the Second OID Units Closing, Hexin Global Ltd. (“Hexin”) and Walleye agreed to the cancellation of an unsecured promissory note issued to Hexin on December 28, 2022 for the principal amount of $750,000 for gross proceeds of $1,750,000 (the “Hexin Promissory Note”) and the Walleye Promissory Note, respectively, and Frank Maresca Jr. (“Mr. Maresca”) agreed to the cancellation of certain indebtedness, in exchange for OID Units and related agreements, as described below.
| 38 |
First, under a Cancellation and Exchange Agreement, dated as of May 30, 2023 (the “Hexin Cancellation Agreement”), between the Company and Hexin, Hexin agreed to cancel the Hexin Promissory Note in exchange for: (i) the execution of an OID Units Purchase Agreement, dated as of May 30, 2023, between the Company and Hexin, Walleye and Mr. Maresca (the “Second OID Units Purchase Agreement”), (ii) the execution of an OID Units Registration Rights Agreement, dated as of May 30, 2023, between the Company and Hexin, Walleye and Mr. Maresca (the “Second OID Units Registration Rights Agreement”), and (iii) the issuance of 9,578,040 OID Units consisting of (a) an OID Convertible Note in the principal amount of $957,804 for a subscription equal to $814,133 (the aggregate amount of principal plus accrued and unpaid interest under the Hexin Promissory Note as of May 30, 2023), convertible into 9,578,040 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment (the “Hexin OID Convertible Note”), (b) a Class E Warrant for the purchase of 11,972,550 shares of common stock at $0.10 per share, subject to adjustment (the “Second Hexin Class E Warrant”), and (c) a Class F Warrant for the purchase of 11,972,550 shares of common stock at $0.20 per share, subject to adjustment (the “Second Hexin Class F Warrant”). The Hexin Cancellation Agreement contains a release of claims against the Company relating to the Hexin Promissory Note.
Second, under a Cancellation and Exchange Agreement, dated as of May 30, 2023, between the Company and Walleye (the “Walleye Cancellation Agreement”), Walleye agreed to cancel the Walleye Promissory Note in exchange for: (i) the execution of the Second OID Units Purchase Agreement, (ii) the execution of the Second OID Units Registration Rights Agreement, and (iii) the issuance of 14,705,890 OID Units consisting of (a) an OID Convertible Note in the principal amount of $1,470,589 for a subscription equal to $1,250,000 (the aggregate amount of principal under the Walleye Promissory Note as of May 30, 2023), convertible into 14,705,890 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment (the “Second Walleye OID Convertible Note”), (b) a Class E Warrant for the purchase of 18,382,362 shares of common stock at $0.10 per share, subject to adjustment (the “Second Walleye Class E Warrant”), and (c) a Class F Warrant for the purchase of 18,382,362 shares of common stock at $0.20 per share, subject to adjustment (the “Second Walleye Class F Warrant”). The Walleye Cancellation Agreement contains a release of claims against the Company relating to the Walleye Promissory Note.
Third, under a Cancellation and Exchange Agreement, dated as of May 30, 2023, between the Company and Mr. Maresca, Mr. Maresca agreed to cancel $150,000 of the aggregate short-term indebtedness to Mr. Maresca, which arose in the ordinary course of business for certain consulting services provided by Mr. Maresca to the Company, in exchange for: (i) the execution of the Second OID Units Purchase Agreement, (ii) the execution of the Second OID Units Registration Rights Agreement, and (iii) the issuance of 1,764,710 Units consisting of (a) an OID Convertible Note in the principal amount of $176,471 for a subscription equal to $150,000 (the amount of the indebtedness being cancelled), convertible into 1,764,710 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment (the “Maresca OID Convertible Note”), (b) a Class E Warrant for the purchase of 2,205,887 shares of common stock at $0.10 per share, subject to adjustment (the “Maresca Class E Warrant”), and (c) a Class F Warrant for the purchase of 2,205,887 shares of common stock at $0.20 per share, subject to adjustment (the “Maresca Class F Warrant”). The Maresca Cancellation Agreement contains a release of claims against the Company relating to the cancelled indebtedness.
The Hexin OID Convertible Note, the Second Hexin Class E Warrant and the Second Hexin Class F Warrant are subject to the terms and conditions of the Hexin Cancellation Agreement. The Second Walleye OID Convertible Note, the Second Walleye Class E Warrant and the Second Walleye Class F Warrant are subject to the terms and conditions of the Walleye Cancellation Agreement. The Maresca OID Convertible Note, the Maresca Class E Warrant and the Maresca Class F Warrant are subject to the terms and conditions of the Maresca Cancellation Agreement. The Second OID Units Purchase Agreement and the Second OID Units Registration Rights Agreement are also subject to the terms and conditions of each respective Cancellation and Exchange Agreement.
Univest did not receive a fee in connection with the Second OID Units Closing because there were no gross proceeds.
Third Closing of OID Units Private Placement
On July 10, 2023, the Company conducted the third closing (the “Third OID Units Closing”) of the OID Units Private Placement under an OID Units Purchase Agreement between Hexin, which represented that it is an “accredited investor” as such term is defined by Rule 501(a) of the Securities Act, and the Company. In connection with the Third OID Units Closing, on July 10, 2023, Hexin paid a subscription amount of $1,000,000, and the Company issued 11,764,710 OID Units consisting of (i) an OID Convertible Note in the principal amount of $1,176,471, convertible into 11,764,710 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment, (ii) a Class E Warrant for the purchase of 14,705,880 shares of common stock at $0.10 per share, subject to adjustment, and (iii) a Class F Warrant for the purchase of 14,705,880 shares of common stock at $0.20 per share, subject to adjustment. See below for additional related discussion of these securities. In connection with the Third OID Units Closing, after deducting Univest’s 8% fee of $80,000 and $50,000 for reimbursement of Univest’s legal fees pursuant to the April 2023 PAA, and, pursuant to the 2021 Placement Agency Agreement, after deducting Univest’s outstanding fees of $140,000 or 8% from the prior issuances of the Walleye Promissory Note for the principal amount of $1,000,000 on February 6, 2023 and the Hexin Promissory Note, the Company received net proceeds from the Third OID Units Closing of $730,000.
Fourth Closing of OID Units Private Placement
On August 30, 2023, the Company conducted the fourth closing (the “Fourth OID Units Closing”) of the OID Units Private Placement under an OID Units Purchase Agreement. Each investor represented that it is an “accredited investor” as such term is defined by Rule 501(a) of the Securities Act. In connection with the Fourth OID Units Closing, on August 30, 2023, 12 of the investors paid an aggregate subscription amount of $825,000, and the Company issued to these investors an aggregate 9,705,960 OID Units consisting of (i) OID Convertible Notes in the aggregate principal amount of $970,596, convertible into 9,705,960 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment, (ii) Class E Warrants for the purchase of 12,132,448 shares of common stock at $0.10 per share, subject to adjustment, and (iii) Class F Warrants for the purchase of 12,132,448 shares of common stock at $0.20 per share, subject to adjustment. In connection with the Fourth OID Units Closing, after deducting Univest’s 8% fee of $66,000 and $25,000 for reimbursement of Univest’s legal fees pursuant to the April 2023 PAA, the Company received net proceeds of $734,000.
Also in connection with the Fourth OID Units Closing, under a Cancellation and Exchange Agreement, dated as of August 30, 2023, between the Company and Mr. Maresca (the “August 2023 Maresca Cancellation Agreement”), Mr. Maresca agreed to cancel $200,000 of aggregate short-term indebtedness to Mr. Maresca, which arose in the ordinary course of business for certain consulting services provided by Mr. Maresca to the Company, in exchange for: (i) the execution of the respective OID Units Purchase Agreement, (ii) the execution of the respective OID Units Registration Rights Agreement, and (iii) the issuance of 2,352,950 OID Units consisting of (a) an OID Convertible Note in the principal amount of $235,295 for a subscription equal to $200,000 (the amount of the indebtedness being cancelled), convertible into 2,352,950 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment (the “August 2023 Maresca OID Convertible Note”), (b) a Class E Warrant for the purchase of 2,941,187 shares of common stock at $0.10 per share, subject to adjustment (the “August 2023 Maresca Class E Warrant”), and (c) a Class F Warrant for the purchase of 2,941,187 shares of common stock at $0.20 per share, subject to adjustment (the “August 2023 Maresca Class F Warrant”). The August 2023 Maresca Cancellation Agreement contains a release of claims against the Company relating to the cancelled indebtedness.
The August 2023 Maresca OID Convertible Note, the August 2023 Maresca Class E Warrant and the August 2023 Maresca Class F Warrant are subject to the terms and conditions of the August 2023 Maresca Cancellation Agreement. Mr. Maresca’s rights under the respective OID Units Purchase Agreement and the respective OID Units Registration Rights Agreement are also subject to the terms and conditions of the August 2023 Maresca Cancellation Agreement.
Univest did not receive a fee in connection with the transactions conducted pursuant to the August 2023 Maresca Cancellation Agreement because there were no related gross proceeds.
| 40 |
OID Units Purchase Agreements
Each OID Units Purchase Agreement provides a right of first offer to investor parties to any proposed offer or sale of equity securities by the Company until the first anniversary of the First OID Units Closing (i.e., May 12, 2024). Each OID Units Purchase Agreement also contains certain liquidated damages provisions, including for any failure of the Company to meet the requirements for the OID Convertible Notes or the Class E and F Warrants to be converted or exercised for non-restricted shares of common stock under Rule 144, and on every 30th day (pro-rated for periods totaling less than 30 days) thereafter, until cured or such Rule 144 requirements no longer apply, up to a maximum of 25% of each affected investor’s subscription amount. Each OID Units Purchase Agreement also contains a most-favored nations clause that provides that in connection with any subsequent equity financing of the Company for consideration (a “Subsequent Financing”), each investor may accept the securities and terms of the Subsequent Financing in substitution of the securities and terms of each OID Units Purchase Agreement, upon notice from an investor, subject to the terms and conditions of each OID Units Purchase Agreement. Each OID Units Purchase Agreement, the OID Convertible Notes and the Class E and F Warrants will be amended to incorporate the terms and forms of the securities sold in the Subsequent Financing upon the closing of the Subsequent Financing. Each OID Units Purchase Agreement will terminate upon certain events including mutual written consent, by either party upon notice if a closing has not occurred within 15 business days of the date of the agreement, an event of default under the OID Convertible Notes, the full conversion or repayment of the OID Convertible Notes and the non-ownership of any shares of common stock issuable upon conversion of the OID Convertible Notes or exercise of the Class E and F Warrants. Each OID Units Purchase Agreement also contains indemnification of the investors relating to claims relating to the transactions under each OID Units Purchase Agreement which will survive termination. Each investor’s rights under the OID Units Purchase Agreement may be assigned to another “accredited investor” as defined by Rule 501(a) of the Securities Act.
OID Convertible Notes
The OID Convertible Notes will mature nine months after the date of the First OID Units Closing with respect to OID Convertible Notes issued in the first two closings of the OID Units Private Placement and will mature nine months after the date of issuance for subsequent closings. The OID Convertible Notes accrue 10% of interest per annum on the outstanding principal amount. The OID Convertible Notes will be unsecured and subordinated to any senior indebtedness of the Company. The OID Convertible Notes’ principal and accrued interest may generally be converted at any time at a conversion price of $0.10 per share, subject to adjustment, at the option of the holder, into shares of common stock, subject to certain limitations on receiving shares upon conversion of an OID Convertible Note, including that such shares may be received only to the extent that the holder (together with any other person with which the holder is considered to be part of a “group” under Section 13 of the Exchange Act or with which the holder otherwise files reports under Section 13 and/or Section 16 of the Exchange Act) would not become the “beneficial owner” (as such term is defined in the Exchange Act and the rules and regulations thereunder) of in excess of 4.99% of the shares of common stock outstanding, subject to automatic increase to 9.99% if the holder becomes a beneficial owner of more than 4.99%, subject to a 61-day notice requirement. This limitation does not apply to certain provisions of the OID Convertible Notes. In the event the Company offers, sells, grants, issues, or otherwise disposes of common stock or securities with rights to common stock, or announces the intention to do one of such things, before the listing of the common stock on a National Stock Exchange, at a lower price per share than the OID Convertible Notes’ conversion price while the OID Convertible Notes are outstanding, then generally the conversion price of the OID Convertible Notes will be lowered to such price per share. This adjustment provision will apply one time only. The OID Convertible Notes also have customary antidilution provisions in the event of stock splits, certain changes of control or similar transactions, and rights offerings. While the OID Convertible Notes are outstanding and for 12 months after the Company lists its common stock on a National Stock Exchange, the Company may not exchange or cooperate to exchange any indebtedness or securities, reduce or change the conversion, exercise or exchange price of any securities convertible, exercisable or exchangeable for common stock, amend non-convertible debt to convertible debt, issue securities at a price based on or varying with trading prices or quotations for the common stock or with a price reset term, or agree to sell securities at a future determined price. Until 30 days after the OID Convertible Notes are converted or repaid in full, the Company may not sell any securities in a capital or debt raising transaction or series of related transactions which grant to an investor the right to receive additional securities based upon future transactions of the Company on terms more favorable than those granted to such investor in such transaction or series of related transactions. The OID Convertible Notes may not be prepaid by the Company. In the event of default under the OID Convertible Notes, subject to certain cure rights, interest under the OID Convertible Notes will increase to the lower of 18% and the maximum legal interest rate, and the outstanding balance will become immediately due and payable. The OID Convertible Notes have the registration rights set forth in the respective OID Units Registration Rights Agreement. See “—OID Units Registration Rights Agreement” below.
| 41 |
Class E and F Warrants
The Class E and F Warrants are generally exercisable from the date of the Capital Event Amendment until five years from the date of issuance. The exercise right is subject to a beneficial ownership limitation such that shares of common stock may be received upon exercise only to the extent that the holder (together with any other person with which the holder is considered to be part of a “group” under Section 13 of the Exchange Act or with which the holder otherwise files reports under Section 13 and/or Section 16 of the Exchange Act) would not become the “beneficial owner” (as such term is defined in the Exchange Act and the rules and regulations thereunder) of in excess of 4.99% of the shares of common stock outstanding, subject to automatic increase to 9.99% if the holder becomes a beneficial owner of more than 4.99%, subject to a 61-day notice requirement. This limitation does not apply to certain provisions of the Class E and F Warrants. The Class E and F Warrants provide for exercise on a cashless net exercise basis if there is no effective registration statement registering or current prospectus available for the resale of shares of common stock issuable under the Class E and F Warrants (a “Registration Default”) after 180 days following the issue date (the “Registration Deadline”). In addition, for each 30 days following the Registration Deadline, or portion of any 30-day period thereafter in which a Registration Default exists, the amount of shares issuable under the Class E and F Warrants shall be automatically increased by 5%, prorated for a partial month, not to exceed in the aggregate an additional 25%. In the event the Company sells, grants, issues, or otherwise disposes of common stock or securities with rights to common stock, or announces an intention to do so, at a lower effective price per share than the exercise prices of the Class E and F Warrants, while any such Class E and F Warrants are outstanding, then generally the applicable Class E and F Warrants’ exercise price(s) will be reduced to the greater of such lower price or a floor price as determined by any applicable National Stock Exchange. The Class E and F Warrants have the registration rights set forth in the respective OID Units Registration Rights Agreement. The Class E and F Warrants also have customary antidilution provisions in the event of stock splits, certain changes of control or similar transactions, and rights offerings. The Class E and F Warrants may be transferred subject to their terms.
OID Units Registration Rights Agreements
Under each OID Units Registration Rights Agreement, as amended if applicable, the Company is required to file a registration statement with the SEC registering the resale of the shares of common stock issuable pursuant to conversion of the OID Convertible Notes and exercise of the Class E and F Warrants within 67 days of the date of the respective closing of the OID Units Private Placement and to cause the registration statement to become effective within 120 days after such filing date. The Company must maintain the effectiveness of the registration statement until the earlier of the first anniversary of its effectiveness date and the date that the shares registered for resale may be resold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information regarding our contractual obligationsrequirement under Rule 144. If the Company fails to file the registration statement by the filing deadline, or, prior to the effective date of a registration statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the SEC in respect of such registration statement within 30 calendar days after the receipt of comments by or notice from the SEC that such amendment is required in order for such registration statement to be declared effective, or cause it to become effective by the effectiveness deadline, or the registration statement ceases to be effective or the related prospectus becomes unavailable for resales for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, then on the date of such failure and every 30 calendar days after such date until the failure is cured, the Company must pay to each investor partial liquidated damages equal to 1% of the aggregate purchase price paid by such investor pursuant to the respective OID Units Purchase Agreement, up to a maximum of 10% of the aggregate subscription amount paid by the investor. If the Company fails to pay the partial liquidated damages within seven days of any such failure, the Company will pay interest thereon at a rate of the lesser of 18% per annum or the maximum amount permitted under applicable law to each investor, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. Additional liquidated damages requirements will end when the applicable failure is cured or Rule 144 becomes available for resale of all the shares of common stock otherwise required to be registered for resale under each OID Units Registration Rights Agreement. Liquidated damages will not apply to a failure that is due to limits imposed by the SEC’s interpretation of Rule 415 under the Securities Act. In addition, if there is not an effective registration statement covering all shares of common stock subject to the registration rights under each OID Units Registration Rights Agreement at any time when required and the Company proposes to file a registration statement to register certain other offerings, not including an underwritten public offering of its securities for its own account or the account of others or certain other types of registration statements, then the Company must provide notice to investor parties and include the shares otherwise required to be registered under each OID Units Registration Rights Agreement within 15 days of such notice, unless they are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements). Each OID Units Registration Rights Agreement contains related procedural and filing requirements and investor notice and review rights as to certain events and filings relating to the registration statement. The Company will be responsible for all fees and expenses relating to compliance with each OID Units Registration Rights Agreement, as well as up to $10,000 in reasonable attorney fees for the investors’ review of the registration statement. Each OID Units Registration Rights Agreement contains mutual indemnification provisions for claims relating to a registration statement. The investor’s rights under the OID Units Purchase Agreement may be assigned to another “accredited investor” as defined by Rule 501(a) of the Securities Act.
| 42 |
Holders of rights to 67% or more of the shares issuable upon conversion of the OID Convertible Notes and exercise of the Class E and F Warrants may agree to amend or waive the requirements of each respective OID Units Registration Rights Agreement. As described under “—Recent Developments – Amendment to Certain OID Units Registration Rights Agreements”, under an Amendment to Registration Rights Agreement, dated as of July 6, 2023, sufficient holders of such rights agreed to amend each OID Units Registration Rights Agreement then in effect to provide that the initial filing of the registration statement required by such OID Units Registration Rights Agreement shall be made on or before the date that is 67 days after the date of the respective closing of the OID Units Private Placement. Each subsequent OID Units Registration Rights Agreement also contains the amended term.
April 2023 PAA
Under the April 2023 PAA, Univest acted as the Company’s exclusive placement agent in connection with the OID Units Private Placement. The Company agreed to pay Univest a cash placement fee equal to 8% of the gross proceeds from the sale of the OID Units, 8% of the gross proceeds from the exercise of the Class E and F Warrants, and certain Placement Agent Warrants. The Company further agreed to reimburse Univest for the fees and expenses of its due diligence and legal counsel of up to $200,000. The April 2023 PAA provides indemnification rights to Univest and its affiliates in the event of certain claims relating to the April 2023 PAA or related transactions. Under the April 2023 PAA, Univest has the right to act as the Company’s sole placement agent or an underwriter for any future equity financing occurring during the 18-month period following the consummation of the OID Units Private Placement. The term of the April 2023 PAA continues until the completion of the OID Units Private Placement, subject to termination after 15 days’ notice after July 31, 2023 or earlier in the case of termination for cause. Univest will also receive fees and Placement Agent Warrants on the same basis as described above with respect to any private or public offering or other financing or capital raising transaction of any kind of the Company within 12 months of the termination or expiration of the April 2023 PAA with an investor whom Univest has, directly or indirectly, introduced to the Company during the term of the April 2023 PAA.
Pursuant to the April 2023 PAA, in connection with closings of the OID Units Private Placement, as of September 30, 2023, the Company had paid Univest $80,000 in total fees and $50,000 as reimbursement of Univest’s legal fees.
Amendment to Certain OID Units Registration Rights Agreements
In connection with the First OID Units Closing, an OID Units Registration Rights Agreement, dated as of May 12, 2023 (the “May 12, 2023 Registration Rights Agreement”), between the Company and Walleye, provided that the Company file a registration statement within 60 days of such closing, registering the resale of the shares of common stock issuable pursuant to conversion of the 15% original issue discount unsecured subordinated convertible promissory note and exercise of the Class E Warrant and Class F Warrant issued to that investor in connection with such closing, and contained other terms and conditions. Also in connection with the First OID Units Closing, pursuant to the Hexin Promissory Note, on May 22, 2023, the Company issued Hexin a Class E Warrant and a Class F Warrant, which provide for registration rights under the May 12, 2023 Registration Rights Agreement. As previously reported in a Current Report on Form 8-K filed on June 5, 2023, in connection with the second closing of the OID Units Private Placement, which occurred on May 30, 2023, an OID Units Registration Rights Agreement, dated as of May 30, 2023 (the “May 30, 2023 Registration Rights Agreement” and each of the May 30, 2023 Registration Rights Agreement and the May 12, 2023 Registration Rights Agreement respectively, the “Amended OID Units Registration Rights Agreements”), between the Company and Walleye, Hexin and Mr. Maresca, also provided that the Company file a registration statement within 60 days of such closing, registering the resale of the shares of common stock issuable pursuant to conversion of the OID Convertible Notes and exercise of the Class E Warrants and Class F Warrant issued to these investors in connection with such closing, and contained other terms and conditions.
| 43 |
Holders of rights to 67% or more of the shares issuable upon conversion of the OID Convertible Notes and exercise of the Class E Warrants and the Class F Warrants may agree to amend or waive the requirements of each of the respective Amended OID Units Registration Rights Agreements. Under an Amendment to Registration Rights Agreement, dated as of July 6, 2023 (“Amendment to Registration Rights Agreement”), Walleye and Hexin, being holders of such rights, agreed to an amendment to each of the Amended OID Units Registration Rights Agreements to provide that the initial filing of the registration statement required by such Amended OID Units Registration Rights Agreements shall be made on or before the date that is 67 days after the date of the respective closing of the OID Units Private Placement.
Partial Liquidated Damages Incurred Under OID Units Registration Agreements
Pursuant to each applicable OID Units Registration Rights Agreement, on July 18, 2023, the Company filed a registration statement with the SEC to register for resale the shares of common stock issuable upon conversion of the OID Convertible Notes and shares issuable upon exercise of the Class E and F Warrants issued as of such date in the OID Units Private Placement, as well as other shares held by existing stockholders or issuable upon conversion or exercise of other outstanding securities. On July 21, 2023, the SEC issued a letter containing comments with respect to the registration statement. As indicated above, under each applicable OID Units Registration Rights Agreement, the Company was disclosedrequired, among other things, to file a pre-effective amendment to the registration statement and otherwise respond in Management’s Discussionwriting to comments made by the SEC with respect to the registration statement. However, the Company did not file a pre-effective amendment to the registration statement and Analysisrespond to this letter until October 12, 2023. The filing of Financial Conditionthe pre-effective amendment was delayed in order to allow additional time for the Company to include the registration of the resale of additional shares of common issuable upon conversion of the OID Convertible Notes and Resultsshares issuable upon exercise of Operationsthe Class E and F Warrants issued subsequent to the initial filing of the registration statement. Due to the failure of the Company to respond and file within 30 calendar days of receipt of the letter issued by the SEC with respect to the registration statement, on August 20, 2023, the date of such failure, and every 30 calendar days after such date until the failure was cured on October 12, 2023, the Company became required to pay partial liquidated damages to each investor party in the first, second, third, and fourth closings of the OID Units Private Placement equal to 1% of the aggregate purchase price paid by such investor pursuant to the respective OID Units Purchase Agreement, up to a maximum of 10% of the aggregate subscription amount paid by the investor. The Company failed to pay the partial liquidated damages within seven days of such failure. As a result, the Company will pay interest thereon at a rate of the lesser of 18% per annum or the maximum amount permitted under applicable law to each investor, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full.
Issuance of OID Units Placement Agent Warrants
Under the April 2023 PAA and the forms of placement agent warrants agreed to in connection with the April 2023 PAA, the Company also agreed, upon Univest’s payment of $100.00, to issue certain placement agent warrants (the “OID Units Placement Agent Warrants”) to Univest and/or its designee(s) at each closing of the OID Units Private Placement. The OID Units Placement Agent Warrants were required to be issued for the purchase of 8% of the aggregate number of shares of common stock initially issuable upon conversion of the OID Convertible Notes at $0.10 per share, 8% of the aggregate number of shares of common stock initially issuable upon exercise of the Class E Warrants at $0.10 per share, and 8% of the aggregate number of shares of common stock initially issuable upon exercise of the Class F Warrants at $0.20 per share, subject to adjustment. On September 12, 2023, Univest notified the Company that the OID Units Private Placement’s final closing had occurred, and on September 13, 2023, made a payment to the Company of $100.00. Accordingly, on September 13, 2023, OID Units Placement Agent Warrants were issued to Univest and its designees, Bradley Richmond, Bartholemew Pan-Kita, and Azem Nesimi, to purchase a total of 4,356,687, 6,695,616, 635,294, and 7,059 shares of common stock at $0.10 per share, respectively, which in aggregate was equal to 8% of the shares issuable upon conversion or exercise of the OID Convertible Notes and the Class E Warrants issued in each of the closings of the OID Units Private Placement as of that date, and a total of 2,585,479, 3,878,218, 0, and 0 shares of common stock at $0.20 per share, respectively, which in aggregate was equal to 8% of the shares issuable upon exercise of the Class F Warrants issued in each of the closings of the OID Units Private Placement as of that date.
The OID Units Placement Agent Warrants are generally exercisable from the date of issuance until August 16, 2028. The exercise right is subject to the following beneficial ownership limitation: Exercise is permitted only if it would not cause the holder (together with its Affiliates (as defined by Rule 405 under the Securities Act), and any other persons acting as a group together with the holder or any of the holder’s Affiliates), to beneficially own in excess of the percentage of the outstanding securities that are permitted to be beneficially owned (as described below), which, for purposes of the limitation, includes shares issuable upon exercise of the OID Units Placement Agent Warrants, excludes shares issuable upon exercise of the unexercised portion of the OID Units Placement Agent Warrants and exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company subject to an analogous limitation on conversion or exercise beneficially owned by the holder or any of its Affiliates, and otherwise calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of the OID Units Placement Agent Warrants, the number of outstanding shares of common stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the exercised portion of the OID Units Placement Agent Warrants, by the holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The maximum percentage of beneficial ownership of the Company’s outstanding securities that applies to an exercise of each OID Units Placement Agent Warrant is 9.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise of the OID Units Placement Agent Warrant. The holder, upon notice to the Company, may increase or decrease the percentage limit, provided that the limitation in no event exceeds 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the OID Units Placement Agent Warrant. Any increase in the limitation will not be effective until the 61st day after such notice is delivered to the Company. This limitation does not apply to certain provisions of the OID Units Placement Agent Warrants.
The OID Units Placement Agent Warrants provide for exercise by payment of cash or on a cashless net exercise basis. In the event the Company sells, grants, issues, or otherwise disposes of common stock or securities with rights to common stock, or announces an intention to do so, at a lower price per share than the applicable OID Units Placement Agent Warrants’ exercise price, before the listing of the common stock on a National Stock Exchange, while such OID Units Placement Agent Warrants are outstanding, then the applicable OID Units Placement Agent Warrants’ exercise price will be reduced to the greater of such lower price or a floor price as determined by any applicable National Stock Exchange. The OID Units Placement Agent Warrants provide for equivalent registration rights as provided for under the August 2023 OID Units Registration Rights Agreement. The OID Units Placement Agent Warrants also have customary antidilution provisions in the event of stock splits, certain changes of control or similar transactions, and rights offerings. The OID Units Placement Agent Warrants also provide mutual indemnification relating to claims relating to a registration statement under which shares issuable upon exercise of the OID Units Placement Agent Warrants may be sold to the same or equivalent extent as the indemnification provision contained in ourthe OID Units Purchase Agreement.
| 44 |
Exercise of Somahlution Warrants at Reduced Exercise Price
On December 15, 2019, the Company entered into an asset purchase agreement (the “Somahlution Agreement”), as amended on March 31, 2020, May 29, 2020, and July 30, 2020, with Somahlution. Pursuant to the terms of the Somahlution Agreement, as amended, the Company agreed to the purchase of the Somahlution Assets (the “Somahlution Acquisition”). On August 4, 2020, the Somahlution Acquisition closed. As consideration for the Somahlution Acquisition, the Company issued to Somahlution’s former owners (the “Former Somahlution Owners”) a total of 10,000,000 restricted shares of common stock (the “Somahlution Purchase Shares”) and five-year warrants to purchase an additional 2,999,955 shares of common stock with an exercise price of $5.00 per share (the “Somahlution Warrants”).
On April 13, 2023, the Company delivered offer letter agreements (the “Somahlution Warrant Offer Letter Agreements”) to the Former Somahlution Owners, which offered to allow the Former Somahlution Owners to exercise the Somahlution Warrants to purchase the number of restricted shares of common stock issuable under the Somahlution Warrants at an exercise price reduced by the Company from $5.00 per share to $0.10 per share, on or prior to April 21, 2023, for maximum total cash proceeds of $299,995.50. As of the conclusion of this offer period, four of the Former Somahlution Owners had entered into Somahlution Warrant Offer Letter Agreements and had exercised their Somahlution Warrants to purchase a total of 2,652,159 shares of common stock for gross proceeds of approximately $265,216 (the “Somahlution Warrants Exercise”). Univest as the Company’s placement agent, which facilitated the Somahlution Warrants Exercise, waived any fees or reimbursable expenses that would otherwise have been payable with respect to the Somahlution Warrants Exercise pursuant to the 2021 Form 10-K.Placement Agency Agreement.
Adjustments to Conversion Price of Convertible Notes and Exercise Price of Class C Warrants and Number of Underlying Shares
As described under “—Convertible Notes” below, during the fiscal years ended December 31, 2021 and 2022, the Company conducted a private placement of units (the “Units Private Placement”) consisting of the Convertible Notes and the Class C Warrants, as were modified or amended from time to time, the general terms of which are described in detail in that section. Among their other terms, the Convertible Notes and Class C Warrants provide that a lower price per share, or more favorable terms, respectively, under subsequent equity issuances, not including any Qualified Financing (as defined in “—Convertible Notes”) and certain other exempt issuances, will be applicable to the conversion or exercise rights under the Convertible Notes and Class C Warrants, respectively. In addition, under a Letter Agreement between the Company and Univest as placement agent for the investors in the Units Private Placement, dated January 12, 2023 (the “January 2023 Letter Agreement”), the parties agreed that simultaneously with any adjustment to the exercise price under the Class C Warrants as a result of any equity issuances, not including any Qualified Financing and certain other exempt issuances, the number of shares of common stock that are issuable under the Class C Warrants will be increased such that the aggregate exercise price of such shares will be the same as the aggregate exercise price in effect immediately prior to the adjustment (without regard to any limitations on exercise contained in the Class C Warrants).
At the time of the Somahlution Warrants Exercise, the balance under the Convertible Notes was convertible at a conversion price of $1.75 per share and the Class C Warrants were exercisable at an exercise price of $2.25 per share. Outstanding Convertible Notes had underlying principal of $14,471,177, and outstanding Class C Warrants were exercisable to purchase a total of 16,538,473 shares of common stock. As the Somahlution Warrants Exercise constituted a financing at a lower price per share that the conversion price and exercise price of the Convertible Notes and Class C Warrants, respectively, and such financing was not a Qualified Financing, as a result of the Somahlution Warrants Exercise and pursuant to the adjustment provisions described above, the conversion price of the Convertible Notes and the exercise price of the Class C Warrants adjusted to $0.10 per share, and the number of shares of common stock into which the Convertible Notes may be converted and the Class C Warrants may be exercised to purchased increased proportionately by 1,750% and 2,225%, respectively. See “—Recent Developments – Letter Agreement to Amend Convertible Notes to Permit Conversion of Mandatory Default Amount” for a discussion of a subsequent development which further increased the number of shares of common stock into which the outstanding Convertible Notes may be converted based on the Mandatory Default Amount.
| 45 |
Default Under Promissory Note
On February 6, 2023, under a securities purchase agreement, the Company issued the Walleye Promissory Note to Walleye for $1,000,000 with a maturity date of May 7, 2023. The Walleye Promissory Note did not carry interest. The principal amount under the Walleye Promissory Note was required to be repaid in full on the maturity date. In the event that the principal amount was not repaid in full on the maturity date, the principal amount was to increase to $1,250,000. As of May 8, 2023, the Company had not repaid the Walleye Promissory Note. Accordingly, the principal outstanding under the Walleye Promissory Note increased to $1,250,000. See “—Cross-Default under Convertible Notes” and “—OID Units Private Placement – Second Closing of OID Units Private Placement” below for related developments.
Cross-Default Under Convertible Notes
Each of the Convertible Notes provides that any default on indebtedness of more than $100,000, other than indebtedness under the respective Convertible Notes, will also result in default under the Convertible Notes. The Convertible Notes provide that such default is not subject to any cure period. Due to the non-repayment of the initial principal amount of $1,000,000 under the Walleye Promissory Note by its maturity date, May 7, 2023, the Company also defaulted under the Convertible Notes on the same date. The Convertible Notes provide that due to this default, the Company became obligated to pay the Mandatory Default Amount. The Mandatory Default Amount may be declared due by each holder immediately. The aggregate Mandatory Default Amount that may be due under the Convertible Notes was $21,871,646 on the date of the default, or approximately $5.3 million more than would otherwise have been due under the Convertible Notes on the date of the default.
Under the unit purchase agreement entered into on May 27, 2021 with certain holders of several of the Convertible Notes, each of the Company’s subsidiaries entered into a guaranty to guarantee the repayment of the Company’s obligations under the Convertible Notes, and the Company and its subsidiaries entered into security agreements granting security interests in all of their respective assets for up to the dollar value owed under the respective Convertible Notes. The respective Convertible Notes were issued for aggregate principal of approximately $1.2 million. Under each unit purchase agreement entered into with respect to subsequent issuances of the Convertible Notes, the Company and its subsidiaries were obligated to enter into similar security agreements and guaranties, but did not do so.
The holders of the Convertible Notes have not exercised any remedies applicable to the Convertible Notes or given notice of any intention to do so as of the date of this report. If Univest, as the appointed representative of the Convertible Note holders, remains so appointed, no investor other than Univest may pursue any remedy with respect to the Convertible Notes. However, if the amount owed due to the default is not repaid upon demand, the holders of the Convertible Notes may nonetheless seek to remove Univest from this appointed position, take possession of some or all of the Company’s and its subsidiaries’ assets, force the Company and its subsidiaries into bankruptcy proceedings, or seek other legal remedies against the Company and its subsidiaries. In such event, the Company’s business, operating results and financial condition may be materially adversely affected.
Convertible Notes
During the years ended December 31, 2022 and 2021, the Company issued 147,711,770 units in the Units Private Placement, consisting of Convertible Notes and Class C Warrants, at a post-adjustment price per unit of $0.10, giving effect to the adjustments in the terms of the Units Private Placement resulting from the Somahlution Warrants Exercise as described above under “—Adjustments to Conversion Price of Convertible Notes and Exercise Price of Class C Warrants and Number of Underlying Shares”, for gross cash proceeds of approximately $14.2 million. Of the total 147,711,770 units issued, the following were issued for no cash payment: 2,786,780 units were issued to settle notes payable assumed on acquisition of My Health Logic, 400,000 units were issued to settle accounts payable, and 3,000,000 units were issued in exchange for services rendered to the Company in the year ended December 31, 2022. The number of units issued in the Units Private Placement corresponds with the number of shares of common stock into which the principal underlying the Convertible Notes may be converted. The cash proceeds from the Units Private Placement were used to sustain the Company’s growth and meet its capital obligations.
In connection with the Units Private Placement, we issued the Convertible Notes, which in aggregate were initially convertible into an aggregate of 8,269,228 shares of common stock. The balance outstanding under outstanding Convertible Notes as of September 30, 2023 was $19,162,953. Each Convertible Note was initially convertible into common stock of the Company at a price per share of $1.75, subject to adjustment. All outstanding Convertible Notes provide that a lower price per share under subsequent equity issuances, not including Qualified Financings, will be applied to the conversion price of the Convertible Notes, and have customary antidilution provisions. As a result of the adjustments applicable to the Convertible Notes described under “—Adjustments to Conversion Price of Convertible Notes and Exercise Price of Class C Warrants and Number of Underlying Shares”, the conversion price of the Convertible Notes was reduced to $0.10 per share. In addition, due to the event triggering of the cross-default provision under the Convertible Notes described above under “—Cross-Default Under Convertible Notes”, and the Convertible Notes Letter Agreement, the aggregate Mandatory Default Amount that may be due under the Convertible Notes was $21,871,631 on the date of the default, or approximately $5.7 million more than would otherwise have been due under the Convertible Notes on the date of the default.
The Convertible Notes mature 24 months after their issuance date and accrue 10% of simple interest per annum on the outstanding principal amount. As amended by the Convertible Notes Letter Agreement, the Convertible Notes provide that the Mandatory Default Amount or the Convertible Notes’ principal and accrued interest may be converted into shares of common stock at any time at the option of each holder at the conversion price, subject to any applicable beneficial ownership limitations on receiving shares upon such conversion. Any conversion by the holder will be applied toward the Mandatory Default Amount until it is fully converted. If the Mandatory Default Amount is fully converted, the Mandatory Default Amount and any outstanding principal and accrued interest will be fully extinguished.
| 46 |
As amended by the Convertible Notes Letter Agreement, the Convertible Notes provide that if at any time following the 60-day anniversary of the final closing date or termination of the Units Private Placement, and provided there is an effective registration statement permitting the issuance or resale of the shares of common stock into which the Convertible Notes may be converted, if (A) the common stock is listed on a senior national securities exchange, (B) the daily volume-weighted average price for the prior twenty (20) consecutive trading days is $6.00 or more (adjusted for splits and similar distributions) and (C) the daily trading volume is at least $1,000,000 during such 20-day period, then the Company will have the right to require the Convertible Notes to convert all or any portion of the Mandatory Default Amount then remaining under the Convertible Notes into shares of common stock at the above conversion price in effect on the mandatory conversion date.
As amended by the Convertible Notes Letter Agreement, the Convertible Notes also provide that upon the occurrence of a Qualified Financing, the conversion price of the Convertible Notes will be adjusted to the price per share equal to 75% of the price per equity security in such financing.
Under the Unit Purchase Agreement entered into on May 27, 2021 with certain holders of several of the Convertible Notes, each of the Company’s subsidiaries entered into a guaranty to guarantee the repayment of the Company’s obligations under the Convertible Notes, and the Company and its subsidiaries entered into security agreements granting security interests in all of their respective assets for up to the dollar value owed under the respective Convertible Notes. The respective Convertible Notes were issued for aggregate principal of approximately $1.2 million. Under each Unit Purchase Agreement entered into with respect to subsequent issuances of the Convertible Notes, the Company and its subsidiaries were obligated to enter into similar security agreements and guaranties, but did not do so.
Shares of common stock may not be received pursuant to a conversion of a Convertible Note to the extent that the holder (together with any other person with which the holder is considered to be part of a “group” under Section 13 of the Exchange Act or with which the holder otherwise files reports under Section 13 and/or Section 16 of the Exchange Act) would otherwise become the “beneficial owner” (as such term is defined in the Exchange Act and the rules and regulations thereunder) of in excess of 4.99% of the shares of common stock outstanding, subject to automatic increase to 9.99% if the holder becomes a beneficial owner of more than 4.99%, subject to a requirement that any increase in the limitation will not be effective until the 61st day after notice is delivered to the Company. This limitation does not apply to certain provisions of the Convertible Notes.
The Convertible Notes have certain registration requirements as to the shares of common stock underlying the Convertible Notes upon the final closing of the Units Private Placement under the respective registration rights agreements between the Company and the purchasers of the Convertible Notes. By executing certain lock-up agreements with Univest acting as the representative of the underwriters of a proposed public offering that we no longer intend to pursue or waiver agreements with the Company, the purchasers of the Convertible Notes agreed that doing so amounted to a waiver of their rights under the respective registration rights agreements, and that any such registration rights will be afforded to such purchasers in a subsequent registration statement. The assignees of certain Convertible Notes and the holders of the Replacement Convertible Notes have also entered into a waiver and consent with the Company providing for the waiver and deferral of all registration rights applicable to the respective Convertible Notes until a date and time that the Company shall determine in its sole discretion that it may provide for such rights.
Each Convertible Note provides that its holder may vote with the shares of common stock, on an as-converted to common stock basis, with respect to all corporate matters of the Company on which the holders of common stock are entitled to vote, subject to any applicable beneficial ownership limitations. Under the NRS the right to vote is generally a feature of a share of any class or series of stock of a corporation and, thus, a right granted to stockholders of a corporation. Under the NRS, convertible promissory notes (or any other form of bond, debenture or other obligation) typically do not provide holders with voting rights. However, Section 78.197 of the NRS provides that a corporation organized in Nevada “may provide in its articles of incorporation that the holder of a bond, debenture or other obligation of the corporation may have any of the rights of a stockholder in the corporation.” At the Special Stockholders Meeting, the stockholders of the Company approved the Voting Rights Amendment, and on August 16, 2023, the Company filed the Certificate of Amendment with the Nevada Secretary of State providing for, among other things, the Voting Rights Amendment, and the Certificate of Amendment became effective upon filing. Accordingly, upon the filing of the Certificate of Amendment, among other things, (i) the Company’s board of directors may grant any of the rights of stockholders to any of the holders of any of the Company’s bonds, debentures or other obligations; and (ii) all of the holders of the Convertible Notes issued between December 21, 2021 and August 12, 2022 became entitled to vote with the shares of the Company’s common stock, on an as-converted to common stock basis without actually having converted the Convertible Notes to shares of the Company’s common stock, with respect to all corporate matters of the Company on which the holders of common stock are entitled to vote, as provided in the Convertible Notes. Pursuant to the Certificate of Amendment, the board of directors extended these voting rights to all other holders of the Convertible Notes issued since August 12, 2022. Accordingly, all holders of the Convertible Notes are entitled to vote with the shares of the Company’s common stock, on an as-converted to common stock basis without actually having converted the Convertible Notes to shares of the Company’s common stock, with respect to all corporate matters of the Company on which the holders of common stock are entitled to vote, as provided in the Convertible Notes.
| 47 |
The 2021 Placement Agency Agreement and form of unit purchase agreement relating to the Units Private Placement provide that up to $18 million and $17 million of the units containing the Convertible Notes may be sold, respectively. On August 12, 2022, we completed the final closing of the Units Private Placement.
On June 14, 2023, a Convertible Note with $119,980 underlying principal, approximately $14,693 accrued interest, and a Mandatory Default Amount of $180,123 was converted into 1,346,410 shares of common stock at the applicable conversion price of $0.10 per share at the election of the Convertible Note holder. Pursuant to the Convertible Notes Letter Agreement, the Convertible Note remains convertible into 454,819 shares of common stock.
Other Contractual Obligations and Commitments
Royalties and Other Commitments
Upon receiving the FDA clearance for the DuraGraft and other key intellectual products,On December 15, 2019, the Company will:entered into the Somahlution Agreement to acquire the Somahlution Assets, including DuraGraft®. The Somahlution Agreement was amended on March 31, 2020 and May 29, 2020 to extend the termination date. On July 30, 2020, the Company and Somahlution entered into Amendment No. 3 to the Somahlution Agreement (“Amendment No. 3”). Pursuant to the terms of this amendment, it was agreed that, as part of the Somahlution Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc., in addition to the Somahlution Assets. This change to the Somahlution Agreement was made comply with certain requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the EEA. In Amendment No. 3, the Company agreed to assume certain payables of Somahlution related to clinical and medical expenses. The parties also orally agreed that the payments on the assumed debts would be recorded as a prepaid royalty against future royalties.
Pursuant to the Somahlution Agreement and in consideration of the outstanding capital stock of Somahlution, Inc., the Company agreed to pay to certain beneficial owner designees of Somahlution, among other consideration:
| ● | ||
| ● |
| ■ | Royalties to be paid on all net sales of the product | ||
| ■ | |||
| ■ | |||
| ■ | Upon the sale of DuraGraft products, the Company will pay pro rata the Somahlution designees 15% of the net sale proceeds towards the liquidation preference maximum amount of $20 million described below; |
| ● |
| ■ | Royalties to be paid on all net sales of the product of 6% on the first $50 million of international net sales, 4% for greater than $50 million up to $200 million, and 2% for greater than $200 million; | |
| ■ | Upon the sale of DuraGraft products, the Company will pay pro rata the Somahlution designees 15% of the net sale proceeds towards the liquidation preference maximum amount of $20 million described below; |
| ● | Somahlution Assets-derived over-the-counter products: |
| ■ | Royalties to be paid on all net sales of the product of 6% on the first $50 million of international net sales, 4% for greater than $50 million up to $200 million, and 2% for greater than $200 million; |
| ○ | Other Somahlution Assets-derived products from existing Somahlution pipelines: |
| ■ | Royalties to be paid on all net sales of the product of 1%; and |
| ● | A liquidation preference, up to a maximum of $20 million, |
| 48 |
For additional discussion of this transaction, see “Item 13. Certain Relationships and Related Transactions, and Director Independence – Transactions with Related Persons” of the 2022 Form 10-K.
Office and Laboratories Space Lease Commitments
The Company has entered into arrangements for office and laboratories spaces. As at September 30, 2022,2023, minimum lease payments in relation to lease commitments were payable as outlined in “Note 4 – Leases”, included in “Item 1. Financial Statements” of this Quarterly Report on Form 10-Q.
Other Promissory Notes
On October 23, 2022, the Company issued a note payable to Hub International Limited for $204,050 bearing interest at the annual rate of 6.75% per annum, due September 23, 2023, payable monthly starting November 23, 2022. As of September 30, 2023, the balance of note payable due was $0 (December 31, 2022 - $164,729).
On December 28, 2022, the Company issued the Hexin Promissory Note 5for the principal amount of $750,000 bearing interest at the annual rate of 20% per annum, due June 28, 2023. For the three and nine months ended September 30, 2023, the Company accrued $25,914 and $64,133 in interest on the promissory note (September 30, 2022 - $0 and $0 respectively). On May 30, 2023, Hexin agreed to cancel and exchange the Hexin Promissory Note for the issuance of 11,764,710 OID Units as described above under “—Third Closing of OID Units Private Placement”.
On February 2, 2023, the Company issued the Walleye Promissory Note for $1,000,000 with a maturity date of May 7, 2023. The note has no interest and the principal amount shall be paid in full on the maturity date. In the event that the principal amount is not repaid in full on maturity date, the principal amount shall be increased to $1,250,000. The Company did not repay the note upon its maturity, and as of the date of this report, the principal outstanding under the note had been increased to $1,250,000. Walleye agreed to cancel and exchange the Walleye Promissory Note for the issuance of 14,705,890 OID Units as described above under “—Third Closing of OID Units Private Placement”.
As part of the My Health Logic acquisition, Marizyme assumed an aggregate of $468,137 in notes payable. The notes were unsecured, and bore interest at a rate of 9% per annum with no maturity date. The Company settled an aggregate of $278,678 of these notes payable by issuing Convertible Notes in exchange for these notes’ cancellation in connection with the Units Private Placement during the year ended December 31, 2022 (see “Note 7 – Convertible Promissory Notes and Warrants”, included in “Item 1. Financial Statements” of this Quarterly Report on Form 10-Q ). For the nine months ended September 30, 2023, the Company accrued $10,235 in interest on the notes payable (September 30, 2022 - $4,501). As of September 30, 2023, the balance of the remaining note payable was $241,404 (December 31, 2022 - $218,100). The note is in default for non-payment.
Going Concern
The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and had an accumulated deficit of $141,570,688 as of September 30, 2023 (December 31, 2022 - $85,989,433). Additionally, the Company had negative working capital of $47,354,926 as of September 30, 2023 (December 31, 2022 - $966,464) and $474,944 as of September 30, 2023 (December 31, 2022 - $510,865) of cash on hand, which may not be sufficient to fund operations for the next twelve months. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
| 49 |
The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The ability of the Company to continue its operations is dependent on the execution of management’s plans, which include the raising of capital through the debt and/or equity markets, until such time that funds provided by operations are sufficient to fund working capital requirements. If the Company were not to continue as a going concern, it would likely not be able to realize its assets at values comparable to the interimcarrying value or the fair value estimates reflected in the balances set out in the preparation of the consolidated financial statements.
There can be no assurances that the Company will be successful in generating additional cash from the equity/debt markets or other sources to be used for operations. The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary. Based on the Company’s current resources, the Company will not be able to continue to operate without additional immediate funding. Should the Company not be successful in obtaining the necessary financing to fund its operations, the Company would need to curtail certain or all operational activities and/or contemplate the sale of its assets, if necessary.
The Company has been impacted by the COVID-19 pandemic and related supply chain shortages and other economic conditions, and some of its earlier plans to further diversify its operations and expand its operating subsidiaries were delayed as a result. See “–Impact of COVID-19 Pandemic” above.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
For a description ofWhile our criticalsignificant accounting policies please seeare more fully described in “Note 3 – Summary of Significant Accounting Policies”, included in “Item 1. Financial Statements” of this Quarterly Report on Form 10-Q, we believe that the section entitled “Management’s Discussionfollowing accounting policies are the most critical for fully understanding and Analysisevaluating our financial condition and results of operations.
Deferred Offering Cost
The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process capital stock financings as deferred offering costs until such financings are consummated. After consummation of the financing, these costs are recorded in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations. As of September 30, 2023, the Company had recorded deferred offering costs of $Nil (December 31, 2022 - $387,412) reported as a prepaid expense on the accompanying balance sheets, and expensed $1,203,537 of deferred offering costs in connection with the extinguishment of indebtedness pursuant to exchange agreements in November 2021 and December 2021 which provided for the cancellation and exchange of certain outstanding convertible promissory notes. See “Note 7 – Convertible Promissory Notes and Warrants” included in “Item 1. Financial ConditionStatements” of this Quarterly Report on Form 10-Q.
Fair Value Measurements
The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:
| ● | Level 1 – Quoted prices for identical assets or liabilities in active markets. |
| ● | Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. |
| ● | Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. |
| 50 |
The Company utilizes valuation techniques that maximize the use of observable inputs and Resultsminimize the use of Operations - Critical Accounting Policies and Estimates” contained in our 2021 Form 10-K. There have not been any material changesunobservable inputs to the critical accounting policies discussed therein duringextent possible and considers counterparty credit risk in its assessment of fair value.
The carrying amounts of certain accounts and other receivables, accounts payable and accrued expenses, note payable, and amounts due to related parties approximate fair value due to the short-term nature of these instruments.
The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk.
The contingent liabilities assumed on the Somahlution Acquisition consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy.
| i. | The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19%, expected volatility of 69.62%, expected dividend of $0, and expected life of 5.96 years. For the three and nine months ended September 30, 2023, changes in these assumptions resulted in a $406,000 increase and $800,000 decrease in fair value of these liabilities, respectively (September 30, 2022 – $1,999,000 decrease and $899,000 increase, respectively). At September 30, 2023, the fair market value of performance warrants and pediatric vouchers warrants liabilities was $627,000 (December 31, 2022 – $1,427,000). | |
| ii. | The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6%. For the three and nine months ended September 30, 2023, changes in these assumptions resulted in a $1,262,000 and $466,000 increase in fair value of this liability, respectively (September 30, 2022 – $516,000 decrease and $1,288,000 increase, respectively). At September 30, 2023, the fair market value of royalty payments was $5,868,000 (December 31, 2022 – $5,402,000). | |
| iii. | Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6%. For the three and nine months ended September 30, 2023, changes in these assumptions resulted in a $10,000 decrease and $22,000 increase in fair value of this liability, respectively (September 30, 2022 – $8,000 and $56,000 decrease, respectively). At September 30, 2023, the fair market value of rare pediatric voucher sales liability was $1,077,000 (December 31, 2022 – $1,055,000). | |
| iv. | The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21%, expected volatility of 78.93%, expected dividend of $0, and expected life of 5 years. No changes to the fair value of liquidation preference liability were recorded in the three and nine months ended September 30, 2023 and 2022. At September 30, 2023, the fair market value of liquidation preference was $1,823,000 (December 31, 2022 – $1,823,000). |
The derivative liabilities consist of optional and automatic conversion features and the share redemption feature attached to the convertible notes, issued pursuant to certain convertible promissory notes and warrants transactions (see “Note 7 – Convertible Promissory Notes and Warrants”, included in “Item 1. Financial Statements” of this Quarterly Report on Form 10-Q).
The detachable warrants attached to the OID Convertible Notes (See Note 7) met the definition of a derivative liability. These warrants were valued using the Black-Scholes pricing method. The following weighted average assumptions were used in the Black-Scholes option pricing model: risk free rate of 4.76%, expected volatility of 253.46%, expected dividend of $Nil, and expected life of 0.56 years. For the three and nine months ended September 30, 2022.2023, changes in these assumptions resulted in a $14,454,397 increase in fair value of this liability (September 30, 2022 – $Nil). At September 30, 2023, the fair market value of the detachable warrant liability was $25,555,092 (December 31, 2022 – $Nil).
The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.
| 51 |
Marizyme measures the following financial instruments at fair value on a recurring basis. As of September 30, 2023, and December 31, 2022, the fair values of these financial instruments were as follows:
| Fair Value Hierarchy | ||||||||||||
| September 30, 2023 | Level 1 | Level 2 | Level 3 | |||||||||
| Liabilities | ||||||||||||
| Derivative liabilities | $ | - | $ | - | $ | 25,555,092 | ||||||
| Contingent liabilities | - | - | 9,395,000 | |||||||||
| Total | $ | - | $ | - | $ | 34,950,092 | ||||||
| Fair Value Hierarchy | ||||||||||||
| December 31, 2022 | Level 1 | Level 2 | Level 3 | |||||||||
| Liabilities | ||||||||||||
| Derivative liabilities | $ | - | $ | - | $ | 4,823,725 | ||||||
| Contingent liabilities | - | - | 9,707,000 | |||||||||
| Total | $ | - | $ | - | $ | 14,530,725 | ||||||
The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs:
| Derivative and Contingent Liabilities | Derivative Liabilities | Contingent Liabilities | ||||||
| Balance at December 31, 2022 | $ | 4,823,725 | $ | 9,707,000 | ||||
| Change in fair value of contingent liabilities | - | (312,000 | ) | |||||
| Derivative liabilities extinguished pursuant to Unit Purchase Agreement (Note 7) | (4,823,725 | ) | - | |||||
| Derivative liabilities issued pursuant to OID Purchase Agreement (Note 7) | 11,100,695 | - | ||||||
| Change in fair value of derivative liabilities | 14,454,397 | - | ||||||
| Balance at September 30, 2023 | $ | 25,555,092 | $ | 9,395,000 | ||||
Research and Development Expenses and Accruals
All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, for individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of DuraGraft, and costs related to manufacturing DuraGraft for clinical trials. The Company has entered into various research and development contracts with various organizations. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advance are reflected in the accompanying balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be required in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.
Stock-Based Compensation
Stock-based compensation expense for employees and directors is recognized in the Condensed Consolidated Statements of Operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, the Company estimates the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. The Company estimates the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, the Company estimates the grant date fair value using its closing stock price on the date of grant. The Company recognizes the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. The Company recognizes the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which share-based awards vest.
Off-Balance Sheet Arrangements
As of September 30, 2022,2023, the Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
| 52 |
ITEM 4. CONTROLS AND PROCEDURES
Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures
We evaluated the effectiveness of our disclosure controls and procedures as defined by Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this quarterly report, with the participation, and under the supervision, of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”). Based upon this evaluation, our CEO and CFO concluded that as of September 30, 2022, our disclosure controls and procedures were ineffective due to the material weakness described below.
Disclosure controls and procedures meansare defined in Rule 13a-15(e) under the Exchange Act to mean controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuerus in the reports that it fileswe file or submitssubmit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. A material weakness in
At the end of the period covered by this Quarterly Report on Form 10-Q an evaluation was carried out under the supervision of and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operations of our disclosure controls and procedures includes(as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2023. This conclusion was based on the material weaknesses in our internal control over financial reporting as further described below.
Material Weaknesses
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the registrant’sour annual or interim consolidated financial statements will not be prevented or detected and corrected on a timely basis by the company’s internal controls.
basis. As previously reported in our annual report onthe 2022 Form 10-K, for the year ended December 31, 2021, management concluded that, as of such date, our disclosure controls and procedures were not effective due to the existence of a material weaknessweaknesses in the design and operating effectiveness ofour internal controls related to inadequate internal technical staffing levels and lack of board or management oversight. control over financial reporting. These material weaknesses were as follows:
| ● | We did not have adequate policies and procedures in place to ensure the timely, effective review of assumptions used in measuring the fair value of certain financial instruments, and | |
| ● | We did not have sufficient resources with appropriate knowledge, experience and/or training commensurate with our financial reporting requirements to assist us in our timely and efficient preparation and review over our financial reporting. |
In connection with our preparation of our interim condensed consolidated financial statements for the three and nine months ended September 30, 2022,2023, we identified material weaknesses in our disclosure controls and procedures due to the material weaknesses in internal control over financial reporting related to the following:
| ● | We did not | |
To remediate the material weaknessesweakness described above, in addition to the measures that management has taken as described under ““—Changes in Internal Control Over Financial Reporting” below, management will continue to add controls to further enhance and revise the design of the existing controls including:
| ● | ||
| ● | ||
| ● | ||
| ● | Maintenance of adequate internal qualified personnel to properly supervise and review the information provided by the outside consulting technical experts to ensure certain significant complex transactions and technical matters were properly accounted for. |
We believecannot assure you that these ongoing or planned measures will remediatein response to the material weakness in our internal control over financial reporting and disclosure controls and procedures described above.will be sufficient to remediate such material weakness or to avoid potential future material weaknesses.
Changes in Internal Control Over Financial Reporting
As discussed above, the management is working on remediatingintends to remediate the material weakness in internal control over financial reporting identified above. In the ninethree months ended September 30, 2022,2023, the Company took the following steps in order to improve its internal controls over financial reporting:
| ● | ||
During the nine months ended September 30, 2022, management of the Company will continue to work on addressing to remediate the material weaknesses in internal controls over financial reporting described above.
| 53 |
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. Other than the legal proceedings described below, weWe are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.
DeVito Litigation
On June 7, 2022, Nicholas DeVito, a former Interim Chief Executive Officer and Interim Chief Financial Officer of the Company, filed a Complaint in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, Case No. 50-2022-CA-005437 (the “Florida Circuit Court”), against the Company (the “DeVito Complaint”). The DeVito Complaint claimed breach of contract, declaratory relief, specific performance, breach of an implied covenant of good faith and fair dealing, and unjust enrichment against the Company with respect to the Company’s alleged breach of the common stock issuance requirements of an Incentive Stock Option Agreement between Mr. DeVito and the Company, dated as of July 13, 2019 (the “DeVito ISO”). Under the DeVito ISO, on July 13, 2019, the Company granted an option to Mr. DeVito to purchase 125,000 shares of common stock at $4.04 per share, subject to certain vesting terms. The DeVito ISO provided that it would terminate twelve (12) months after the end of Mr. DeVito’s “Continuous Service,” which was not defined by the DeVito ISO. On August 27, 2020, as part of a Mutual Release of Claims Agreement between Mr. DeVito and the Company dated as of that date (the “DeVito Release”), the Company agreed to immediately vest the unvested portion of the DeVito ISO such that the DeVito ISO became fully vested, to pay Mr. DeVito $20,000 to add in the transition during the month of September 2020, and that Mr. DeVito would retain all of his rights under the DeVito ISO. Under the DeVito Release, Mr. DeVito agreed to step down from his positions as Interim Chief Executive Officer and Interim Chief Financial Officer on September 1, 2020, to assist Marizyme with its transition to a new Chief Executive Officer and Chief Financial Officer for the month of September 2020, and effective as of September 1, 2020 would no longer act as an officer of Marizyme in any capacity. The DeVito Release also recited that the Company requested that Mr. DeVito be available for additional consulting going forward as the needs of the business dictate. The DeVito Release also provided for a general mutual release of claims by the Company and Mr. DeVito apart from continuing employment obligations and corporate officer indemnification obligations of Marizyme. The DeVito Complaint alleged that Mr. DeVito continued his role as an advisor and consultant to the Company. Due to the Company’s alleged nonperformance of Mr. DeVito’s exercise rights under the DeVito ISO, the DeVito Complaint sought declaratory relief, specific performance, direct and consequential damages in an unspecified amount of more than $30,001.00, damages prescribed by the DeVito ISO, reasonable attorney’s fees and costs, prejudgment interest, and such other relief as the court deems equitable. On July 21, 2022, the Company filed a motion to dismiss the claims of declaratory relief, specific performance, and breach of an implied covenant of good faith and fair dealing in the DeVito Complaint. On August 3, 2022, Mr. DeVito filed an amended complaint without a hearing (the “Amended DeVito Complaint”). The Amended DeVito Complaint includes two claims, for breach of contract and unjust enrichment, and otherwise realleges substantially all of the factual allegations of the DeVito Complaint. On August 26, 2022, the Company filed an Answer to the Amended DeVito Complaint denying substantially all of the allegations. The Company is determining whether to file a counterclaim. As of November 2022, this case is pending. [NTD: Please confirm/update]
Chandler Litigation
On January 28, 2022, the Company filed a Complaint in the Florida Circuit Court, case number 50-2022-CA-000859-XXX-MB, against Amy Chandler (the “Chandler Complaint”). The Chandler Complaint sought damages for breach of fiduciary duty, breach of contract, negligence, conversion, and civil theft. The Chandler Complaint alleged that, prior to her resignation in September 2021, Ms. Chandler intentionally and recklessly took actions to cancel the CE certificate required by European Union regulations in order for Marizyme and its subsidiary, Somahlution, LLC, to ship and distribute certain products to/within the European Union. The Chandler Complaint also alleged that Ms. Chandler disregarded her fiduciary duty to Marizyme and responsibilities as the top regulatory and compliance official of Marizyme. As a result, the Chandler Complaint alleged that Ms. Chandler’s actions caused significant disruption and damage to Marizyme’s business, including, but not limited to, financial damages and damage to Marizyme’s reputation and business relationships. The Chandler Complaint further alleged that prior to her last day, Ms. Chandler stole confidential, proprietary files governing Marizyme’s quality management system, which related to internal business operations, and that Marizyme incurred significant costs to recreate these files. The Chandler Complaint alleged damages in excess of thirty thousand dollars ($30,000.00), exclusive of interest, attorneys’ fees, and costs.
On February 28, 2022, Ms. Chandler filed an Answer, Affirmative Defenses and Counterclaim with the Florida Circuit Court (the “Answer”). The Answer denied the claims in the Chandler Complaint and most of the factual allegations regarding Ms. Chandler’s alleged actions. The Answer also asserted a counterclaim against the Company for defamation per se. The Answer sought to recover monetary damages, attorneys’ fees, and court costs in connection with this litigation. The Answer also demanded a trial by jury on all triable issues.
On March 18, 2022, the Company filed a Motion to Dismiss Ms. Chandler’s Counterclaim with the Florida Circuit Court (the “Motion to Dismiss”). The Motion to Dismiss stated that Ms. Chandler’s Counterclaim for defamation per se should be dismissed with prejudice. On July 13, 2022, the court ruled that the counterclaim of defamation was dismissed with prejudice. Ms. Chandler’s deposition is now scheduled for September 21, 2022. At that time, the Company’s counsel will attempt to obtain the admissions necessary to confirm Chandler’s liability and to potentially add James Sapirstein and his company, First Wave BioPharma, as defendants. In the coming months, the Company expects to retain a consultant to assist it with quantifying the substantial damages caused by Chandler’s actions. As of August 2022, the remaining matters under litigation in this case are pending.
Campbell/Harmon Litigation
On August 19, 2021, Dr. Neil Campbell, former President, Chief Executive Officer and director of the Company, and Bruce Harmon, former Chief Financial Officer and Secretary of the Company, each filed a Complaint and Demand for Jury Trial in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, case numbers No. 50-2021-CA-009938 and No. 50-2021-CA-009954, respectively, against the Company and Insperity Peo Services, L.P., a Delaware limited partnership (“Insperity”), a joint employer of Dr. Campbell and Mr. Harmon with the Company under a Client Service Agreement, dated November 30, 2020 (collectively, the “Campbell/Harmon Complaints”). Both Campbell/Harmon Complaints alleged that the Company and Insperity violated Section 448.105 of the Florida Private Whistleblower Act as a result of the constructive terminations of Dr. Campbell and Mr. Harmon after the occurrence of violations of federal and state law, including federal securities law, at the Company that exposed Dr. Campbell and Mr. Harmon to civil and criminal forms of liability and that the Company was not addressing to their satisfaction. Both of the Campbell/Harmon Complaints demanded approximately $30,000-$50,000 in back pay and benefits, interest on back pay, front pay and/or lost earning capacity, compensatory damages, costs and attorney’s fees, and such other relief as the court deems equitable.
Pursuant to a Joint Stipulation of Voluntary Dismissal With Prejudice filed in each of these cases, the arbitrator of these cases dismissed Dr. Campbell and Mr. Harmon’s actions with prejudice on April 18, 2022 and April 14, 2022, respectively, and the court subsequently dismissed Dr. Campbell and Mr. Harmon’s actions with prejudice on April 22, 2022 and April 14, 2022, respectively.
ITEM 1A. RISK FACTORS.
There have been no material changes to the risk factors disclosed in the 20212022 Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, AND USE OF PROCEEDS.PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES.
During the three-month period ended September 30, 2022,2023, we did not conduct any unregistered sales of our equity securities that were not previously disclosed in a current report on Form 8-K and we did not repurchase any of our common stock.stock
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.We have no information to disclose that was required to be disclosed in a Current Report on Form 8-K during the three months ended September 30, 2023 but was not reported. There have been no material changes to the procedures by which security holders may recommend nominees to our board of directors where those changes were implemented after the Company last provided disclosure of such procedures.
ITEM 6. EXHIBITS
The following exhibits are filed as part of this report or incorporated by reference:
| 55 |
| 56 |
* Filed herewith
** Furnished herewith
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: November 14, | MARIZYME, INC. | |
| /s/ David Barthel | ||
| Name: | David Barthel | |
| Title: | ||
| (Principal Executive Officer) | ||
| /s/ George Kovalyov | ||
| Name: | George Kovalyov | |
| Title: | Chief Financial Officer | |
| (Principal Accounting and Financial Officer) | ||